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PREFACE 
May this project aide in taking our worries away, decreasing the number of lives lost to suicide, 
and allowing us all to live our lives to the fullest and enjoy every day. 
 
“We love them. We miss them. We grieve them. And so, we live our lives to make them proud.” 
– Anonymous 
 
“Those we love don’t go away; they walk beside us every day, unseen, unheard, but always 
near, still loved, still missed, and very dear.” - Anonymous 
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ABSTRACT 
Generalized anxiety disorder (GAD) is highly prevalent in the United States with at least 12% of 
the population affected (Edmund & Sheppard, 2018). GAD can pose significant distress and 
debilitation throughout the lifespan (Bystritsky, Khalsa, Cameron, & Schiffman, 2013; Edmund & 
Sheppard, 2018). Barriers to treatment include adverse effects, inaccessibility, and expense. 
The purpose of this project was to implement an evidence-based protocol involving combination 
therapy with self-administered cognitive behavioral therapy (CBT) and selective serotonin 
reuptake inhibitor (SSRI) medication in order to improve patient outcomes through more 
accessible, affordable, and standardized treatment of GAD. The Neuman Systems Model and 
Stetler Model were utilized to guide this project among a sample population of 20 adults with 
GAD at a nurse practitioner-owned family practice clinic in Northwest Indiana. In fulfillment of 
the protocol, each participant was prescribed an SSRI in combination with independent 
completion of a CBT workbook for anxiety over 12 weeks. Anxiety symptoms via the 
Generalized Anxiety Disorder 7-item (GAD-7) Scale and depression symptoms via the Patient 
Health Questionnaire (PHQ-9) were measured at baseline, week 4, week 8, and week 12. A 
one-way repeated-measures analysis of variance (ANOVA) indicated that while mean GAD-7 
scores decreased from baseline (M = 4.20, SD = 4.32) to week 12 (M = 1.60, SD = 2.12), there 
was no statistically significant decrease found (F(3,27) = 1.94, p > 0.05). Mean PHQ-9 scores 
decreased from baseline (M = 4.80, SD = 3.58) to week 12 (M = 1.90, SD = 2.81), and there 
was a statistically significant decrease found (F(3,27) = 4.34, p < 0.05). Participants were 
satisfied (44.4%), very satisfied (33.3%), and extremely satisfied (22.2%) with self-administered 
CBT. Providers are recommended to implement combined self-administered CBT and SSRI 
medication as a cost-effective, accessible, and effective method to decrease anxiety and 
depression symptoms among patients with GAD. 
 
 
xi 
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CHAPTER 1 
INTRODUCTION 
Background 
As one of the most common psychiatric illnesses addressed in the primary care setting, 
generalized anxiety disorder (GAD) is highly prevalent in the United States as well as in other 
countries and poses a significant problem for not only adults, but also for children and 
adolescents (Edmund & Sheppard, 2018). As many as 264 million people suffered from an 
anxiety disorder worldwide in 2015 (World Health Organization, 2017). This indicated a 15% rise 
since 2005 in the number of individuals affected with further rise expected. The lifetime 
prevalence of GAD alone is reportedly 12% in the United States with a higher prevalence 
suspected due to a lack of care sought by affected individuals (Edmund & Sheppard, 2018). 
Despite many invisible and intangible characteristics of GAD, it can cause significant debilitation 
(Bystritsky, Khalsa, Cameron, & Schiffman, 2013). GAD is “…characterized by excessive worry 
or anxiety about everyday events and problems to the point at which the individual experiences 
considerable distress and difficulty in performing day to day tasks” (Campbell, 2016, p. 1). 
Decreased quality of life, decreased productivity, negative impact on well-being, increased 
morbidity and mortality, and increased abuse of drugs and alcohol are often associated with 
GAD (Bystritsky et al., 2013; Edmund & Sheppard, 2018). Approximately 32.3% of individuals 
with GAD reportedly have serious impairment, 44.6% have moderate impairment, and 23.1% 
have mild impairment (National Institute of Mental Health, 2017). Anxiety is considered the sixth 
largest contributor to global disability (World Health Organization, 2017). The impact of anxiety 
on functional impact has led to a total of 24.6 million years lived with disability according to 2015 
data. 
The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) 
provides specific diagnostic criteria for GAD (American Psychiatric Association, 2013). In order 
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to classify as a diagnosis of GAD, A) such excessive anxiety and worry about multiple events or 
activities must be present for a majority of days throughout a time period of at least 6 months, B) 
the worry is difficult to control, C) the anxiety and worry are associated with three or more of the 
following six symptoms in adults or one or more of the following six symptoms in children: 1. 
feeling restless or on edge, 2. easily fatigued, 3. difficulty concentrating or remembering 
thoughts, 4. irritability, 5. muscle tension, 6. sleep disturbance (trouble falling or staying asleep, 
restlessness during sleep, feeling unsatisfied with sleep), D) significant impairment in 
functioning, social, and/or occupational aspects, E) the anxiety, worry, and symptoms are not 
associated with the use of a substance (drug abuse or medication use) nor another medical 
condition, F) there is a lack of a better explanation for such difficulty including another medical 
disorder, mental disorder, or anxiety disorder (American Psychiatric Association, 2013).  
There is evidence to support the influence of both environmental and genetic factors 
associated with GAD. Individuals with parents who have been diagnosed with an anxiety 
disorder are more likely to develop an anxiety disorder themselves (Edmund & Sheppard, 
2018). Overprotective or overcontrolling and negative or highly critical parenting styles can also 
contribute to the development of GAD in adolescents. Disturbances among norepinephrine, 
serotonin, and gamma-aminobutyric acid may also be responsible. Data support that 
dysregulation in areas of the brain that control emotional processing, such as the anterior limbic 
network, may contribute to the development of GAD (McBride, 2015). Such brain structures 
among individuals with GAD react easily to stimuli that elicit fear and other strong emotions 
among individuals with GAD. The development of GAD is associated with behavioral inhibition, 
which is defined as the likelihood to feel distress and to withdraw from unfamiliar or new stimuli. 
The median age of onset of GAD is characterized as 30 years old, but symptoms may 
begin years sooner (Edmund & Sheppard, 2018). Women are affected twice as often as men. 
Poverty, loss, other mental disorders, and life events perceived as negative increase the 
likelihood of GAD development. There are conflicting data regarding the relationship of 
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socioeconomic status and the risk of GAD development with some studies indicating that lower 
occupational status, income, and education level are associated with higher risk of GAD 
development and others indicating that lower socioeconomic status is linked to lower rates of 
GAD than those of higher statuses (McBride, 2015). Additional risk factors for GAD include 
personality characteristics of behavioral inhibition, negative affect, low self-esteem, decreased 
adaptability, and poor self-regulation. Conflict among parents and children or among siblings as 
well as interparental violence, separation, and divorce can increase GAD risk. Report of suicidal 
ideation and past attempts of self-harm are more common among adolescents with GAD than 
those without. Additional risks associated with GAD in adolescence include alcohol and 
cigarette abuse, academic difficulties, conflicts at home, struggles in social situations, negative 
self-image, rejection by peers, and being left out of activities with peers. Adolescents with GAD 
may have fewer friendships and be less liked by their peers as a result of such relationship 
struggles. Being the victim of bullying, in particular, is the most influential factor among peer 
relationships in the development of GAD. Depressive disorders are highly correlated with GAD 
(Edmund & Sheppard, 2018). The correlation is so great that coexisting depression among 
patients with symptoms of GAD is not only possible, but likely probable. In 2015, approximately 
322 million individuals suffered from depression worldwide (World Health Organization, 2017). 
Depression also strongly correlates with suicide deaths, which total approximately 800,000 per 
year. Common psychiatric comorbidities of individuals with GAD include substance use/abuse, 
social anxiety disorder, obsessive compulsive disorder, post-traumatic stress disorder, and 
bipolar disorder (Edmund & Sheppard, 2018). 
Statement of the Problem 
Data from the Literature Supporting Need for the Project 
Anxiety disorders are the most prevalent mental health disorders, which supports the 
need to make them a priority to help a large number of individuals (Bystritsky et al., 2013). 
Anxiety disorders are such a significant problem in the United States, yet they often do not 
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receive as much recognition and care as other psychological disorders. There are a multitude of 
challenges associated with understanding, diagnosing, and treating GAD in primary care. Many 
symptoms of GAD can be associated with other disorders, such as anemia, hyperthyroidism, 
cardiac dysrhythmias, or substance abuse, contributing to the misdiagnosis and underdiagnosis 
of GAD that often occurs (Edmund & Sheppard, 2018). The physical symptoms that patients 
with GAD report may be nonspecific, confusing, or ill-defined, and they may be variable, 
disappearing on the weekends or during vacations (McBride, 2015). In addition, other health 
conditions and comorbidities often take priority over the treatment of GAD, leading to a lack of 
timely and proper treatment. Another challenge is the lack of affected individuals seeking care 
with only a reported one third of individuals with GAD presenting for help (Edmund & Sheppard, 
2018). Further adding to these dilemmas include the barriers associated with treatment, such as 
a lack of cognitive behavioral therapy (CBT) therapists or cost-prohibitive CBT services 
(Bystritsky et al., 2013). These challenges lead to the underdiagnosis and undertreatment of 
GAD.  
According to the American Psychiatric Association, combination pharmacotherapy and 
psychotherapy, especially CBT, elicits great response rates in the majority of patients (Edmund 
& Sheppard, 2018). Such combination therapy has been shown to yield the best results and 
helps to reduce relapse, relieve symptoms, and develop coping strategies (Edmund & 
Sheppard, 2018; McBride, 2015). Approximately 81% of patients with GAD have responded well 
to combination CBT and pharmacotherapy compared with a 60% response rate for CBT alone 
and 55% response rate for pharmacotherapy alone (McBride, 2015). Therefore, patients with 
GAD should be provided with these options for treatment.  
CBT is a form of psychotherapy that aims to modify thinking in order to combat 
dysfunctional thinking and encourage positive thoughts (Bystritsky et al., 2013; McBride, 2015). 
It allows patients to change their negative and distorted thoughts into more positive and realistic 
ones and to confront the situations and beliefs that cause them to feel anxious and fearful. Side 
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effects of CBT are minimal but may include emotional vulnerability, emotional discomfort, 
frustration, crying, anger, feeling physically drained, temporary stress, and temporary anxiety as 
a result of addressing such sensitive thoughts (May Clinic, 2018a). CBT is a long-term therapy 
that typically yields success with higher patient engagement and attendance (Bystritsky et al., 
2013). It often involves the use of manuals or daily homework to promote the learning of 
methods to reduce negative reactions to anxiety, modification of irrational thoughts, and 
development of coping skills. There are many different types of CBT programs. However, 
efficacy and long-term outcomes are comparable among those most commonly used (McBride, 
2015). Due to the lack of available CBT therapists and affordable sessions, there is a call for 
making CBT more accessible in primary care through education and training (Bystritsky et al., 
2013). Self-administered CBT currently serves to help fill this void. There is evidence to support 
the effectiveness of self-administered CBT, and its efficacy via different methods of 
dissemination continues to be further explored through research and evidence-based practice 
(EBP). 
 Evidence supports the effectiveness of pharmacologic therapy for GAD with selective 
serotonin reuptake inhibitors (SSRIs), which are classified as antidepressant medications 
(Edmund & Sheppard, 2018). SSRIs are considered first-line therapy. Several weeks of SSRI 
use may be necessary to achieve maximal effects. SSRIs work by increasing serotonin activity 
(Hirsch & Birnbaum, 2019). Serotonin, or 5-hydroxytrptamine (5-HT), is a neurotransmitter 
released in the brain. The pharmacodynamics of SSRIs allows them to decrease action of the 
presynaptic serotonin reuptake pump by 60-80%, increasing the amount of time that serotonin is 
thus available at the synapse. This, in turn, increases serotonin activity by increasing the 
number of receptors occupied by serotonin at the postsynaptic neuron. Examples of SSRI 
medications include fluoxetine, paroxetine, citalopram, escitalopram, and sertraline. Side effects 
of SSRIs may include gastrointestinal symptoms such as nausea and diarrhea, sexual 
dysfunction such as decreased libido or erectile dysfunction, insomnia, headache, blurred 
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vision, drowsiness, dry mouth, nervousness, agitation, restlessness, dizziness, and possible 
weight gain (Edmund & Sheppard, 2018; Mayo Clinic, 2018b). Drug interactions, serotonin 
syndrome, and pregnancy risks are associated with some SSRIs. Paroxetine and escitalopram 
are the only Food and Drug Administration (FDA) approved SSRIs. Other medications often 
used in the treatment of GAD that are not first-line agents include serotonin-norepinephrine 
reuptake inhibitors (SNRIs) and benzodiazepines. Examples of SNRIs include venlafaxine, 
desvenlafaxine, and duloxetine. SNRIs may cause side effects including weight gain, nausea, 
insomnia, constipation, sweating, and increased blood pressure. Venlafaxine and duloxetine are 
the only FDA approved SNRIs. Buspirone is another medication often used. However, it is often 
incorrectly prescribed as needed rather than on a scheduled basis. Despite its efficacy, it can 
increase the risk of serotonin syndrome in patients taking additional serotonergic medications. 
Benzodiazepines also are effective yet pose a multitude of risks including the potential for 
dependence, tolerance concerns, difficulty weaning or discontinuing, and adverse reactions of 
amnesia, rebound anxiety, diminished psychomotor performance, or withdrawal symptoms. 
Additional information regarding anti-anxiety medications is presented in Table 1.1 (Bystritsky, 
2019; Hirsch & Birnbaum, 2019). 
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Table 1.1 
Anti-Anxiety Medications 
Medication Class Use Examples Risks Side Effects 
 
Selective 
Serotonin 
Reuptake 
Inhibitors 
(SSRIs) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Serotonin-
Norepinephrin
e Reuptake 
Inhibitors 
(SNRIs) 
 
 
 
 
 
Benzodiazepin
es 
 
 
 
 
 
 
 
 
Anti-
depressant 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Anti-
depressant 
 
 
 
 
 
 
 
 
Sedative/ 
Hypnotic/ 
Anxiolytic  
 
 
 
 
 
 
 
First line 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NOT first line 
 
 
 
 
 
 
 
 
 
NOT first line 
 
 
 
 
 
 
 
 
 
Citalopram 
Escitalopram 
Fluoxetine 
Fluvoxamine 
Paroxetine 
Sertraline 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Desvenlafaxin
e 
Duloxetine 
Levomilnacipr
an 
Milnacipran 
Venlafaxine 
 
 
 
Alprazolam 
Clonazepam 
Diazepam 
Lorazepam 
 
 
 
 
 
 
Generally well 
tolerated and 
safe; risks – 
serotonin 
syndrome, 
drug 
interactions, 
pregnancy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Potential for 
dependence, 
tolerance 
concerns, 
difficulty 
weaning or 
discontinuing 
 
 
 
Gastrointestin
al symptoms 
such as 
nausea and 
diarrhea, 
sexual 
dysfunction 
such as 
decreased 
libido or 
erectile 
dysfunction, 
insomnia, 
headache, 
blurred vision, 
drowsiness, 
dry mouth, 
nervousness, 
agitation, 
restlessness, 
dizziness, 
weight gain 
 
 
 
Weight gain, 
nausea, 
insomnia, 
constipation, 
sweating, 
increased 
blood pressure 
 
 
 
Amnesia, 
rebound 
anxiety, 
diminished 
psychomotor 
performance, 
or withdrawal 
symptoms 
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Serotonin 
Modulators 
 
 
 
 
 
 
 
 
 
 
Tricyclic and 
Tetracyclic 
Antidepressan
ts (TCAs) 
 
 
 
 
 
 
 
 
 
 
 
 
Atypical 
Agents 
 
 
 
 
 
 
 
 
 
 
 
Monoamine 
Oxidase 
Inhibitors 
 
 
 
 
 
 
 
Anti-
depressant 
 
 
 
 
 
 
 
 
 
 
Anti-
depressant 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Anti-
depressant 
 
 
 
 
 
 
 
 
 
 
 
Anti-
depressant 
 
 
 
 
 
 
 
 
NOT first line 
 
 
 
 
 
 
 
 
 
 
 
NOT first line 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NOT first line 
 
 
 
 
 
 
 
 
 
 
 
 
NOT first line 
 
 
 
 
 
 
 
 
 
Nefazodone 
Trazodone 
Vilazodone 
Vortioxetine 
 
 
 
 
 
 
 
 
Amitriptyline 
Amoxapine 
Clomipramine 
Desipramine 
Doxepin 
Imipramine 
Maprotiline 
Nortriptyline 
Protriptyline 
Trimipramine 
 
 
 
 
 
 
Agomelatine 
Bupropion 
Mirtazapine 
 
 
 
 
 
 
 
 
 
 
Isocarboxazid 
Phenelzine 
Selegiline 
Tranylcypromi
ne 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Drowsiness, 
orthostatic 
hypotension, 
QTc 
prolongation, 
gastrointestina
l upset, weight 
gain, sexual 
dysfunction 
 
 
 
Anticholinergic 
effects, 
drowsiness, 
insomnia, 
agitation, 
orthostatic 
hypotension, 
QTc 
prolongation, 
gastrointestina
l upset, weight 
gain, sexual 
dysfunction 
 
 
 
Drowsiness, 
anticholinergic 
effects, 
insomnia, 
agitation, QTc 
prolongation, 
gastrointestina
l upset, weight 
gain, sexual 
dysfunction 
 
 
 
Anticholinergic 
effects, 
drowsiness, 
insomnia, 
agitation, 
orthostatic 
hypotension, 
gastrointestina
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Azapirones 
 
 
 
 
 
 
 
Anxiolytic/ 
Antipsychotic 
 
 
 
 
 
 
 
NOT first line 
 
 
 
 
 
 
 
 
 
Buspirone 
Gepirone 
Ispaprione  
 
l upset, weight 
gain, and 
sexual 
dysfunction 
 
 
 
Dizziness, 
nausea, 
headache, 
insomnia, 
agitation 
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There is a call among the literature for providers to be more aware of the prevalence and 
severity of GAD, express greater sensitivity in the treatment of mental health, be more diligent 
and knowledgeable in assessing and diagnosing those affected, make treatment of GAD a 
priority, and provide better and earlier management of GAD among children, adolescents, and 
adults (McBride, 2015). This call also includes a need for more knowledgeable administration of 
effective interventions in primary care and the communication of such effective treatment to the 
public (Bystritsky et al., 2013). It is important to raise awareness that GAD is treatable and to 
widely disseminate best practice (McBride, 2015). There is overwhelming support that the best 
treatment for GAD is the combination of an SSRI and CBT. The development of a trusting 
relationship between the provider and patient with a team-based approach including patient 
involvement in treatment decisions has been shown to be beneficial (Edmund & Sheppard, 
2018). Effective treatment requires time and effort on behalf of both the provider and patient. 
There is much evidence to support a need for this project, which includes all of these necessary 
components based upon best practice and aims to improve these shortcomings in current 
clinical practice. 
Data from the Clinical Agency Supporting Need for the Project 
 The clinical agency where this EBP project was conducted was a family practice clinic in 
Northwest Indiana (E. Strutz, personal communication, July 10, 2018). This clinic is owned by a 
nurse practitioner (NP) who is the sole provider in office. A collaborative agreement with a 
physician located outside of the practice is in place who reviews 5% of the patient charts. Two 
medical assistants also provide patient care. The NP and office manager approved the project 
and served as the site facilitators. Clinical agency data were provided by the office manager. 
This primary care office was opened in April 2012. Care is provided to an age range of infants to 
adults, from birth to death. Approximately 105 patients are seen in the office each week, and 
approximately 15% of these patients have depression and/or anxiety, with data remaining rather 
consistent throughout the entire year. 
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 The rural town in which this clinical agency is located has a population of approximately 
909 residents with a diversity index of 20, which represents the likelihood on a scale from 0 to 
100 that two people selected at random from the town will be of different race or ethnicity (Home 
Town Locator, Inc. 2018). A population consisting of only one race and one ethnic group would 
have a diversity index of 0, indicating a lack of diversity. When there is an even distribution of 
two or more race or ethnic groups in an area, the diversity index is 100. When compared to 
other Indiana towns, this town is considered to be within the upper quartile for diversity. The 
average household income of residents is $54,153, the average home value is $146,272, and 
the average family size is three (Home Town Locator, Inc., 2018). The unemployment rate in 
this town is 7.6%, and 8.7% live in poverty. Approximately 45.5% of residents have obtained a 
high school diploma, and approximately 6.2% have obtained a bachelor’s degree. The median 
age of town residents is 29.6 compared to 37.4 for the state of Indiana (Stats America, 2016). 
The clinical agency provides care to patients from this town as well as neighboring towns. 
 The office manager, NP, and medical assistants at this office have passionately 
supported this EBP project, its goals, and its great need in practice since initial contact and 
proposal of the project (L. K***, personal communication, June 11, 2018). They discussed that a 
significant number of patients present to their office with GAD, and the stigma and barriers to 
treatment pose great challenges. They have mentioned their struggles with and reservations in 
prescribing benzodiazepines for patients as well as the reluctance of some patients to fulfill their 
referrals to psychiatric care and counseling. As a result of such challenges, they have 
expressed their difficultly in consistently following best practice recommendations. A protocol 
such as the one developed by this EBP project has not been previously implemented nor 
currently exists at the practice. The staff has expressed their interest in the help that this project 
can provide them in effectively treating patients with GAD and improving patient outcomes. The 
project manager and staff at the clinical agency believe that this project can be very beneficial to 
this practice, make a difference in the quality of life and symptomology of their patients with 
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GAD, and help serve as a guide for NPs to facilitate such positive outcomes and proper 
treatment plans. This is congruent with the mission statement of the clinical agency which 
expresses this practice’s commitment to high quality of life (K. Family Medicine, 2018). 
Purpose of the Evidence-Based Practice Project 
Compelling Clinical Question 
 The purpose of this EBP project titled, Anxiety is Something to Worry About: The Effects 
of a Cognitive Behavioral Therapy and Selective Serotonin Reuptake Inhibitor Intervention 
Protocol on Generalized Anxiety Disorder, was to improve treatment of GAD by developing and 
implementing an evidence-based protocol including CBT and SSRI use. Thus, a protocol for 
NPs and other providers to utilize in order to provide proper and consistent treatment of patients 
with GAD via SSRI use and CBT to yield best patient outcomes was provided. The project 
explored the effects of SSRI use and self-administered CBT on symptoms of GAD experienced 
by patients across much of the lifespan. The aims of the project included decreasing patient 
symptoms of GAD, increasing knowledge of providers regarding appropriate care of patients 
with GAD, and raising awareness for GAD and its treatable nature. EBP involves the translation 
of the best available evidence into clinical practice in order to foster the highest quality of care 
and best patient outcomes. It begins with clinical inquiry, which entails gathering data to 
evaluate available treatment in order to determine the best choice. Such clinical inquiry led to 
the development of the following compelling clinical question (Melnyk & Fineout-Overholt, 
2015). What is the best way to decrease symptoms of generalized anxiety disorder (GAD) 
among affected adults in primary care?  
PICOT Question 
 Clinical questions are often clearly posed in PICOT format with (P) standing for patient 
population/disease of interest, (I) for intervention or issue of interest, (C) for comparison 
intervention or issue of interest, (O) for outcome of interest, and (T) for time over which the 
population is observed (Melnyk & Fineout-Overholt, 2015). The following PICOT question was 
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developed to guide the EBP project: Among adults presenting with generalized anxiety disorder 
(GAD) in the family practice setting (P), does the introduction of an intervention protocol to treat 
patients with a selective serotonin reuptake inhibitor (SSRI) and self-administered cognitive 
behavioral therapy (CBT) via bibliotherapy (I) compared to the current practice of no protocol 
(C), improve GAD symptoms as measured by patient-reported scores on the Generalized 
Anxiety Disorder 7-item (GAD-7) scale (O) over a 12-week period (T)? 
Significance of the EBP Project 
 As treatment of GAD often begins in primary care, providers in this setting have a vital 
role in ensuring that those affected receive proper care. This project aimed to implement a 
practice change based on current, quality evidence-based practice recommendations. Such 
practice change consisted of a protocol including SSRI and CBT use for the best treatment of 
patients affected by GAD in the family practice setting. This EBP project aimed to fight the 
stigma associated with mental illness and to give GAD the recognition it deserves in order for 
individuals with GAD to receive timely care that allows them to live healthier lives. Accurate 
measurement of outcomes provided greater understanding of interventions and their effects on 
a multitude of different aspects, including symptom severity, comorbid depression, acceptability 
of treatment, and much more. The project ultimately served to significantly reduce worry, 
decrease the rate of suicide, and allow individuals affected by GAD to gain back control of their 
lives and enjoy every day. As application of this protocol expands to other family practice 
settings, it can assist providers in gaining further knowledge and skills regarding appropriate 
treatment of GAD and thus, better equip them to care for this population. This will aide in 
continuity and quality of care provided, as there is currently much discourse and lack of unity in 
the treatment of GAD. In addition, this will support early treatment of GAD and help to prevent 
delays in care. Finally, by implementing such best practice recommendations, patients can 
receive greater relief of GAD symptoms, which may translate into improvement of many areas 
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of their lives, including greater quality of life. By facilitating a focus on self-care, wellness can be 
achieved.  
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CHAPTER 2 
THEORETICAL FRAMEWORK, EBP MODEL, AND REVIEW OF LITERATURE 
Theoretical Framework 
 After thorough review of many theoretical frameworks and EBP models, the Neuman 
Systems Model and Stetler Model respectively, were selected to aide in the development of this 
EBP project based on their applicability to the core components of the project. The Neuman 
Systems Model was highly applicable due to its premise of environmental stressors eliciting a 
reaction in a person based in part on his or her ability to cope with such stressors as well as the 
model’s aim for the person to achieve their highest level of wellness possible (Neuman & 
Fawcett, 2011). These components are important as this project included the incorporation of 
best practice for the treatment of GAD in order to help patients learn to cope with stressors that 
cause them anxiety to yield improved quality of life. The Stetler Model served as a guide for the 
EBP process of this project with its five detailed steps for development, implementation, and 
analysis in order to foster successful integration of practice change and worthwhile conclusions 
(Melnyk & Fineout-Overholt, 2015). A comprehensive review of the literature was performed in 
order to determine best practice interventions for the treatment of GAD as well as details 
regarding their efficacy and the best methods of implementation. A description, appraisal, and 
synthesis of such literature will be presented in order to disseminate best practice 
recommendations in the form of a protocol for patients with GAD. 
Overview of Theoretical Framework 
The Neuman Systems Model was utilized to guide this endeavor due to its ideal 
relevance to examining the influence of the use of SSRIs and self-administered CBT among 
patients presenting with GAD. This model’s development began in 1970 by Betty Neuman after 
her efforts in teaching University of California, Los Angeles (UCLA) graduate students led her to 
the conclusion that nurse educators and practitioners were in need of a comprehensive  
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framework to guide a variety of nursing contexts (Neuman, 1982). It served an initial purpose as 
a teaching tool and a way to unify student learning (Neuman & Fawcett, 2011). The model was 
first published in 1972 in an article in Nursing Research, and in 1982, Neuman published the 
first edition of a book detailing the model and its application to nursing. 
A holistic, wellness-oriented focus can describe the Neuman Systems Model, which has 
an overall nursing goal to “facilitate optimal wellness for the client through retention, attainment, 
or maintenance of client system stability” (Neuman & Fawcett, 2011, p. 3). Optimal wellness is 
deemed the highest degree of system stability at any given point in time, and wellness is 
gauged on a continuum from the highest degree of wellness to severe illness or death (Neuman 
& Fawcett, 2011). The client is viewed as an open system and can refer to individuals, groups, 
families, communities, or societies. The client system considers a holistic perspective that 
includes the following five variables: physiological, psychological, sociocultural, developmental, 
and spiritual. The model is based on the client’s continuous relationship with and potential 
reaction to stressors within the environment. The open system includes input, output, and 
feedback and allows for an individual to adjust to internal and external environmental stressors. 
Thus, flexibility and change exist to help the client conquer challenges and meet the model’s 
goal of attaining stability. 
The model is pictorially represented by a centrally located basic structure that is 
surrounded by concentric circles depicting lines of resistance and defense (Neuman & Fawcett, 
2011). The basic structure possesses characteristics common to all organisms, including human 
processes, genetic features, and survival factors, as well as characteristics that are unique to 
each client, including the five aforementioned variables. The lines of resistance surround the 
basic structure. The normal line of defense surrounds the lines of resistance. The flexible line of 
defense surrounds the normal line of defense. A greater degree of protection is provided 
amongst the outer most concentric circle as compared to the inner most concentric circle. The 
lines of resistance are called to action when the normal line of defense has been invaded by 
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stressors. These resistance lines, which are made of internal and external resources that the 
client may be consciously aware of or unaware of, strive to protect the integrity of the system. 
The normal line of defense denotes the stability and integrity of the system and is dynamic as 
the client faces different stressors at different times of life. The flexible lines of defense are also 
dynamic and form a protective barrier to prevent stressors from impacting the client’s state of 
stability. When such lines of defense are unsuccessful in preventing penetration by stressors, a 
reaction is elicited by the client. Coping methods, lifestyle, and developmental, spiritual, and 
cultural factors influence the success or failure of the lines of resistance and defense. 
Application of Theoretical Framework to EBP Project 
There is a strong relationship between the concepts of stress and anxiety. Stress can be 
defined as the interaction between environmental stimuli, or stressors, and stress response 
systems. Anxiety is characterized by behavioral, cognitive, and physiologic responses that occur 
when faced with uncertain or threatening stimuli (Chen, George, & Liberzon, 2017). Anxiety may 
characterize a client’s response to stress or may serve as a potential stressor. The Neuman 
Systems Model “takes into account all variables affecting a client’s possible or actual response 
to stressors and explains how system stability is achieved in relation to environmental stressors 
imposed on the client” (Neuman & Fawcett, 2011, p. 3). Thus, the Neuman Systems Model is 
applicable to this EBP project centered upon utilizing best practice interventions implemented by 
NPs to decrease symptoms and feelings of anxiety among patients presenting with GAD in the 
family practice setting. Thus, the best practice interventions of SSRIs and CBT contribute to the 
model’s goal of attaining stability as their purpose is to help patients identify, respond to, and 
cope with their environmental stressors in a healthy manner that can be maintained.  
Neuman believed in using her philosophy of “helping each other live” in order to 
contribute to the development of this model (Neuman & Fawcett, 2011). This philosophy is 
upheld by the NPs assessing, diagnosing, treating, and evaluating patients with GAD as their 
goal is to help patients with anxiety live better and achieve and maintain an optimal level of 
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wellness through coping with and reducing anxiety levels. The Neuman Systems Model can 
help guide practicing nurses and NPs caring for patients with GAD as it allows them to explore 
complexities of the individual and develop assessment and intervention skills that stem from 
such nursing model. It is also useful in guiding the education and practical training of nursing 
students and helps teach them to treat clients as individuals. GAD is often unique to each 
individual and complex in nature to treat due to a multitude of factors, including the challenge of 
addressing the mind, which can be considered intangible and invisible. Thus, use of the 
Neuman Systems Model can greatly aide in the treatment of GAD. 
Strengths and Limitations of Theoretical Framework for EBP Project 
Strengths of the use of the Neuman Systems Model as the theoretical framework for the 
EBP project include its global applicability, which allows for its use among the variety of cultures 
present at the project site as well as for generalizability across all cultures (Neuman & Fawcett, 
2011). In addition, the model has a holistic perspective, which is at the forefront of the discipline 
of nursing. The four concepts of the nursing metaparadigm, including human beings, 
environment, health, and nursing, are related to the main concepts of the model. The model’s 
goal of forming a relationship between clients and caregivers and establishing desired “goals for 
optimal health retention, restoration, and maintenance” is consistent with the goal of the EBP 
project (Neuman & Fawcett, 2011, p. 12). The EBP project aimed to establish a trusting 
relationship between patient and NP in the treatment of GAD utilizing best practice interventions 
and patient motivation in order to minimize the damage cause by stressors by decreasing 
anxiety. This was achieved through the use of this model due to such congruent values. 
 Limitations of the use of the Neuman Systems Model include the risk of oversimplifying 
its application and failing to address all parts and subparts of the system as well as their 
relationship to one another and the environment (Neuman & Fawcett, 2011). “When used 
correctly, however, a systems model dramatically and convincingly demonstrates the nature of a 
process, which leads to better understanding and more accurate prediction of outcomes” 
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(Neuman & Fawcett, 2011, p. 9). Thus, this advocates for proper use of the theoretical 
framework and the consideration of complex phenomena, such as that of GAD. It may be 
difficult to view client system variables and boundaries clearly due to their dynamic and ever-
changing nature. However, each part and subpart of the system must be studied individually in 
order to understand its role in relationships and stability of the whole system. Thus, continually 
adapting to changing stressors and causes of anxiety throughout the patient’s lifespan is vital to 
maintenance of stability and optimal wellness. 
Evidence-based Practice Model 
Overview of EBP Model 
In addition to a theoretical framework, an EBP model, the Stetler Model, was also 
selected to facilitate this EBP project. The Stetler Model has transformed through numerous 
revisions since its debut in 1976 and has broadened its focus from that of research utilization to 
evidence-based nursing practice (Melnyk & Fineout-Overholt, 2015). While the model originally 
only referred to the application of research findings to practice, the latest version encompasses 
research findings, quality improvement data, operational data, and “…the consensus of 
recognized experts and affirmed experience to substantiate practice” [Stetler et al., 1998, p. 
49])” (Melnyk & Fineout-Overholt, 2015, p. 279). The inclusion of external evidence, which 
results from rigorous research, as well as internal evidence, which results from projects within 
the clinical practice setting is a key component. The model is centered on the movement of 
evidence to practice, utilization of critical thinking, improvement in current practice, change in 
current ways of thinking, and implementation of safe and effective findings.  
It “outlines a series of steps to assess and use research findings to facilitate safe and 
effective evidence-based nursing practice” (Melnyk & Fineout-Overholt, 2015, p. 279). These 
five steps are clearly delineated and described and include 1) preparation, 2) validation, 3) 
comparative evaluation/decision making, 4) translation/application, 5) evaluation, which 
contribute to the ease with which this model can be followed in order to implement an EBP 
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project successfully (Melnyk & Fineout-Overholt, 2015). Detailed graphics of these steps 
provided by the model aide in its understanding. The preparation phase is characterized by 
determining a need worth addressing and beginning a relevant literature search. The validation 
phase includes a critical appraisal of each piece of evidence as well as synthesizing this 
evidence. During the comparative evaluation/decision making phase, utilization criteria are used 
to determine whether evidence should be used for the practice change. The next phase of 
translation/application requires planning and implementing an EBP change by converting 
findings into operational use. Finally, during the evaluation phase, goals are evaluated for 
completion, and implementation of the plan is reviewed. 
There are many important assumptions of the Stetler Model (Melnyk & Fineout-Overholt, 
2015). The model assumes that research findings can be utilized in the clinical setting. 
Consideration of patient individuality and preferences is necessary to implement the model 
appropriately for each patient. Practitioners who are competent in research utilization and EBP 
can use this model to improve practice, alter ways of thinking, and develop new strategies. 
Advanced-level practitioners are better equipped to accomplish such advances in clinical 
practice due to their advanced critical thinking skills and knowledge. Baccalaureate-prepared 
providers should be encouraged to contribute to these endeavors in collaboration with 
advanced-level providers. Another assumption of the model is the ability to use research 
findings and other evidence in varying ways. Strength of the evidence must be considered for 
safe use of evidence in multiple ways.  
Application of EBP Model to EBP Project 
The Stetler Model is applicable to this EBP project for a variety of reasons. The evidence 
supporting the interventions of CBT and an SSRI for the reduction of anxiety symptoms among 
with GAD strongly calls for the inclusion of patient preferences, which is also a central 
component of this model (Melnyk & Fineout-Overholt, 2015). Facilitating safe and effective 
evidence-based nursing practice through the translation of evidence to practice describes the 
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purpose of the Stetler Model, which also is the purpose of the EBP project with an aim to 
change current treatment of GAD in accordance with best practice recommendations to yield 
the most effective outcomes.  
The five steps of the Stetler Model served as a detailed guide for the project. During the 
preparation phase, the project manager identified a problem with current treatment of GAD and 
a need to address this after experience in the clinical setting with a significant number of 
patients presenting with GAD. An exhaustive literature search was completed in order to 
determine best practice that included a search of seven databases as well as citation chasing. 
The validation phase of the model fostered a critical analysis, quality appraisal, and summary of 
the evidence by the project manager, which yielded sources of good and high quality evidence 
that supported best practice via combined CBT and SSRI use. Throughout the comparative 
evaluation/decision making phase, the evidence was organized and a decision to use the 
evidence was made based on sufficient, strong, and current available evidence. The 
translation/application phase allowed the project manager to apply these findings to practice 
and implement a feasible plan in a family practice clinic with the support of NPs who were 
greatly invested in the project. Finally, the evaluation phase was utilized to evaluate outcomes 
of the practice change, attainment of goals, success of the implementation, overall effect of the 
intervention on symptoms of anxiety and other measures, and sustainability of the practice 
change. 
Strengths and Limitations of EBP Model for EBP Project 
Limitations of the use of the Stetler Model to guide the EBP project include its complex 
appearance via graphic representation including the five steps, numerous components within 
each step, and multi-directional arrows to indicate fluidity (Melnyk & Fineout-Overholt, 2015). A 
thorough review of the model is necessary to facilitate understanding and obtain clarity. While 
the model helps to anticipate important needs and aspects regarding the intended practice 
change, certain variables may be unpredictable. Thus, despite adequate use of the five phases 
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of the Stetler Model, a level of flexibility must be maintained, and changes to the original plan 
may be necessary. For example, the model was used by Romp and Kiehl (2009) in order to 
improve a nursing preceptor program at a large medical facility. After careful development using 
the appropriate stages of the model, it was discovered during implementation that many 
preceptors were unable to attend scheduled classes while interest in the classes continued. 
Thus, additional classes as well as both individual and group sessions were scheduled to aide 
in this unforeseen problem that occurred. 
Strengths of the Stetler Model as a guide for the EBP project include its revisions to 
remain current and encompass not only research findings, but also EBP (Melnyk & Fineout-
Overholt, 2015). The model is useful for individual practitioners, including NPs with knowledge 
in their area of practice, and also for groups to translate research to practice (Snyder et al., 
2011). Its detailed steps emulate the nursing process and can be followed to increase the 
likelihood of successful practice change and to answer the clinical question at hand. In addition, 
the model encourages the evaluation of such practice change and promotes further research. 
The model strongly supports critical thinking as well as changes in ways of thinking (Snyder, 
Facchiano, & Brewer, 2011; Stetler, 2001). It involves making decisions regarding feasibility, 
applicability, and the substantiality of evidence and aims to reduce barriers to practice change. 
The study by Romp and Kiehl (2009) showed that by exploring a multitude of aspects among 
each of the five phases of the Stetler Model, considerations that may have been otherwise 
overlooked were able to be addressed in order to help avoid challenges and failures. Successful 
outcomes were yielded as the Stetler Model helped to develop a detailed plan, thoughtful 
preparation, and effective application of EBP to increase nurses’ satisfaction with their 
preceptors and ultimately, increase rates of nurse retention with an improved nursing preceptor 
program. Positive outcomes were also elicited by another study conducted by Snyder and 
colleagues (2011) in which the Stetler Model was followed in order to change practice by 
increasing screening for anxiety among patients with Parkinson’s Disease. This model allowed 
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for several quality aspects to be upheld through this translation of EBP to practice, including 
patient safety, effectiveness of interventions, patient-centered care, timely and early recognition 
and treatment, efficient utilization of best practice, and equal opportunity for care.  
Literature Search 
Sources Examined for Relevant Evidence 
An exhaustive relevant literature search was performed in order to support the spirit of 
inquiry regarding best practice for the treatment of GAD in the family practice setting by NPs. A 
total of seven databases were searched, including CINAHL, ProQuest, MEDLINE via EBSCO, 
Joanna Briggs Institute, National Guideline Clearinghouse, PsycINFO, and Cochrane Library. 
CINAHL, ProQuest, and MEDLINE were selected based on their ability to yield large volumes of 
individual studies. The Joanna Briggs Institute and Cochrane Library were utilized due to their 
inclusion of high levels of evidence of multiple studies. The National Guideline Clearinghouse 
was selected as it includes clinical guidelines regarding a wide variety of healthcare topics. 
PsycINFO was utilized based on its applicability to the psychological topic of GAD upon which 
the project centers. Citation chasing from the results yielded was also utilized in order to explore 
all relevant evidence. After trialing a multitude of searches in each database, the keywords 
selected for the final best literature search yielding the most relevant and appropriate quantity of 
results were “generalized anxiety disorder*” OR “anxiety disorder*” AND (treat* OR manag*) 
AND (“primary care” OR “family practice”). MeSH (medical subject heading terms) and CINAHL 
subject headings in CINAHL, MEDLINE via EBSCO, ProQuest Nursing and Allied Health 
Database, and PsycINFO for generalized anxiety disorder and anxiety disorders were used in 
the search to encompass all terms describing such topic. Truncation symbols, quotation marks, 
and parentheses also helped to yield all relevant sources.  
Inclusion criteria for the literature search consisted of scholarly, peer-reviewed sources, 
date range of 2013 to 2018 for sources published within the last five years, English language, 
and age groups of child: 6-12 years, adolescent: 13-18 years, adult: 19-44 years, middle aged: 
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45-64 years, aged: 65+ years, and aged, 80 and over. It was decided that such criteria would 
lead to the most trustworthy, current, understandable, and applicable evidence. Additional 
inclusion criteria included evidence that pertained to the primary care, family practice, or 
outpatient setting, a population of children, adolescents, and/or adults, and a population 
diagnosed with anxiety disorder or generalized anxiety disorder. Exclusion criteria was defined 
as pertaining to the hospital or inpatient setting, population of infants or children under 6-years-
old, outcomes comparing anxiety levels prior to and after surgical procedures, poor initial quality 
appraisal, and diagnoses of depression only, social anxiety disorder only, panic disorder only, 
post-traumatic stress disorder only, health anxiety only (also known as hypochondriasis), or 
mental health disorder with no further classification of generalized anxiety disorder or anxiety 
disorder specified. Initially, it was determined to exclude sources focused on anxiety related to 
health conditions or diseases, such as cancer. However, this was revised after further 
exploration as comorbidities are very prevalent in the United States and often cause or 
exacerbate anxiety in patients, and a patient’s stated reason for anxiety is always valid as it is 
his or her own feeling. After a thorough literature search indicated that the majority of available 
evidence supported interventions including SSRIs and CBT, pieces of evidence detailing 
treatment focused on diet, exercise, mindfulness interventions, or classes of medications other 
than SSRIs were excluded. Evidence related to CBT was individually evaluated for relevance to 
self-administered CBT in the form of workbooks for anxiety and excluded if deemed irrelevant or 
inapplicable to such administration method. Exceptions were made on a case by case basis 
when literature was deemed worthy of inclusion despite lack of self-administration method of 
CBT. Some evidence regarding CBT in general, without specification of administration method, 
was included. 
An initial literature search began in the Joanna Briggs Institute database. A search using 
the keyword anxiety and a publication date within the last five years (2013 to current) proved too 
broad as 774 results were yielded. After modifying the search with the keywords generalized 
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anxiety disorder and the same date range limiter, an acceptable quantity of 21 results to review 
was populated. However, upon review of titles, it was determined that this search was too 
narrow. After many different search attempts, the most appropriate, relevant, and inclusive 
search was deemed as the aforementioned best search, which encompassed both generalized 
anxiety disorder and anxiety disorder as well as plural forms of the word disorder, the goal of the 
EBP project to treat or manage the condition, and the intended setting of primary care or family 
practice. A total of 17 sources were yielded, and four were accepted for inclusion in the final 
literature review. 
A thorough search of the Cochrane Library was then performed. A minor modification in 
the search terms utilized for this database was approved by the Valparaiso University library 
liaison, Kim Whalen, who assisted the literature search process. The terms “primary care” and 
“family practice” were omitted from the search to allow for inclusion of the most relevant pieces 
of evidence as several applicable pieces were not yielded when these terms were included. The 
final search yielded a total of 23 results, and 8 were deemed worthy of further review after 
assessing titles. Several were eliminated based on method of delivery of CBT intervention 
inapplicable to the EBP project, protocol only available, and treatment irrelevant to CBT or 
SSRIs. One was accepted to provide supporting evidence for the EBP project.  
The National Guideline Clearinghouse was searched for clinical guidelines to support the 
EBP project utilizing the initial best search. Although the National Guideline Clearinghouse 
database was no longer available after July 16, 2018, the EBP project manager decided to take 
advantage of the limited opportunity remaining as worthwhile, high quality, high level evidence 
can be obtained from this database. Twenty-two results populated, and upon initial review, it 
seemed than there were no applicable sources. However, further exploration led to further 
review and acceptance of two clinical guidelines for inclusion in the literature review.  
Upon continuing the literature search, the database CINAHL was searched for relevant 
evidence. Prior to implementing subject headings into the search, thousands of results were 
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yielded. Thus, after receiving guidance from Valparaiso University’s library liaison, it was 
deemed necessary to utilize CINAHL headings, which greatly refined the search. The final 
search utilizing (MH “Generalized Anxiety Disorder”) OR (MH “Anxiety Disorders”) AND (treat* 
OR manag*) AND (“primary care” OR “family practice”) with limiters of scholarly, peer-reviewed 
sources, published within the last five years, English language, and age groups of child: 6-12 
years, adolescent: 13-18 years, adult: 19-44 years, middle aged: 45-64 years, aged: 65+ years, 
and aged, 80 and over yielded a total of 28 results. After further review of 10 pieces of evidence, 
three were selected for the literature review. 
A search of the database MEDLINE via EBSCO included the MeSH subject heading 
(MH “Anxiety Disorders/CL/DI/DT/NU/PC/TH”). Such abbreviations stand for subheadings that 
were utilized to further narrow the search and include classification (CL), diagnosis (DI), drug 
therapy (DT), nursing (NU), prevention and control (PC), and therapy (TH). Such refining of the 
search helped to yield a sufficient number of relevant articles of which to review. Specifically, 
152 articles were yielded. After removing duplicates that had previously been reviewed through 
CINAHL and reviewing articles that were deemed worthy of further review, two were chosen as 
supporting evidence for the EBP project. 
ProQuest Nursing and Allied Health Database were then searched for applicable 
evidence using the MeSH subject heading Exact (“Anxiety Disorders”) as well as additional 
keywords and limiters aforementioned. A total of 42 articles were populated from this search. A 
total of seven duplicate articles that had already been found in CINAHL and/or MEDLINE were 
removed. After review of titles and abstracts of several pieces, no articles were deemed worthy 
of final inclusion. 
To conclude the literature search, the database PsycINFO was explored. Subject terms 
including DE “Generalized Anxiety Disorder” OR DE “Anxiety Disorders” were included in the 
search. Age groups selected were consistent with the other searches but had minor variances in 
categorization and those selected were school age (6-12 years), adolescence (13-17 years), 
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adulthood (18 years and older), young adulthood (18-29 years), thirties (30-39 years), middle 
age (40-64 years), aged (65 years and older), and very old (85 years and older). This yielded 
145 results. Although a large quantity of results, it was deemed that the search was 
appropriately narrowed and such a large amount of information regarding anxiety disorders 
could be expected to be found in a database related to psychological topics. After accounting for 
and removing a large total of 59 duplicates as well as reviewing relevant sources, no pieces 
were included as evidence for the project.  
Nine additional pieces of evidence were obtained via citation chasing from the reference 
lists of results yielded. Three were deemed worthy of inclusion. One was obtained from a 
citation chase of a Cochrane Library systematic review. A version of the review published in 
2016 was withdrawn from the Cochrane Library due to the review being “passed onto a new 
group of authors.” A 2003 version of this review was then found via citation chasing of the 2016 
piece, and an exception to accept this evidence with an older publication date was granted due 
to the circumstances and the meeting of inclusion criteria. Another systematic review was 
citation chased from an accepted evidence summary and met inclusion criteria. A third piece of 
evidence, a randomized controlled trial (RCT), was found via citation chasing through a relevant 
excerpt of the study found through CINAHL. 
In total, 436 pieces of evidence were yielded from the literature search. A review of titles 
led to the elimination of many sources due to failure to meet inclusion or exclusion criteria or 
irrelevance to GAD or the proposed interventions. Duplicate articles were accounted for and 
removed. Upon further review of titles and abstracts, 74 sources were deemed as warranting 
further, more extensive review based on inclusion criteria, applicability to the EBP project, and 
initial quality appraisal. After such review, a decision was made to include 15 of these pieces of 
evidence in the final literature review based on their ability to provide strong support for the EBP 
project. Data regarding the evidence search results are depicted in Table 2.1. 
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Table 2.1 
Evidence Search Table  
 
Note. Databases are listed in order of searches performed. JBI is Joanna Briggs Institute. NGC 
is National Guideline Clearinghouse. ProQuest is ProQuest Nursing & Allied Health Source. 
 
 
 
 
 
 
Database 
 
 
Yielded 
 
Duplicates 
 
 
Reviewed 
 
Accepted  
 
JBI 
 
 
 
17 
 
0 
 
9 
 
4 
Cochrane 
 
23 0 8 1 
NGC 
 
22 0 4 2 
CINAHL 
 
26 0 10 3 
MEDLINE 
 
152 10 19 2 
ProQuest 
 
42 7 4 0 
PsycINFO 145 59 11 0 
Citation Chase 9 0 9 3 
Total 436 76 74 15 
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Levels of Evidence 
In order to rank each piece of evidence appropriately by strength, Melnyk and Fineout-
Overholt’s (2015) Hierarchy of Evidence was utilized for this project. Such seven-level ranking 
system guides categorization among different types of literature in order to appraise the strength 
of the evidence. Greater strength of the evidence indicates a higher level of confidence that the 
evidence is likely to reliably answer a clinical question. This Hierarchy of Evidence includes 
Level I through Level VII evidence listed in order from highest level of evidence to lowest. This is 
currently depicted as a table with Level I evidence listed at the top as the highest level of 
evidence and Level VII evidence listed at the bottom as the lowest level of evidence. To begin, 
Level I evidence is evidence from systematic reviews or meta-analyses of all relevant RCTs, 
and level II evidence refers to evidence obtained from well-designed RCTs. Proceeding through 
the table, Level III evidence is characterized as evidence obtained from well-designed controlled 
trials without randomization while Level IV evidence includes evidence from well-designed case-
control and cohort studies. Level V evidence is described as evidence from systematic reviews 
of descriptive and qualitative studies whereas Level VI evidence is evidence from single 
descriptive or qualitative studies. Finally, level VII evidence is defined as evidence from the 
opinion of authorities and/or reports of expert committees. Fifteen total pieces of evidence were 
included for the final review of literature, including three evidence summaries (Level I), four 
systematic reviews (Level I), two clinical guidelines (Level I), four RCTs (Level II), one non-
randomized controlled trial (Level III), and one evidence summary (Level V). The levels of the 
selected pieces of evidence are illustrated in Table 2.2. 
 
 
 
 
Table 2.2 
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Levels of Evidence 
 
 
 
 
 
 
 
 
 
 
 
 
Appraisal of Relevant Evidence 
 
Level 
 
Included 
 
Quality 
 
Design 
 
I 
 
9 
 
A (6) 
B (3) 
 
Evidence Summary (3) 
Systematic Review (4) 
Clinical Guideline (2) 
 
 
II 4 A (2) 
B (2) 
 
 
 
RCT (4) 
 
 
 
III 1 B (1) Non-Randomized 
Controlled Trial (1) 
 
 
 
V 1 A (1) Evidence Summary (1) 
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 In addition to ranking the evidence by level, a critical appraise of the quality of each 
evidence was also conducted. Quality was appraised using the Johns Hopkins Research and 
Non-Research Evidence Appraisal Tool as well as the Appraisal of Guidelines for Research & 
Evaluation (AGREE II) Instrument. Permission was granted to utilize the Johns Hopkins 
Research and Non-Research Evidence Appraisal Tool, and such documentation is presented in 
Appendix B. The AGREE II Instrument is allowed to be reproduced and used for education and 
quality appraisals. The AGREE II Instrument was used for quality appraisal of evidence 
summaries and clinical guidelines, and the Johns Hopkins Research and Non-Research 
Evidence Appraisal Tool was used for quality appraisal of the remainder of the evidence, 
including systematic reviews, randomized controlled trials, and non-randomized controlled trials.  
The Johns Hopkins Research and Non-Research Evidence Appraisal Tool provides a 
thorough algorithm for determining the type of study design and assessing the quality of the 
evidence through a multitude of yes/no questions about the evidence (Dearholt & Dang, 2017). 
This tool delineates high quality (A) as evidence with “consistent, generalizable results; 
sufficient sample size for the study design; adequate control; definitive conclusions; consistent 
recommendations based on comprehensive literature review that includes thorough reference to 
scientific evidence” (Dearholt & Dang, 2017, p. 286). Good quality (B) is considered evidence 
with “reasonably consistent results; sufficient sample size for the study design; some control, 
and fairly definitive conclusions; reasonably consistent recommendations based on fairly 
comprehensive literature review that includes some reference to scientific evidence” (Dearholt & 
Dang, 2017, p. 286). Low quality or major flaws (C) is defined as “little evidence with 
inconsistent results; insufficient sample size for the study design; conclusions cannot be drawn” 
(Dearholt & Dang, 2017, p. 286). Of the 15 pieces of literature accepted for inclusion, nine were 
deemed of high quality, six were deemed of good quality, and none were deemed of low quality. 
Table 2.3 presents a summary and appraisal of the relevant evidence listed in alphabetical 
order by author. 
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The AGREE II Instrument provides a detailed structured format consisting of a total of 23 
items of consideration within six main domains as well as two items of global rating, or overall 
assessment, for determining the quality of guidelines (AGREE Next Steps Consortium, 2017). 
The six domains include scope and practice, stakeholder involvement, rigour of development, 
clarity of presentation, applicability, and editorial independence. The 23 core items are each 
scored via a 7-point Likert scale with 1 indicating strongly disagree and 7 indicating strongly 
agree. Domain scores are calculated by adding the scores of the items in each domain and 
using a mathematical equation including the obtained score and minimum and maximum scores 
possible to yield a percentage. These scores can be used to compare the quality of different 
guidelines. However, the tool has not differentiated scores indicating high, good, and poor 
quality but rather recommends that the user should consider all aspects of the tool and make 
this decision regarding quality.  
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Table 2.3 
 
Appraisal of Evidence 
 
 
 
Citation (APA) 
 
Purpose 
 
Design 
 
 
Sample 
 
Measurement/ 
Outcomes  
 
 
Results/Findings 
 
Level/ 
Quality  
Andersen, B. L., 
DeRubeis, R. J., 
Berman, B. S., 
Gruman, J., 
Champion, V. L., 
Massie, M. J., 
Holland, J. C., 
Partridge, A. H., 
Bak, K. 
Somerfield, M. R., 
& Rowland, J. H. 
(2014). Guideline 
summary: 
Screening, 
assessment, and 
care of anxiety 
and depressive 
symptoms in 
adults with cancer: 
An American 
Society of Cllinical 
Oncology 
guideline 
adaptation. 
Journal of Clinical 
Oncology, 32(15), 
1605-1619. doi: 
The purpose of 
this clinical 
guideline was to 
present the best 
screening, 
assessment, and 
care methods that 
should be utilized 
in the treatment of 
anxiety and 
depressive 
symptoms among 
adults with a 
coexisting 
diagnosis of 
cancer. 
 
 
This was a clinical 
guideline adapted 
from the American 
Society of Clinical 
Oncology. 
 
Pharmacologic 
and 
nonpharmacologic 
as well as 
psychological and 
psychosocial 
interventions were 
explored. 
 
The target sample 
population 
included adults 18 
years of age and 
older with any type 
of cancer, any 
disease stage, and 
undergoing any 
types of 
treatments who 
also were 
experiencing 
symptoms of 
depression and 
anxiety. 
 
A thorough 
systematic 
literature search 
was performed.  
 
The Generalized 
Anxiety Disorder 
(GAD)-7 scale was 
strongly 
recommended to 
measure 
symptoms of 
anxiety. 
 
Anxiety should be 
measured at the 
initial visit and at 
appropriate 
intervals 
depending on 
clinical indication, 
including change 
in disease status 
or transition to 
palliative care.  
 
Preferably, 
outcomes should 
be measured once 
per month, but at a 
minimum should 
be measured pre 
Patient 
preferences, 
shared decision 
making, and both 
pharmacologic 
and 
nonpharmacologic 
treatments are 
recommended. 
 
Psychological 
interventions 
should be based 
on treatment 
manuals that 
explain content 
and guide delivery. 
 
If there is no 
improvement in 
symptomology 
after 8 weeks of 
treatment, 
additional 
treatments should 
be added to the 
treatment regimen, 
Level I 
High quality 
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10.1200/JCO.2013
.52.4611 
 
 
and post-
treatment, in order 
to assess 
effectiveness, 
patient 
compliance, and 
patient 
satisfaction. 
 
medication should 
be changed, or the 
patient should be 
referred to 
psychotherapy. 
 
Assessment and 
Management of 
Risk for Suicide 
Working Group 
(2013). Guideline 
summary: VA/DoD 
clinical practice 
guideline for 
assessment and 
management of 
patients at risk for 
suicide. 
Department of 
Veterans Affairs, 
Department of 
Defense, 1-190. 
Retrieved from 
The National 
Guideline 
Clearinghouse. 
 
The purpose of 
this clinical 
guideline was to 
promote evidence-
based 
management of 
patients at risk for 
suicide. 
 
This was a clinical 
guideline. 
 
Interventions 
discussed 
included 
psychotherapy 
methods, including 
CBT, and 
medications, 
including 
antidepressants. 
 
 
 
The sample 
population 
included adult 
patients 18 years 
of age or older at 
risk for suicide 
with or without a 
mental disorder in 
the Department of 
Veterans Affairs 
(VA) and 
Department of 
Defense (DoD) 
clinical settings.  
 
A thorough 
literature search 
was performed. 
 
Patients with 
anxiety disorders 
should be asked 
about suicidal 
thoughts and 
behavior directly. 
 
Reassessment of 
suicidal ideation 
should regularly 
occur, particularly 
with changes in 
circumstances. 
 
Treatment with 
CBT and 
antidepressants 
may be beneficial 
for patients with 
anxiety disorders 
at risk for suicide. 
 
Close monitoring 
of patients who 
are prescribed 
antidepressants is 
necessary to 
assess for the 
emergence or 
worsening of 
suicidal thoughts 
during the initiation 
phase or after 
change in dose. 
 
Level I 
High quality 
 
Calleo, J. S., 
Bush, A. L., Cully, 
J. A., Wilson, N. 
L., Kraus-
Schuman, C., 
Rhoades, H. M., 
The purpose of 
this study was to 
explore the 
feasibility, 
satisfaction, and 
clinical outcomes 
The study design 
was a non-
randomized 
controlled trial. 
Participants 
engaged in CBT 
The sample 
included a total of 
19 older adults 
aged 60 years of 
age and older with 
GAD who were 
Outcomes 
measured 
included feasibility 
via attrition rates, 
satisfaction via exit 
interviews, worry 
Participants felt 
satisfied with 
treatment and felt 
that it helped them 
manage their 
Level III 
Good quality 
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Novy, D. M., 
Masozera, N., 
Williams, S., 
Horsfield, M., 
Kunik, M. E., & 
Stanley, M. A. 
(2013). Treating 
late-life 
generalized 
anxiety disorder in 
primary care: An 
effectiveness pilot 
study. The Journal 
of Nervous and 
Mental Disease, 
201(5), 414-420. 
doi: 
10.1097/NMD.0b0
13e31828e0fd6 
 
associated with 
CBT delivered by 
experienced and 
nonexperienced 
counselors. 
 
for 3 months 
provided by 
anxiety counselor 
specialists (ACSs) 
or counselors with 
no previous 
mental health 
training or 
experience.  
 
recruited in 
primary care 
clinics in the 
United States. 
 
via the Penn State 
Worry 
Questionnaire 
(PSWQ), and 
anxiety severity 
via the 
Generalized 
Anxiety Disorder 
Severity Scale 
(GADSS), the 
Beck Anxiety 
Inventory, and the 
Structured 
Interview Guide for 
the Hamilton 
Anxiety Scale. 
 
Outcomes were 
measured at 
baseline, 3 months 
after treatment 
initiation, and 6 
months after 
treatment 
initiation. 
 
anxiety (mean 
[SD], 3.61 [0.49]).  
 
PSWQ and 
GADSS scores 
significantly 
declined from 
baseline to 
3months among 
those who 
completed 
treatment. Other 
anxiety measures 
did not yield 
statistically 
significant effect 
size changes. 
 
There were no 
significant 
differences in 
results among 
patients treated by 
ACSs or 
counselors without 
training. 
 
Campbell, J. 
(2016). Evidence 
Summary: Anxiety 
disorders 
(Generalized 
Anxiety Disorder): 
Pharmacotherapy. 
The Joanna Briggs 
Institute, 1-3. 
The purpose of 
this evidence 
summary was to 
determine the best 
evidence for the 
pharmacologic 
treatment of GAD. 
 
This was an 
evidence 
summary. 
 
Interventions 
consisted of 
psychological 
therapy, 
medication, and 
The sample 
included patients 
with GAD from 
seven systematic 
reviews, one 
evidence-based 
guideline, one 
clinical guideline, 
one prospective 
Outcomes 
measured 
included the 
efficacy and 
tolerability of a 
multitude of 
medications 
including 
duloxetine (SNRI), 
The use of 
antidepressants 
for the treatment 
of GAD was given 
a Grade A 
recommendation. 
Fluoxetine (SSRI) 
was 
recommended for 
Level V 
High quality 
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self-care. CBT, 
anticonvulsants, 
antidepressants, 
and antipsychotic 
medications were 
involved in many 
of the studies 
included. 
 
trial, and one 
qualitative study. 
 
escitalopram 
(SSRI), fluoxetine 
(SSRI), lorazepam 
(benzodiazepine), 
paroxetine (SSRI), 
pregabalin 
(anticonvulsant), 
sertraline (SSRI), 
tiagabine 
(anticonvulsant), 
venlafaxine 
(SNRI), buspirone, 
and hydroxyzine.  
 
Anxiety symptoms, 
response rates, 
and remission 
status were also 
measured.  
 
its associated 
response and 
remission, and 
sertraline (SSRI) 
was 
recommended for 
its tolerability.  
 
SSRIs were found 
to reduce anxiety 
symptoms and 
should be 
considered first-
line treatment for 
GAD. 
 
CBT was also 
recommended in 
the treatment of 
GAD with a Grade 
B 
recommendation. 
 
The addition of 
CBT to the 
treatment regimen 
of patients taking 
an SSRI led to 
sustained 
remission from 
symptoms of 
anxiety and 
prevented long-
term 
pharmacotherapy. 
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Freshour, J. S., 
Amspoker, A. B., 
Yi, M., Kunik, M. 
E., Wilson, N., 
Kraus-Schuman, 
C., Cully, J. A., 
Teng, E. Williams, 
S., Masozera, N., 
Horsfield, M., 
Stanley, M. 
(2016). Cognitive 
behavior therapy 
for late-life 
generalized 
anxiety disorder 
delivered by lay 
and expert 
providers has 
lasting benefits. 
International 
Journal of 
Geriatric 
Psychiatry, 31(1), 
1225-1232. doi: 
10.1002/gps.4431 
 
 
The purpose of 
this study was to 
explore the effects 
of CBT delivered 
by bachelor-
prepared lay 
providers as 
compared to CBT 
delivered by PhD 
expert providers. 
 
This was a 
randomized 
controlled trial.  
 
Participants were 
randomly assigned 
to three groups 
including CBT 
administered by 
lay providers, CBT 
administered by 
expert providers, 
or usual care. 
 
A sample of 112 
older adults aged 
60 years or older 
were included and 
were recruited 
from internal 
medicine, family 
practice, and 
geriatrics clinics in 
Texas. 
 
Primary outcomes 
measured worry 
via the 
Generalized 
Anxiety Disorder 
Severity Scale and 
anxiety via the 
State-Trait Anxiety 
Inventory and the 
Structured 
Interview Guide for 
the Hamilton 
Anxiety Scale.  
 
Secondary 
outcomes 
measured 
included 
depression via the 
Patient Health 
Questionnaire, 
mental health 
quality of life via 
the Medical 
Outcomes Study 
Short Form, and 
sleep via the 
Insomnia Severity 
Index. 
 
Outcomes were 
measured 6 
months and 12 
months post 
initiation of 
treatment.  
There was no 
significant 
difference in 
outcomes among 
participants who 
received CBT 
delivered by 
bachelor-prepared 
lay providers and 
those who 
received CBT 
delivered by PhD 
expert providers 
(p>0.05).  
 
Improvements in 
worry and anxiety 
outcomes as well 
as changes in 
depression, 
mental health-
related quality of 
life, and insomnia 
were maintained 
at 6 and 12 month 
follow up. 
 
Level II 
High quality 
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Glenn, D., Rose, 
R. D., Stein, M. B., 
Bystritksy, A., 
Golinelli, D., Roy-
Byrne, P., 
Sullivan, G., & 
Sherbourne, C. 
(2013). Who gets 
the most out of 
cognitive 
behavioral therapy 
for anxiety 
disorders? The 
role of treatment 
dose and patient 
engagement. 
American 
Psychological 
Association, 81(4), 
639-649, doi: 
10.1037/a0033403 
 
 
The purpose of 
this study was to 
explore treatment 
dose and patient 
engagement as 
predictors of 
treatment 
outcome. 
This study design 
was a randomized 
controlled trial.  
 
Participants were 
randomized to the 
intervention group 
or the usual care 
group. Participants 
randomized to the 
intervention group 
could then select 
CBT only, 
pharmacotherapy 
only, or CBT and 
pharmacotherapy 
combined. 
A total of 1,004 
participants with a 
diagnosis of panic 
disorder, 
generalized 
anxiety disorder, 
social anxiety 
disorder, or 
posttraumatic 
stress disorder 
were enrolled in 
the study. 
The primary 
outcome of anxiety 
was measured via 
the Brief Symptom 
Inventory.  
 
Secondary 
outcomes 
measured 
included 
depression via the 
Patient Health 
Questionnaire and 
functional status 
via the Sheehan 
Disability Scale. 
 
Outcomes were 
measured at 
baseline, 12 
months, and 18 
months after the 
start of treatment. 
Results indicated 
that at both 12 and 
18 months, 
participants with 
low attendance in 
CBT sessions had 
higher scores on 
all outcome 
measures than 
patients with high 
attendance 
(p<0.029). 
 
Participants who 
were less 
homework 
adherent scored 
significantly higher 
on outcome 
measures at 12 
and 18 months 
than those who 
were more 
homework 
adherent 
(p<0.012). 
 
Level II 
Good quality 
James, A. C., 
James, G., 
Cowdrey, F. A., 
Soler, A., & 
Choke, A. (2015). 
Cognitive 
behavioural 
therapy for anxiety 
The purpose of 
this review was to 
explore the 
effectiveness of 
CBT in the 
treatment of 
childhood and 
The study design 
is a Cochrane 
systematic review.  
 
The CBT 
intervention within 
the studies 
consisted of 
A thorough 
literature review 
among multiple 
databases was 
performed. 
 
A total of 41 RCTs 
consisting of 1,806 
The primary 
outcome 
measured was 
remission via the 
Anxiety Disorder 
Interview 
Schedule for 
Parents, Children, 
Findings 
concluded that 
58.9% of 
participants who 
received CBT 
achieved 
remission while 
16% of 
Level I 
Good quality 
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disorders in 
children and 
adolescents 
(Review). 
Cochrane 
Database of 
Systematic 
Reviews, 2, 1-30. 
doi: 
10.1002/14651858
.CD004690.pub4 
 
adolescent anxiety 
disorders. 
individual, group, 
or family/parental 
involvement 
manualized, or 
modular, CBT 
alone or CBT with 
medication. 
participants were 
included in the 
review. 
 
Participants within 
the studies were 
ages 4-19, met 
diagnostic criteria 
for an anxiety 
disorder, and were 
recruited from 
research settings. 
or Adolescents 
and Parents. 
 
The Clinical Global 
Impression Scale 
assessed 
treatment 
response. 
 
Acceptability was 
measured by the 
number of 
participants lost to 
follow up. 
 
Reduction of 
anxiety symptoms 
was measured by 
several scales. 
 
Outcomes were 
measured at six 
and 24 months. 
 
participants who 
did not receive 
CBT achieved 
remission, but 
these results were 
not significant 
(p=0.23).  
 
There were no 
differences 
between the 
outcomes of 
individual, group, 
or family CBT nor 
between the rates 
of participants lost 
to follow up among 
the CBT versus 
control groups. 
These findings 
were significant 
(p=0.02). 
Jayasekara, R. 
(2016a). Evidence 
Summary: Anxiety 
disorders: 
Psychotherapy. 
The Joanna 
Briggs Institute, 1-
3. 
 
The purpose was 
to determine the 
best evidence 
regarding 
psychotherapy for 
patients with GAD. 
 
This was an 
evidence 
summary. 
 
Psychotherapy 
interventions, 
including CBT, 
were utilized in the 
studies included in 
the evidence 
summary. 
Persons with GAD 
including children, 
adolescents, 
adults, and older 
adults from two 
Cochrane 
systematic 
reviews, one 
meta-analysis, two 
systematic 
reviews, and five 
RCTs were 
The effect of CBT 
on anxiety levels, 
relapse of anxiety 
symptoms, and 
secondary 
symptoms of worry 
and depression 
was measured.  
 
Use of CBT was 
determined to be 
effective for 
children, 
adolescents, the 
working-age 
population, and 
older adults with 
GAD and received 
a Grade B 
recommendation. 
CBT reduced 
Level I 
High quality 
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included in the 
sample. 
 
anxiety levels, 
symptoms of worry 
and depression, 
prevented relapse, 
and results were 
maintained at 
follow up. 
 
Jayasekara, R. 
(2016b). Evidence 
Summary: Anxiety 
disorders: Self 
help. The Joanna 
Briggs Institute, 3-
5. 
 
The purpose of 
this evidence 
summary was to 
determine the best 
available evidence 
regarding self-help 
interventions for 
patients with 
anxiety disorders. 
The study design 
was an evidence 
summary. 
 
Self-help 
interventions were 
explored among 
the studies 
reviewed. 
The sample 
included persons 
with anxiety 
disorders, 
including panic 
disorders, social 
anxiety disorder, 
phobias, 
generalized 
anxiety disorder, 
and post-traumatic 
stress disorder. 
Five meta-
analyses, four 
systematic 
reviews, one 
Cochrane review, 
and one RCT were 
included in the 
evidence 
summary. 
The effectiveness 
of self-help 
interventions was 
the primary 
outcome. 
 
Symptoms of 
anxiety and 
depression were 
measured. 
Self-help CBT was 
found to be 
effective as 
compared to 
controls including 
wait list, treatment 
as usual, and 
placebo, and the 
effect size did not 
vary depending on 
the type of self-
help CBT 
administered, 
including guided, 
minimal contact, or 
self-administered. 
 
Participants 
should work on 
self-help materials 
for at least six 
weeks. 
 
Self-help 
bibliotherapy CBT 
may serve as a 
low-cost 
intervention for 
Level I 
High quality 
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persons with 
anxiety. 
 
Kapczinski, F., dos 
Santos Souza, J. 
J. S. S., Batista 
Miralha da Cunha, 
A. A. B. C., & 
Schmitt, R. R. S. 
(2003). 
Antidepressants 
for generalised 
anxiety disorder 
(GAD) (Review). 
Cochrane 
Database of 
Systematic 
Reviews, 2, 1-40. 
doi: 
10.1002/14651858
.CD003592 
 
The purpose was 
to assess 
antidepressants 
for their efficacy 
and acceptability 
in the treatment of 
GAD. 
The design of the 
study was a 
Cochrane 
systematic review.  
 
Duration of 
treatment with 
antidepressants 
among the 
included studies 
ranged from six to 
28 weeks. 
A thorough 
literature search 
within multiple 
databases was 
performed. 
 
A total of 15 RCTs 
regarding 
antidepressants 
were included in 
the review. 
 
Participants in the 
studies were 
outpatients. One 
study included 
children while all 
others included 
adults. Most trials 
were conducted in 
the United States. 
Symptoms were 
often measured 
using the HAM-A.  
 
GAD changes 
were measured by 
the Clinical Global 
Impression score. 
 
Acceptability of 
treatment was 
measured via 
dropout rate and 
side effects.  
Participants who 
received 
antidepressants 
were more likely to 
exhibit treatment 
response than 
those who 
received placebo. 
 
Paroxetine and 
imipramine 
showed similar 
efficacy and were 
well tolerated by 
most patients. 
 
Sertraline was 
more effective 
than placebo in 
the treatment of 
GAD among 
children and 
adolescents.  
 
Level I 
Good quality 
Nguyen, D. H. 
(2017). Evidence 
Summary: 
Generalized 
anxiety disorder: 
Management. The 
Joanna Briggs 
Institute, 1-4. 
 
The purpose of 
this piece of 
evidence was to 
explore the best 
available evidence 
for the 
management of 
GAD. 
 
This was an 
evidence 
summary. 
 
Self-help, 
pharmacological, 
and psychological 
therapy 
The sample 
included persons 
with a diagnosis of 
GAD from three 
clinical practice 
guidelines, six 
Cochrane reviews, 
two meta-analytic 
Effectiveness of 
self-help, 
pharmacological 
therapy 
(antidepressant 
medication), and 
psychological 
therapy was 
measured.  
CBT-based 
psychological 
therapy effectively 
reduced anxiety 
symptoms and 
was more effective 
than placebo.  
Pharmacological 
interventions, 
Level I 
High quality 
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interventions were 
reviewed. 
reviews, and one 
RCT. 
 
 
Outcomes 
measured 
included anxiety 
symptoms.  
 
including the 
prescribing of 
SSRIs, were 
supported with a 
Grade B 
recommendation 
due to their cost 
effectiveness, 
efficacy, safety, 
and ease of use.  
 
Self-help 
interventions, 
including 
bibliotherapy CBT, 
were 
recommended and 
supported for 
reducing barriers 
to traditional CBT.  
 
Considering 
patient 
preferences as 
well as 
implementing CBT 
over a period of 
four months 
received a Grade 
A 
recommendation. 
 
Piacentini, J., 
Bennett, S., 
Compton, S., 
Kendall, P., 
The purpose of 
this study was to 
explore response, 
remission rates, 
The design of the 
study was a 
randomized 
controlled trial.  
A sample of 488 
children and 
adolescents ages 
7-17 years who 
The Clinical Global 
Impression-
Improvement 
Participants who 
received 
combination 
therapy (COMB) 
Level II 
High quality 
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Birmaher, B., 
Albano, A. M., 
March, J., Sherrill, 
J., Sakolsky, D., 
Ginsburg, G., 
Rynn, M., 
Begman, R. L., 
Gosch, E., 
Waslick, B., 
Iyengar, S., 
McCracken, J., 
Walkup, J. (2014). 
24- and 36-week 
outcomes for the 
child/adolescent 
anxiety multimodal 
study (CAMS). 
Journal of the 
American 
Academy of Child 
and Adolescent 
Psychiatry, 53(30, 
297-310. doi: 
10.1016/j.jaac.201
3.11.010 
 
and anxiety 
severity changes 
among CBT, SSRI 
use, and 
combination 
therapy among 
youth. 
 
 
Participants were 
randomized to four 
different groups: 
CBT only (CBT), 
sertraline only 
(SRT), sertraline 
and CBT 
combined 
(COMB), or pill 
placebo (PBO). 
CBT included 
adaptation of the 
“Coping Cat” 
program. A 
maximum daily 
dose of 200 mg of 
sertraline was 
established. 
 
met DSM-IV 
criteria for 
separation, 
generalized, or 
social anxiety 
disorder were 
included in the 
study. They were 
recruited from six 
geographically 
diverse sites. 
 
(CGI-I) measured 
response. 
The Pediatric 
Anxiety Rating 
Scale (PARS) and 
the Clinical Global 
Impressions 
Severity Scale 
(CGI-S) measured 
anxiety severity.  
 
The Children’s 
Global 
Assessment Scale 
measured overall 
functional 
impairment.  
 
exhibited a 
significantly higher 
response rate on 
the CGI-I than 
CBT alone or SRT 
alone. 
 
CBT, SRT, and 
COMB were all 
superior to PBO. 
 
There was no 
significant 
difference in study 
attrition rates for 
each treatment 
group. 
 
Most participants 
maintained gains 
at weeks 24 and 
36. 
 
Despite excellent 
response rates, 
COMB was unable 
to achieve 
statistical 
significance over 
SRT and CBT at 
weeks 24 and 36 
due to significant 
improvement in 
SRT and CBT 
groups during that 
time.  
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Sawyer, M. C., & 
Nunez, D. E. 
(2014). Cognitive-
behavioral therapy 
for anxious 
children: From 
evidence to 
practice. 
Worldviews on 
Evidence-Based 
Nursing, 11(1), 65-
71. doi: 
10.1111/wvn.1202
4 
 
The purpose of the 
review was to 
explore available 
evidence about 
the effectiveness 
of individual CBT 
for children with 
anxiety disorder. 
 
The design was a 
systematic review. 
 
CBT was the 
primary 
intervention 
throughout the 
studies included. 
Eight of the ten 
studies utilized a 
manualized 
version of the 
Coping Cat 
program. 
 
A total of 10 
studies were 
included in the 
review. 
Participants within 
these studies were 
7 to 12 years of 
age, male or 
female, with 
varying primary 
anxiety diagnoses. 
A range of races 
and ethnicities 
were included.  
 
A total of 22 
different 
measurements 
were utilized 
across the studies 
and were not 
mentioned in 
detail. 
 
Diagnostic 
recovery and rates 
of anxiety 
diagnoses were 
also measured. 
 
Individual CBT 
significantly 
decreased the 
rates of anxiety 
diagnoses as 
compared to 
control groups.  
 
Diagnostic 
recovery rates for 
individual CBT 
were equal or 
superior to 
diagnostic 
recovery rates of 
control groups with 
the exception that 
combination 
therapy of 
sertraline and CBT 
was significantly 
more effective 
than monotherapy. 
 
Level I 
High quality 
 
Strawn, J. R., 
Dobson, E. T., 
Giles, L.L. (2017). 
Primary pediatric 
care 
psychopharmacolo
gy: Focus on 
medications for 
ADHD, 
depression, and 
anxiety. Current 
The purpose was 
to explore 
psychopharmaco-
logic interventions 
for the treatment 
of anxiety, ADHD, 
and depression in 
pediatric care. 
The design of the 
study was a 
systematic review. 
 
Psychopharmaco-
logic interventions 
explored included 
SSRIs, particularly 
sertraline, 
SSNRIs, 
stimulants, alpha 2 
The sample 
population 
included youth 
with depressive 
disorders, anxiety 
disorders, and/or 
ADHD. 
 
Several landmark 
studies were 
explored in the 
Outcomes 
measured 
included side 
effects and 
tolerability of 
medications. 
 
Remission, 
response to 
treatment, and 
Sertraline 
effectiveness was 
not statistically 
significant from 
that of CBT but 
was statistically 
significant in 
comparison to 
placebo. 
 
Level I 
Good quality 
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Problems in 
Pediatric and 
Adolescent Health 
Care, 47(1), 3-14. 
doi: 
10.1016/j.cppeds.
2016.11.008 
 
agonists as well as 
CBT. 
review, including 
the CAMS and 
CAMELS studies. 
relapse were also 
measured. 
Combination 
therapy with 
sertraline and CBT 
led to better 
outcomes than 
either treatment 
alone, and gains 
were maintained 
at follow up. 
 
SSRIs and 
SSNRIs have 
similar side effect 
profiles among 
youth, including 
headaches, 
nausea, irritability, 
restlessness, mild 
disinhibition, and 
insomnia. 
 
Multiple meta-
analyses did not 
identify a link 
between 
antidepressant 
use and increased 
risk of suicide, but 
appropriate 
caution should be 
taken. 
 
Wetherell, J. L., 
Petkus, A. J., 
White, K. S., 
Nguyen, H., 
The purpose of 
this study was to 
determine whether 
the addition of an 
The study design 
was a randomized 
controlled trial.  
 
The sample 
included 73 adults 
at least 60 years 
of age with a 
Anxiety outcomes 
were measured 
via the Hamilton 
Anxiety Rating 
Based on the 
results of the Penn 
State Worry 
Questionnaire, 
Level II 
Good quality 
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Kornblith, S., 
Andreescu, C. 
Zisook, S., Lenze, 
E. (2013). 
Antidepressant 
medication 
augmented with 
cognitive-
behavioral therapy 
for generalized 
anxiety disorder in 
older adults. 
American Journal 
of Psychiatry, 
170(7), 782-789. 
doi: 
10.1176/appi.ajp.2
013.12081104 
 
antidepressant 
medication to the 
regimen of CBT 
would increase 
response and 
prevent relapse in 
older adults with 
GAD. 
 
All participants 
received 
escitalopram for 
12 weeks and then 
were randomly 
assigned to one of 
four different 
groups: 1) 
escitalopram and 
CBT followed by 
maintenance 
escitalopram, 2) 
escitalopram alone 
followed by 
maintenance 
escitalopram, 3) 
escitalopram and 
CBT followed by 
pill placebo, 4) 
escitalopram alone 
followed by 
placebo. 
 
primary diagnosis 
of GAD based on 
DSM-IV criteria. 
They were 
recruited from 
three outpatient 
clinics. 
 
Scale (HAM-A) 
every four weeks 
during the 
augmentation 
phase and every 
two weeks during 
the maintenance 
phase. 
 
Outcomes of 
excessive and 
uncontrollable 
worry were 
measured using 
the Penn State 
Worry 
Questionnaire at 
the initiation and 
completion of the 
augmentation and 
maintenance 
phases.  
 
participants who 
received CBT 
were three times 
more likely to 
respond to 
treatment than 
those who did not 
receive CBT 
(p<0.05). 
 
The effect size 
was medium to 
large regarding 
CBT and worry 
symptoms with 
greater 
improvements in 
pathological worry 
exhibited by 
participants who 
received 
escitalopram 
augmented with 
CBT according to 
the Penn State 
Worry 
Questionnaire. 
According to the 
HAM-A, 
participants who 
received CBT did 
not show greater 
improvement in 
anxiety symptoms. 
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Lower relapse 
rates were 
exhibited by 
participants who 
received 
maintenance 
escitalopram or 
CBT with placebo 
as compared to 
participants who 
did not receive 
these treatments 
respectively. 
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 Level I evidence. Nguyen (2017) published an evidence summary exploring the best 
available evidence for the management of GAD. This evidence summary included three clinical 
practice guidelines, six Cochrane reviews, two meta-analytic reviews, and one RCT. It was 
addressed within this summary that clinical practice guidelines provide support that most often, 
patients diagnosed with GAD can be well cared for in the primary care setting. Additional 
conclusions made from U.S. clinical practice guidelines include that psychological therapy 
provides the longest duration of treatment effect followed by the effects of pharmacological 
therapy with antidepressants or self-help interventions. Cochrane reviews and clinical guidelines 
supported that psychological interventions that are grounded in CBT are effective for short-term 
treatment of GAD, have been shown to reduce symptoms of anxiety, and are more effective 
than placebo. The addition of CBT to pharmacotherapy also demonstrated usefulness. Effective 
pharmacological interventions include the use of SSRIs due to cost effectiveness, efficacy, 
safety, tolerable side effects, and ease of use. There are many barriers to typical therapist-
guided CBT, including lack of time, transportation issues, negative stigma, lack of trained 
clinicians, all of which lead to limited patient access to CBT. Thus, self-help, self-administered, 
or distance delivery in the form of telephone or the internet has reduced such barriers. 
Psychological therapy based on CBT principles in the form of books, known as bibliotherapy, is 
recommended as such type of self-help intervention. A Grade B recommendation was assigned 
to the use of an SSRI for the treatment of GAD unless contraindicated as well as to instruct 
patients to take medication as directed to avoid discontinuation or withdrawal symptoms. A 
Grade A recommendation was given to always taking patient preference in consideration for 
care. 
Thus, the evidence summary provided strong, well-supported, clear recommendations 
from current sources (Nguyen, 2017). The objectives as well as the target population of the 
evidence summary were cleared stated. A systematic search of the literature was performed. 
There was a clear relationship between the evidence, conclusions, and recommendations 
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made. Benefits as well as risks were addressed within the recommendations. Multiple options 
for the management of GAD were provided based on patient eligibility, safety, and preference, 
and barriers were discussed. Conclusions were consistent, generalizable, based on results, and 
flowed logically in response to the clinical question. The evidence summary received high 
scores within all six domains. This can be described as level I evidence of high quality based on 
Melnyk and Fineout-Overholt’s (2015) Hierarchy of Evidence and the AGREE II Instrument 
respectively. 
 Level I evidence. An evidence summary published by Jayasekara (2016a) was also 
included in the review of literature due to its relevance to the EBP project. The purpose of the 
summary was to answer the clinical question regarding the best evidence regarding 
psychotherapy for patients diagnosed with GAD. Evidence found that CBT was able to reduce 
anxiety levels more than treatment as usual for patients on a waiting list, and in addition, CBT 
effectively reduced secondary symptoms of worry and depression. CBT was also found to help 
prevent relapse of GAD symptoms. A meta-analysis reviewed found that CBT was more 
effective than non-cognitive therapy in the treatment of worry and that such positive outcomes 
were maintained at follow-up. Evidence supported the effectiveness of CBT for the treatment of 
anxiety disorders in children, adolescents, the working-age population, and older adults.  In 
conclusion, the best practice recommendation for the use of CBT in the treatment of GAD 
across the lifespan, including children, adolescents, adults, and older adults received a Grade B 
recommendation.  
 This evidence summary received a high score for the scope and practice domain with 
the objectives, clinical questions, and intended population for these recommendation clearly 
delineated (Jayasekara, 2016). The evidence was well written, and content was easy to find 
within the document. The stakeholder involvement domain also ranked high as the evidence 
summary clearly identified that these recommendations were useful for children, adolescents, 
adults, and older adults with GAD. A systematic search of evidence-based health care 
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databases was underwent, and details of each piece of evidence were provided leading to a 
strong score in the rigour of development domain. Details of each study were presented, and 
one of the Cochrane systematic reviews included 38 RCTs and a total of 3,214 participants. 
Recommendations were clear and suffice yielding a high score for the clarity of presentation 
domain. Clear advice regarding implementing recommendations and implications for practice 
were discussed among the multiple pieces of evidence included, which provided a strong rating 
for the applicability domain. The editorial independence domain also scored high as it was 
declared that there were no conflicts of interest. Thus, this level I evidence summary was 
deemed of high quality with consistent, generalizable results across the lifespan, sufficient 
sample size, and strong, definitive conclusions. This piece of evidence provided much support 
for the CBT intervention focus and well as the intended population of the EBP project. 
 Level I evidence. Another evidence summary published by Jayasekara (2016b) 
reviewed the best evidence for self-help interventions for patients with anxiety disorders. Self-
help interventions include patients completing psychological treatment protocols independently. 
Most of these self-help interventions are based on CBT, including exposure, cognitive 
restructuring, and relaxation. They can be accessed through books, computers, televisions, 
videos, or the Internet. It is unnecessary to interact with a therapist in order to participate in the 
therapy. Five meta-analyses, four systematic reviews, one Cochrane review, and one RCT were 
included in the evidence summary. Several different types of self-help were included in the 
studies, including unguided self-help, self-help as partial replacement to face-to-face therapy, 
and guided self-help. In conclusion, self-help interventions were recommended for the treatment 
of anxiety disorders and received a Grade A recommendation. Multiple meta-analyses found 
that bibliotherapy, including written texts, computer programs, or audio/video material, was more 
effective than waiting lists, no treatment, or placebo. One meta-analysis in particular determined 
that the effect size did not differ by the type of self-help intervention, including guided, minimal 
contact, and self-administered. Self-help bibliotherapy can serve as a low-cost effective option 
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for patients with GAD. However, overall, there are limited data regarding the cost and feasibility 
of such bibliotherapy. Face-to-face CBT may be clinically superior, but self-help serves as an 
available treatment option for patients when other services may be inaccessible. 
 This level I evidence summary included a thorough description of its scope and purpose 
(Jayasekara, 2016b). The target population, interventions, and comparison were clearly 
delineated. A comprehensive literature review that included reference to scientific evidence was 
included, and sources ranged in publication dates between 2001 to 2016. Thus, not only was 
current evidence included, but data and trends covering a large time period were available. The 
systematic search was relevant and appropriate for the clinical question. Details of the studies 
were presented clearly including brief descriptions of design, sample, methods, results, 
outcomes, strengths, and limitations. Sample sizes for many included studies were large. The 
evidence presented was strong, clear, and consistent and received a Grade A recommendation. 
Thus, this evidence summary was appraised as being of high quality.   
 Level I evidence. Kapczinski, dos Santos Souza, Batista Miralha da Cunha, and 
Schmidt (2003) published a systematic review exploring the efficacy and acceptability of the use 
of antidepressants in the treatment of GAD. This publication was citation chased from the 
version published in 2016. The title of the 2016 version was present within the results yielded 
from the best search. However, the publication was withdrawn from the Cochrane Library 
Database as it was passed on to new authors. Because the version published in 2003 was the 
most recent one available at this time, an exception was made to include this piece of evidence. 
Although it was not published within the last 5 years, it remains published within the last 15 
years. This systematic review of RCTs only involved a search of multiple databases, including 
Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Register, the 
Cochrane Central Register for Controlled Trials, MEDLINE, and LILACS for publications 
published from 1966 to 2002. Additional inclusion criteria included relevant RCTs comparing 
antidepressants to placebo or antidepressants to other pharmacological treatment. Non-
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randomized studies and patients with additional Axis I comorbidities other than GAD were 
excluded. Thorough review was performed by one reviewer, who assessed studies for 
relevance, inclusion and exclusion criteria, and quality. A total of 15 articles were included in the 
review. Most of the included trials were conducted in the United States, and all included 
outpatients. One trial was conducted among children, and the other trials were conducted 
among adults. Duration of treatment ranged from 6 to 28 weeks. 
Each of the trials included outcome measurement of symptoms via various symptoms 
scales with the most common scale used by the Hamilton Anxiety Scale (HAM-A). Additional 
outcomes measured included generalized anxiety changes at the end of the trial (extent of 
response via a Clinical Global Impression (CGI) score) and acceptability of the treatment 
(dropout rate and specific side effects). Data were analyzed by two reviewers. A third reviewer 
solved any disagreement between the two primary reviewers. An analysis of results occurred 
via the use of Review Manager Software 4.1. Relative risk and confidence intervals were 
calculated. Evidence favored antidepressants over placebo and found that antidepressants 
were more effective in treating GAD than placebo. Paroxetine and imipramine were compared 
and shown to have similar efficacy and be well tolerated by most patients with GAD. Sertraline 
was more effective than placebo in the treatment of GAD among children and adolescents. Side 
effects more commonly occurred in the groups treated with antidepressants as compared to 
placebo groups. Side effects included nausea, dry mouth, constipation, and drowsiness. 
However, because dropout rates were not significant between antidepressant and placebo 
groups, evidence supports that antidepressants are well tolerated. Therefore, this systematic 
review provides support for the use of antidepressants in the treatment of GAD across the 
lifespan and describes the efficacy and acceptability of many different antidepressants in 
particular, which can aide in appropriate prescribing by NPs and other providers. 
A good quality rating was assigned to this systematic review as variables of interest 
were clearly identified, key search terms were stated, multiple databases were searched, and 
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exclusion and inclusion criteria were stated (Kapczinski et al., 2003). The data were older than 
the past 5 years, dating back to the past 15 years. This review excluded participants with 
additional Axis I diagnoses other than GAD. This provided benefit in that it allowed for the 
conclusion to be made that the effect of antidepressants to decrease symptoms of anxiety was 
independent from its effects on depression or dysthymia. However, it hindered the 
generalizability of the review as about 90% of patients with a diagnosis of GAD also have 
another psychiatric comorbidity. The sample size for some of the trials, including the one 
involving children and adolescent participants, was small. Definitive conclusions and consistent 
recommendations were yielded from the results. 
 Level I evidence. A systematic review performed by Sawyer and Nunez (2014) 
reviewed literature published between 2007 and 2012 in order to evaluate the effectiveness of 
individual, manualized CBT for anxiety in the pediatric population. Four databases were 
searched, including Cochrane, PubMed, CINAHL, and PsycINFO, and 10 studies were selected 
for final review. Inclusion criteria consisted of evidence from peer-reviewed journals, English 
language, CBT as the primary intervention, and school-age anxious children ages 7-12. 
Exclusion criteria included a comorbid diagnosis of autism, disorder-specific CBT, computer-
assisted, group only, self-help, or school-based CBT, fewer than 10 participants, CBT in 
combination with other therapies, only one component of CBT, any adult participants, and only 
adolescent participants. An exception was made to include this piece of evidence as it was 
determined to be relevant to the EBP project and self-help CBT as an individual, manualized 
form of the Coping Cat program was explored. A total of 40 articles met inclusion and exclusion 
criteria and were further reviewed for level of evidence, quality, and relevance. Of the 10 final 
articles selected, two were systematic reviews, six were randomized controlled trials, and two 
were quasi-experimental studies.  
 The interventions included in this review were individual CBT, with or without parental 
involvement (Sawyer & Nunez, 2014). Eight of the ten studies utilized a manualized form of 
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CBT, and most included the Coping Cat program. Coping Cat is a 14-to-20-session program 
with 60-minute sessions. Additional individual CBT programs utilized in the studies included 
Facing Your Fears, a 12-session program with 60-to-90-minute sessions and FRIENDS, a 14-
session program with 60-minute sessions. CBT sessions were one hour long, and most children 
participated in at least 12 sessions. A total of 22 different tools were utilized among the studies 
in order to measure the outcome of symptom reduction. These tools were not discussed in 
detail but were described as having adequate reliability and validity. Diagnostic recovery was 
also measured, which can be defined as remission from a disorder and no longer meeting 
diagnostic criteria for the disorder. Compared to controls of group CBT, family CBT, education 
or support, and medication, findings supported that individual, manualized, CBT significantly 
decreased anxiety rates and was superior or equivalent to measures of diagnostic recovery. 
There was an exception in that the combination of sertraline and CBT was significantly more 
effective than individual CBT alone. This review called for further dissemination of CBT, cost-
effective programs, accessible manuals, training, and as well as evidence-based CBT programs 
that can be implemented in brief sessions over less visits in the primary care setting in order to 
overcome barriers. Overall, this systematic review provided strong, high level evidence to 
support individual, manualized CBT for the treatment of anxiety disorders in children. 
 This level I systematic review was deemed of high quality after critical appraisal as a 
result of its heterogeneity with the inclusion of both males and females and a variety of races 
and ethnicities (Sawyer & Nunez, 2014). Thus, results are generalizable across the pediatric 
population. An extensive literature review was performed with the inclusion of only high-level 
sources, specifically level I and level II. Key search terms were stated, multiple databases were 
searched, and inclusion and exclusion criteria were delineated. Details of included studies were 
presented, including design, sample, method, results, outcomes, strengths, and limitations. This 
review identified gaps in knowledge regarding CBT for anxiety, provided supporting evidence to 
help close those gaps, and recommended further necessary research.  
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 Level I evidence. Andersen and colleagues (2014) presented a clinical guideline that 
was adapted from the American Society of Clinical Oncology (ASCO). The purpose of the 
guideline was to address appropriate screening, assessment, and care of symptoms of anxiety 
and depression in adults who have cancer. The authors of the guideline stated that all patients 
should be screened for anxiety symptoms when they are diagnosed and onward. Screening at 
initial visits and times of disease status changes, such as post-treatment, recurrence, 
progression, palliative, or end-of life care, was advocated as important. It was also noted that a 
valid and reliable tool is necessary to both screen and assess for anxiety. The Generalized 
Anxiety Disorder (GAD)-7 scale was strongly recommended. Providers should be aware of not 
only anxiety symptoms that patients may present with but also other ways in which the disorder 
may present including concerns or fears. Although it is expected for patients to have worries 
regarding cancer, GAD is likely present when such worries do not align with the actual cancer-
related risk, including worry about symptoms that are not associated with cancer or cancer 
treatments. In addition, a patient with GAD has worries about a large variety of other topics, 
including non-cancer issues. The provider should assess the patient’s home environment, 
relationships, social life, and occupational work to detect any impairments during the time in 
which they experience anxiety symptoms. Referral to a psychiatrist, psychologist, physician, or 
equivalently trained professional should occur if the patient expresses a risk of harm to oneself 
and/or others, severe anxiety or agitation, or psychosis or delirium. Assessments should include 
identifying signs and symptoms of anxiety (panic attacks, trembling, sweating, tachypnea, 
tachycardia, palpitations, sweaty palms), symptom severity, potential stressors (impaired daily 
living), risk factors, times of vulnerability, and potential underlying causes. A confirmation of 
GAD via the DSM-5 criteria is necessary prior to the initiation of treatment.  
Patient preferences and shared decision making should be incorporated into the 
treatment plan, and both pharmacologic and/or nonpharmacologic interventions should be 
considered (Andersen et al., 2014). Patients should be warned of potential adverse effects, 
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tolerability, and potential interactions with other medications if prescribed medications. 
Benzodiazepines should be used with caution, especially with long-term use, due to increased 
potential for abuse and dependence and adverse effect of cognitive impairment. Support, 
education, and information about anxiety, proper management, and when to call the provider 
should be provided to the patient. Well-supported psychological interventions with clear 
explanations regarding guided content and structure, delivery method, and duration of treatment 
should be provided. Outcomes should be measured at various intervals, including a minimum of 
pre- and post-treatment but preferably once per month or until symptoms subside, in order to 
determine the effectiveness of the intervention, monitor patient compliance, evaluate the 
practitioner, assess patient satisfaction with the treatment, and determine solutions to 
compliance issues. After eight weeks of treatment, if there has been no symptom reduction or 
poor patient satisfaction, a psychological or pharmacological intervention should be added, the 
medication should be changed, or the provider should provide a referral to individual or group 
psychotherapy. Detailed information for the treatment of depression was also discussed in the 
guidelines but not thoroughly explained within this report due to the project’s main focus of 
GAD. This clinical guideline provided thorough instructions to providers for the screening, 
assessment, and treatment of GAD among adult patients with cancer and can help to aide in 
achieving positive outcomes for patients when followed. 
This level I evidence was deemed of high quality based on the AGREE II Instrument due 
to its development by key stakeholders, including a highly regarded organization, the ASCO, 
and its detailed conclusions (Andersen et al., 2014). Multiple databases were searched and 
identified, including MEDLINE, EMBASE, the Cochrane Library, and medical specialty websites. 
The target population was identified including clinical condition and comorbidities. Potential 
harms and benefits were addressed. Recommendations were clear, grounded in supporting 
evidence, and provided multiple options patients are likely to accept.  
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 Level I evidence. A clinical guideline by the Assessment and Management of Risk for 
Suicide Working Group (2013) provided information for the assessment and management of 
patients at risk for suicide. This is very applicable to patients with GAD, and the link between 
GAD and risk for suicide is discussed frequently throughout available literature. In addition, in 
contrast to best practice, benzodiazepines are often utilized in the treatment of GAD. The FDA 
has added boxed warnings to benzodiazepines as their use combined with opioid medications 
can lead to slowed or difficult breathing and death. Benzodiazepines should be used with 
caution when prescribed for patients at risk for suicide due to this risk of respiratory depression 
as well as addiction effects. This guideline recommends that any patient diagnosed with a 
mental disorder be assessed for suicide risk. Depression is often a comorbidity with GAD. 
Patients with high scores on depression screening tools should also be assessed for risk of 
suicide. When symptoms of anxiety are present, providers should ask patients directly regarding 
suicidal ideation. It is also important to consider that suicidal ideation can fluctuate, and 
reassessment should regularly occur when circumstances change. Additional warning signs of 
potential suicidal behavior includes anxiety in the form of agitation, irritability, angry outburst, 
wanting to jump out of one’s own skin and dramatic mood changes or lack of interest in usual 
activities or friends. Protective factors should also be assessed, including a patients’ will and 
purpose to live and other factors that may decrease the risk of suicide, such as social support, 
positive personal traits, good coping and problem-solving skills, and access to health care. A 
detailed mental health history should also be obtained.  
CBT and other psychodynamic therapies as well as antidepressants may be beneficial to 
this patient population (Assessment and Management of Risk for Suicide Working Group, 
2013). However, close monitoring of patients who are prescribed antidepressants is warranted 
for the emergence or worsening of suicidal thoughts. Providers should be aware of overdose 
risk and only provide a limited amount of medication at a time. There is no evidence to support 
the use of antipsychotics to reduce suicide risk. In conclusion, there is a call for clinical training 
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programs for mental health in order to help bridge the gap between research and practice and 
to help solve the problem of a shortage of clinicians trained to provide evidence-based 
psychotherapies. In conclusion, this guideline in applicable to the EBP project as it provides 
important recommendations for treating the patient with GAD holistically, assessing for suicide 
risk, and appropriately managing GAD via CBT and antidepressants. 
After a quality appraisal of this level I clinical guideline was conducted, it was assigned a 
rating of high quality in accordance with the AGREE II Instrument (Assessment and 
Management of Risk for Suicide Working Group, 2013). Key terms searched were addressed, 
including suicide and all related terms. Inclusion criteria were listed as peer-reviewed articles, 
published in the English language, population of adults 18 years of age or older, and 
appropriate sample sizes. RCTs, meta-analyses, and systematic reviews of RCTs were 
included to provide the strongest levels of evidence in support of the guideline 
recommendations. A total of 35 RCTs and 38 systematic reviews were included. Studies were 
appraised for quality prior to making decisions to include or exclude. Patient preferences and 
individual situations were considered. Conclusions were developed through a rigorous 
approach.  
 Level I evidence. A Cochrane systematic review by James, James, Cowdrey, Soler, 
and Choke (2015) served a purpose of examining the effectiveness of CBT for children and 
adolescents with anxiety disorders as compared to wait lists, non-CBT interventions and 
treatment as usual (TAU), medications, combination therapy, and placebo as well as the long-
term effects of CBT. A search of multiple databases was performed including The Cochrane 
Library, EMBASE, MEDLINE, and PsycINFO for evidence with a publication date of 1970-2012. 
Inclusion criteria consisted of children and adolescents ages 4-19, meeting diagnostic criteria of 
the DSM II or IV or ICD9 or ICD10 for anxiety disorder, research settings (i.e. university 
outpatient clinics, inpatient services, community clinics, and schools), and comorbidities 
allowable for anxiety disorders per DSM and ICD rules. Exclusion criteria consisted of PTSD, 
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OCD, and simple phobias. A total of 41 RCTs met inclusion criteria, and each arbitrarily involved 
at least nine sessions of CBT and direct contact with children. A total of 1034 participants and 
921 controls were included within the 41 studies. Participants were recruited from outpatient 
clinics, and all had a psychiatric diagnosis of an anxiety disorder ranging from mild to moderate 
(SAD, overanxious disorder (OAD), SOP, panic disorder (PD), GAD, specific phobia (SP)) while 
many had comorbid conditions (depression, conduct disorders (CDs), oppositional defiant 
disorder (ODD), attention-deficit/hyperactivity disorder (ADHD)). 
 The intervention within the studies was required to include manualized, or modular, CBT 
alone, or CBT with medication (James et al., 2015). Individual, group, or family/parental 
involvement were ways in which CBT was administered. CBT was aimed at helping children 
recognize feelings of anxiety and somatic reactions, clarify cognitions, develop coping skills, and 
learn exposure training. Participants in waiting list, treatment as usual, treatment without CBT, 
and placebo groups served as the controls. Placebo treatment included education or 
bibliotherapy without CBT elements. The primary outcome measured was remission, which was 
measured using the Anxiety Disorder Interview Schedule for Parents (ADIS-P), the Anxiety 
Disorder Interview Schedule for Children (ADIS-C), or the Diagnostic Interview Schedule for 
Children, Adolescents and Parents (DISCAP). The interviews were not carried out by the 
treatment team to allow for blinding. The Clinical Global Impressions (CGI) Scale was also 
utilized to assess treatment response. Acceptability was measured by the number of 
participants lost to follow up. Reduction in anxiety symptoms was also measured using multiple 
scales. Outcomes were assessed at follow up periods between 6 months and 24 months. 
Demographic data, including heterogeneity between trials (age, gender, diagnosis, duration and 
severity, comorbidities), were assessed using the Chi test and the I statistic. Only modest 
variability was found. Meta-regression was utilized to determine the influence of disorder 
severity prior to initiation of treatment on outcome.  
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 To summarize the results, 58.9% of participants who received CBT achieved remission 
compared to 16% of controls, but these results were not significant (OR 1.51, 95% CI 0.77 to 
2.96, Z=1.21, P=0.23) (James et al., 2015). The study supported a clear benefit for CBT (95% 
CI), and there were no differences in outcomes for individual, group, or family CBT. There was 
also no difference between the rates of participants lost to follow up among the CBT intervention 
and control groups. Findings were significant and supported the efficacy of CBT over active 
controls (OR 0.52, 95% CI 0.31 to 0.91, Z=2.28, P=0.02). Group and family/parental formats of 
CBT were associated with greater reduction in symptoms than those produced by individual 
CBT formats alone, but findings were not significant (Z=1.66, P=0.1). 
 Overall, this review offers support for the usefulness of CBT as well as its acceptability in 
the treatment of anxiety disorders in children and adolescents (James et al., 2015). CBT was 
shown to be superior to waiting list controls, but its superiority as compared to active controls 
(psychoeducation, bibliotherapy, treatment as usual) could not be confirmed. It was unclear 
whether children younger than 6 years of age have the cognitive maturity to participate in CBT. 
 This level I systematic review was deemed of good quality (James et al., 2015). The use 
of multiple outcome scales did add complexity and posed some challenges to making 
comparisons. All scales utilized were found to have good reliability, validity, and efficacy. 
Included studies involved an age range of 4 to 18 years, but children younger than 7 years old 
were underrepresented. Generalizability was enhanced by inclusion of both genders, a range of 
socioeconomic classes, and multiple comorbidities. However, nine studies did not provide 
details of ethnicity of participants, and generalization to those with severe anxiety was limited as 
only mild to moderate cases were included in the review. A small sample size of 41 studies was 
included. Details of the studies were clearly depicted. There was a potential for bias as 
participants could not be blinded. Conclusions logically flowed from the results of the review and 
were consistent with those of other reviews and meta-analyses. 
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 Level I evidence. Strawn, Dobson, and Giles (2017) recently published a systematic 
review addressing psychopharmacologic interventions utilized in pediatric care for the treatment 
of anxiety as well as attention deficit hyperactivity disorder (ADHD) and depression. Medication 
classes, including SSRIs, SNRIs, stimulants, and alpha 2 agonists, side effects and tolerability 
concerns, and landmark trials of antidepressant medications in children and adolescents were 
reviewed. The Child/Adolescent Anxiety Multimodal Study (CAMS) is one of the largest trials of 
its kind and supports that sertraline has the greatest efficacy in the treatment of GAD in children 
and adolescents. This study included 488 patients, and 78% of them had a primary diagnosis of 
GAD. Randomization to groups occurred, and intervention groups included CBT only, sertraline 
only, or CBT and sertraline in combination. Results indicated that sertraline effectiveness was 
not statistically significant from that of CBT, but was statistically significant in comparison to 
placebo. Combination treatment led to better outcomes than either treatment alone, and 
patients maintained gains at follow up. After completing the 12-week CAMS trial, approximately 
60% of those patients participated in the Child/Adolescent Anxiety Multimodal Extended Long-
term Study (CAMELS). A total of 82 patients who had received combination therapy of sertraline 
and CBT, 79 who received sertraline monotherapy, 83 who received CBT monotherapy, and 44 
who received placebo continued into this trial. Six years following the initiation of the study, 
approximately 47% of patients were in remission. Response to acute treatment was determined 
to be a predictor of long-term outcomes. However, relapse also occurred in about 48% of 
patients, as anxiety often fluctuates. In additional studies, lower likelihood of remission after 
treatment with pharmacotherapy was found to be associated with older age, female gender, 
minority status, lower socioeconomic status, poor family functioning, and severe anxiety at 
baseline. 
 SSRIs and SSRNIs have similar side effect profiles among youth, including headaches, 
gastrointestinal side effects (nausea), and activation, which is characterized by irritability, mild 
disinhibition, increased restlessness, and insomnia (Strawn et al., 2017). Activation occurs more 
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commonly in youth treated with SSRIs than with adults. Multiple meta-analyses did not identify a 
link between antidepressant use and increased risk of suicide, but appropriate caution should 
be taken. Paroxetine and venlafaxine may be more associated with this risk of increased suicide 
due to their short half-lives, and as a result, are not first-line interventions for the treatment of 
anxiety disorders in youth. Within the study, CBT was found to help mitigate the suicidality-
related adverse events associated with venlafaxine.  
 This review supported the importance of early treatment of GAD in youth and celebrated 
the growing volume of evidence for psychopharmacologic interventions in youth with anxiety 
disorders (Strawn et al., 2017). It calls for providers to be astute regarding medication-specific 
tolerability concerns and warnings when prescribing antidepressants. It also provides further 
evidence for the effectiveness and sustained effects of combined CBT and antidepressant use, 
specifically including the SSRI sertraline. 
 After critical appraisal, this level I systematic review was deemed of good quality (Strawn 
et al., 2017). Information regarding key search terms, databases searched, and inclusion and 
exclusion criteria were lacking. Details of included studies were briefly described. Methods for 
appraising the strength of the evidence were not disclosed. Sample sizes of many included 
studies were adequate and allowed for generalizable results across youth ages 7 to 17 years. 
Adequate control was maintained among groups. Definitive conclusions and consistent 
recommendations were based on scientific evidence and provided worthwhile contributions to 
practice. 
 Level II evidence. Wetherell, Petkus, White, Nguyen, Kornblith, Andreescu, Zisook, and 
Lenze (2013) conducted a randomized controlled trial exploring the effects of antidepressant 
medication augmented with CBT for the treatment of GAD in the older adult population. The 
purpose of the study was clearly stated as examining whether such interventions improve 
symptom outcomes (boost treatment response) and decrease relapse rates in this population. A 
sample of 73 adults greater than or equal to 60 years of age with a DSM-IV principal diagnosis 
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of GAD participated in the study. Recruitment of participants occurred between 2008 and 2010 
at primary care practices, mental health clinics, and advertisements at three sites in Pittsburgh, 
San Diego, and St. Louis. Patients with comorbid depression or other anxiety disorders were 
included in the study provided that GAD was their principal diagnosis. Exclusion criteria included 
a history of substance abuse without a minimum of 6 months of full remission, lifetime history of 
psychosis or bipolar disorder, cognitive impairment, current suicidal ideation, ongoing 
psychotherapy, and medical instability. Psychotropic medications were tapered off two weeks 
before the start of the study, and benzodiazepines and sleep aids were also tapered off or 
continued at a consistent, lower dosage throughout the study. Participants were given a 
thorough description of the study and provided written informed consent.  
 Treatment throughout the study was administered in three phases: acute, augmentation, 
and maintenance (Wetherell et al., 2013). During the acute phase, participants received 12 
weeks of treatment with escitalopram, an antidepressant categorized as an SSRI, starting at a 
dosage of 10 mg per day. If symptoms were not improving, the dosage was increased to 20 mg 
per day as tolerated after four weeks of treatment. After 12weeks, participants were randomly 
assigned to one of four groups provided that they received at least a 20% improvement in 
symptoms: 1) escitalopram for 16 weeks and 16 CBT sessions (augmentation phase), followed 
by escitalopram for 28 weeks (maintenance phase); 2) escitalopram for 16 weeks without CBT, 
followed by escitalopram for 28 weeks; 3) escitalopram for 16 weeks with CBT, followed by pill 
placebo for 28 weeks; 4) escitalopram for 16 weeks without CBT, followed by pill placebo for 28 
weeks. The CBT protocol, which was administered by six therapists with doctoral degrees, 
included education modules regarding psycho-education/self-monitoring, relaxation training, 
cognitive therapy, and problem-solving skills. Participants could invite one family member to 
attend one session with them in order to educate them as well and provide support for the 
participant. 
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 Anxiety outcomes were measured using the Hamilton Anxiety Rating Scale (HAM-A), a 
14-item scale conducted via interview by the clinician that measures anxiety by assessing 
somatic symptoms, every four weeks during the augmentation phase and every two weeks 
during the maintenance phase (Wetherell et al., 2013). The HAM-A is considered a gold 
standard for measuring outcomes regarding GAD treatment with pharmacotherapy and has 
excellent reliability with a correlation coefficient of 0.93. Outcomes of excessive and 
uncontrollable worry were measured using the Penn State Worry Questionnaire at the initiation 
and completion of the augmentation and maintenance phases. This self-report scale consisting 
of 16 items is most commonly used in psychotherapy studies for GAD and has high internal 
consistency with a Cronbach’s alpha of 0.87. 
 The study began with a total of 86 participants enrolled (Wetherell et al., 2013). Thirteen 
participants withdrew from the study due to medication side effects or lack of efficacy or were 
lost to follow up. A total of 69 of the 73 randomly assigned participants, or 95%, completed the 
entire protocol. Demographic information of the treatment groups was clearly described and 
depicted in a table. There was no difference among the four groups regarding demographic 
variables, anxiety level, or worry level at pretreatment. It was determined that age, education, 
and age at onset of diagnosis of GAD did not affect the results. Statistical analyses included chi-
square tests for group differences at baselines, Kaplan-Meier survival analysis for HAM-A 
scores and relapse rates, logistic regression for Penn State Worry Questionnaire data, and 
linear mixed models for measuring improvement in anxiety and worry symptoms. Based on the 
results of the Penn State Worry Questionnaire, participants who received CBT were three times 
as likely to exhibit response to treatment in terms of improved symptoms than those who did not 
receive CBT (odds ratio=3.19, 95% CI=1.00-10.14, p<0.05). A medium to large effect size of 
CBT on worry symptoms was found. Participants who received escitalopram augmented with 
CBT exhibited greater improvements in pathological worry than those who received 
escitalopram only (p=0.01). Based on HAM-A scores, participants who received CBT did not 
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exhibit greater improvements in anxiety symptoms (p=0.15). Participants who received 
maintenance escitalopram had significantly lower relapse rates than those receiving placebo 
(p<0.001). Participants who received CBT with placebo had lower relapse rates than those who 
did not receive CBT (p=0.009). There was no statistical significance among relapse rates 
between the participants who received maintenance medication without CBT and participants 
who received CBT without maintenance medication (p=0.11).  A total of 34.0% of particpants 
receiving placebo relapsed, while no participants receiving maintenance medication relapsed. 
Regarding participants receiving placebo, 42.9% of those who did not receive CBT relapsed 
while 25.0% of those who received CBT relapsed. 
 This study provides strong evidence to support the combined use of CBT and SSRIs 
(Wetherell et al., 2013). This sequenced combination treatment led to improved symptoms of 
worry, although not improved symptoms of anxiety in this population. Both maintenance 
medication and CBT were highly able to prevent relapse. Based on these results, the 
augmentation of CBT can improve response to treatment and worry levels when an SSRI is 
insufficient and may allow patients to discontinue long term medication use while remaining in 
good control of GAD. Use of CBT and a maintenance SSRI also provides a safer and more 
efficacious alternative to benzodiazepine use. The relapse prevention findings among older 
adults in this study were found to also be generalizable to the young adult and middle-aged 
population. In conclusion, this RCT provided much support for the addition of CBT after initiation 
of an SSRI for the treatment of GAD in older adults. This was very applicable to the EBP project 
as many patients with GAD at the facility had been taking an SSRI prior to the implementation of 
the project, and thus, the addition of CBT was appropriate at the start of the project for such 
patients. The results were also applicable to the project’s included population of older adults as 
well as young and middle-aged adults.  
 Overall, this level II RCT was found to be of good quality after critical appraisal 
(Wetherell et al., 2013). Moderate control was allocated to the groups as the demographics 
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were similar in both the control and intervention groups, and the settings were similar as 
aforementioned. The instruments utilized to measure data were reliable with a Cronbach’s alpha 
greater than 0.70, and instrument validity was discussed. A high response rate of 95% was 
achieved. Results were clear and consistent, and definitive conclusions were made. Limitations 
of the study were discussed, including the small sample size, lack of control for the CBT 
intervention, and moderately short maintenance phase of 7 months. 
 Level II evidence. Glenn and colleagues (2013) performed an RCT that examined 
predictors of outcomes of CBT for anxiety disorders in regard to treatment dose and patient 
engagement. A total of 1,620 patients with GAD, panic disorder, social anxiety disorder, or 
posttraumatic stress disorder were recruited from primary care settings in the United States, and 
1,004 of these were eligible for the study. Potential applicable participants were directly referred 
for the study by primary care providers and clinical nursing staff. A trained clinician then 
determined eligibility based on inclusion criteria including the requirements of attendance at a 
participating clinic, age 18-75 years old, meeting of DSM-IV diagnostic criteria for the included 
disorders, and a score on the Overall Anxiety Severity and Impairment Scale (OASIS) indicating 
moderate or clinically significant anxiety symptoms. Exclusion criteria included patients with 
unstable conditions, marked cognitive impairment, active suicidal intent or plan, psychosis, or 
Bipolar I disorder, drug or alcohol dependence (abuse was permitted), patients already 
receiving CBT, and patients who could not speak English or Spanish. 
 Using an automated program and stratified permutated block randomization, participants 
were randomized to groups (Glenn et al., 2013). About half of the participants, 503 in total, 
received the intervention. Participants could select their preference to receive pharmacotherapy, 
computer-assisted CBT, or both. A total of 43 of the 503 participants chose to receive 
pharmacotherapy only, 166 chose CBT only, and 273 chose both CBT and pharmacotherapy. 
The CBT intervention was based on Coordinated Anxiety Learning and Management (CALM) 
tools and contained eight modules in which the clinician and patient both viewed the program on 
GENERALIZED ANXIETY DISORDER PROTOCOL 67 
 
 
the screen at the same time. CBT principles included cognitive restructuring, exposure, self-
monitoring, psychoeducation, fear hierarchy, breathing retraining, and relapse prevention. 
Clinicians did not have expertise in anxiety management or CBT. Some had patient care 
experience, and 8 of 14 had prior mental health experience. Six were social workers, five were 
registered nurses, two were master’s-level psychologists, and one was a doctoral-level 
psychologist.  
 Variables included number of CBT sessions attended, number of CBT modules in which 
exposures were conducted to interoceptive cues, trauma memories, catastrophic images, or 
feared or avoided situations, clinician rating of homework adherence, and clinician rating of 
patient overall commitment to CBT per session (Glenn et al., 2013). The Brief Symptom 
Inventory (BSI) 12-item scale was utilized to measure primary outcomes of psychic and somatic 
anxiety and has high internally reliability and validity. Secondary outcomes measured included 
depression via the PHQ-9 and functional status via the Sheehan Disability Scale (SDS). The 
PHQ-9 has high internal reliability with a Cronbach’s alpha of .86 to .89 and high construct, 
external, and criterion validity. The SDS measures impairment in work/school, social life, and 
home life/family and has adequate internal reliability, construct validity, sensitivity, and 
specificity among patients with anxiety disorders. Propensity score weighting was utilized to 
eliminate differences in baseline characteristics between patients in the low and high CBT dose 
and engagement groups. Demographics characteristics identified included ethnicity, age, 
education, gender, and comorbidities.  
 Results included that participants who had lower attendance scored significantly higher 
on all outcome measures (ps < 0.029) at both 12 and 18 months than those who had high 
attendance. Patients who did not complete exposure modules were significantly more 
symptomatic (ps < 0.004) across all measures at 12 and 18 months in comparison with those 
who did complete exposure modules. Patients who were less adherent to homework scored 
significantly higher (ps < 0.012) across all measures at 12 and 18 months than those who were 
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more adherent to homework. Patients who exhibited low commitment to CBT scored 
significantly higher across all measures at 18 months (ps < 0.006) but not at 12 months than 
those who exhibited high commitment to CBT. 
 Findings supported that greater learning and storage strength of learning during CBT 
occurred with greater treatment dose and engagement (Glenn et al., 2013). In addition, greater 
reduction in symptoms and improvements in functioning occurred with higher CBT dose and 
engagement, including completing at least one exposure exercise, having a high attendance 
rate, and completing assigned homework. As a result of exposure completion and higher 
attendance predicting better outcomes, the value of these aspects of CBT as predictors of 
outcomes was emphasized. Further endeavors to make CBT more interesting, understanding, 
and useable, such as through mobile phone applications or computer programs, were 
recommended.  
 A quality rating of good was applied to this level II RCT (Glenn et al., 2013). The purpose 
of the study and data collection methods were described clearly. The instruments were reliable 
with a Cronbach’s alpha greater than 0.70. Tables were presented and consistent with the 
narrative content. A thorough literature review was performed, but sources dated as far back as 
1992. Limitations of the study were discussed, including overlap of variables, a lack of 
assessment of the quality of homework, and some missing data due to clinician error. A 
sufficient sample size was utilized, and results were generalizable due to the inclusion of 
varying cultural and educational demographic information. Consistent recommendations were 
yielded. 
 Level II evidence. A randomized controlled trial by Freshour and colleagues (2016) 
explored the long-term effects of CBT delivered by bachelor-prepared lay providers and CBT 
delivered by PhD expert providers on GAD severity, anxiety, quality of life, and other outcomes 
among older adults. The lay providers were trained and supervised by a licensed psychologist. 
Study participants included adults age 60 years or older who were recruited from internal 
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medicine, family practice, and geriatric clinics in Texas. Inclusion criteria included meeting 
diagnostic criteria for GAD as a principal or co-principal diagnosis. Exclusion criteria included 
patients with active suicide intent, current psychosis or bipolar disorder, substance abuse within 
the past month, or cognitive impairment. A total of 223 participants were enrolled in the study, 
and 112 were randomly assigned to CBT and completed post-treatment assessments. Groups 
included participants randomly assigned using a random number generator to CBT 
administered by lay providers, CBT administered by expert providers, and usual care. CBT was 
administered for a time period of 6 months. The first two sessions were administered in person, 
and subsequent sessions were administered in person or via telephone in accordance with 
patient preference. The first 3 months of CBT included education, awareness training, 
motivational interviewing, deep breathing, coping self-statements, behavioral activation, 
exposure, sleep management, problem solving, progressive muscle relaxation, thought 
stopping, and cognitive restructuring. Patients were called weekly for the following month and 
biweekly for the final two months of CBT to provide support and review of skills. 
Outcomes were assessed using various scales (Freshour et al., 2016). Worry was 
measured via the Generalized Anxiety Disorder Severity Scale (GADSS), a 6-item clinician 
rated scale measuring DSM criteria with adequate reliability and validity among older adults. 
Anxiety was measured using the trait subscale of the State-Trait Anxiety Inventory (STAI-T), a 
20-item self-report measure of general anxiety with a Cronbach’s alpha of 0.92, as well as the 
Structured Interview Guide for the Hamilton Anxiety Scale (SIGH-A), a clinician-rated scale 
aimed at increasing the reliability of the Hamilton Anxiety Scale. Both scales demonstrate good 
sensitivity when used with adults experiencing late-life anxiety. Secondary outcomes measured 
included depressive symptoms via the Patient Health Questionnaire-8 (PHQ-8), mental health 
quality of life via the Medical Outcomes Study Short Form (SF-12), and severity of insomnia via 
the Insomnia Severity Index (ISI). Telephone calls by independent evaluators who were 
unaware of the treatment assignments were used to measure outcomes 6 months and 12 
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months after treatment. Demographic variables, clinical characteristics, and psychotropic 
mediation use at post-treatment was analyzed via t-tests and chi-square analyses. Growth-
curve models were created to analyze the effects of time, treatment group, and the interaction 
among them. 
Results indicated that improvements in both worry and anxiety outcomes were 
maintained at both six- and 12-month follow up and that scores were equivalent for both CBT 
administered by lay providers and CBT administered by expert providers (Freshour et al., 2016). 
Therefore, this study provided support for the sustainable, long-term benefit of CBT for the 
treatment of anxiety among older adults as well as for its administration by lay providers trained 
and supervised by experts. This can allow for expanded access to CBT, a reduction in barriers 
to proper treatment of GAD, and decreased costs of mental health services. In addition, as 
experts can help determine patient appropriateness for CBT and provide training and 
supervision of bachelor-prepared providers, the shortage of geriatric mental health experts can, 
in part, be overcome. 
This recently published level II RCT can be described as high quality (Freshour et al., 
2016). A power analysis indicated that the sample size was sufficient to detect a medium effect 
size for differences among the groups with 97% power. Adequate control among the groups 
was established. Instrument reliability and validity were discussed, and Cronbach’s alpha was 
greater than 0.70. Well-qualified independent evaluators were utilized to measure outcomes and 
were blinded to treatment assignments. They were well qualified in that they were masters-level 
graduate students in clinical psychology and supervised by a licensed psychologist. Results 
were presented clearly, and definitive conclusions were drawn from results. 
Level II evidence. Piacentini and colleagues (2014) conducted the largest RCT to date 
comparing the effects of CBT, SSRIs, and their combined treatment for childhood anxiety. This 
study was aforementioned within the systematic review by Strawn and colleagues (2015). The 
purpose of this study, which is known as the Child/Adolescent Anxiety Multimodal Study 
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(CAMS), was to evaluate response, remission rates, and anxiety severity changes among 
participants within the different groups. A total of 488 children and adolescents ages 7-17 years 
who met DSM-IV criteria for separation anxiety disorder, GAD, and/or social phobia and lived in 
six different geographically diverse areas were included in the study. Comorbid mood, 
psychotic, or pervasive developmental disorder, one prior CBT trial failure, or two SSRI trial 
failures for anxiety described the exclusion criteria. 
Randomization to four different groups occurred: CBT only (CBT), sertraline only (SRT), 
a combination of CBT and SRT (COMB), or pill placebo (PBO) (Piacentini et al., 2014). Blinding 
occurred within the SRT and PBO groups while the COMBO and CBT groups included masking 
to independent evaluator but not to patients and therapists. The CBT intervention was the 
“Coping Cat” program adapted for the CAMS study and included fourteen 60-minute long 
sessions throughout the 12 weeks of the acute phase (Phase I). Therapists were trained in the 
“Coping Cat” program and received supervision throughout the study. The SRT group included 
eight 30-minute long sessions discussing anxiety severity, treatment response, and adverse 
events. A maximum daily dose of sertraline and matching placebo for these participants was 
200 mg, and clinical response and tolerability were considered for dosing. Pharmacotherapists 
were certified psychiatrists and nurse clinicians who received supervision throughout the study. 
Participants in the COMB groups usually received both interventions during the same day. 
Blinding did not occur among COMB psychiatrists in order to create a collaborate care 
approach, which has been linked to improved outcomes and lower required medication doses. 
An initial phase of acute treatment lasted for 12 weeks and was followed by a phase of 6 
months of maintenance treatment (Piacentini et al., 2014). Participants remained in their 
originally assigned groups for the maintenance period. CBT administered during the acute 
phase included new material per session, and CBT administered during the maintenance phase 
included monthly delivery without new material. Medication treatment during the acute phase 
included weekly or biweekly clinic visits with dose increases when necessary while medication 
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treatment during the maintenance phase included continuation of the dose established by the 
end of the acute phase and dose decreases due to side effects if necessary. CBT and 
medications were administered in ways equivalent to how they would be delivered in primary 
care. Two adjunctive services/attrition prevention (ASAP) sessions were allowed during each 
study phase. These additional sessions aimed to address emergent issues, such as significant 
symptom worsening or environmental stressors that endanger safety or increase the risk of 
study attrition. Participants who did not respond to acute phase treatment were referred to 
community providers, and participants who did not respond to placebo were allowed to select 
their choice of CAMS treatment. The study allowed participants to use off-protocol, or 
concomitant, interventions during the maintenance phase, but use of these interventions was 
closely monitored.  
Demographic data, anxiety and comorbidities, and psychosocial functioning were 
reported by participants and their parents at baseline and weeks 4, 8, 12, 24, and 36 (Piacentini 
et al., 2014). Diagnostic criteria was established using the Anxiety Disorders Interview Schedule 
for DSM-IV-TR, Child Version. Demographic data for the sample included a mean age of 10.7 
years with 74.2% 12 years of age or younger. Most participants were white, middle class with 
approximately half female and half male. Most had at least two primary anxiety disorders. 
Response was measured by the Clinical Global Impression-Improvement Scale (CGI-I), 
and those who were rated 1 (“very much improved”) or 2 (“much improved”) were considered as 
responders (Piacentini et al., 2014). The CGI-I also helped to determine a measure of Excellent 
Treatment Response with a score of 1 (very much improved). Anxiety severity was measured by 
the Pediatric Anxiety Rating Scale (PARS), which demonstrated good to excellent internal 
consistency and measures six items for the assessment of anxiety severity, frequency, distress, 
avoidance, and interference over the previous week. Overall functional impairment was rated 
via the Children’s Global Assessment Scale. The Clinical Global Impressions Severity Scale 
(CGI-S) is a clinician rating for anxiety severity and helped determine Remission-Severity as no 
GENERALIZED ANXIETY DISORDER PROTOCOL 73 
 
 
or only occasional symptoms and no impairment related to symptoms. Remission-Diagnosis 
included the absence of GAD diagnosis. Treatment responders were further divided into 
categories of either Always Responders, Always Non-Responders, New Phase II Responder, 
Phase II Relapse, Phase II Regained, or Temporary Responders. There were some missing 
data as 21.8% of participants did not complete 24-week follow-up, and 21.1% did not complete 
36-week follow-up. 
Results found that significantly higher response rates on the CGI-I were achieved with 
COMB (80.7%) as compared to either CBT alone (59.7%) or SRT alone (54.9%) (Piacentini et 
al., 2014). All active treatments were more effective than PBO, and response rates among CBT 
alone and SRT alone did not differ significantly. Study attrition rates were not found to be 
significantly different for each treatment group at week 24 (chi-square=1.18, p=0.55) nor week 
36 (chi-square=2.50, p=0.29). COMB was superior to SRT alone and CBT alone at week 12. 
The responded and excellent responder raters for COMB were maintained through weeks 24 
and 36. However, the rates for both SRT alone and CBT alone improved so much during weeks 
24 and 36 that COMB’s superiority was no longer statistically significant compared to the 
monotherapies at weeks 24 and 36. Most of the participants who showed response to acute 
treatment maintained gains at weeks 24 and 36. COMB treatment was superior over CBT and 
SRT on all outcomes measures (PARS, CGI-S, CGAS) at weeks 24 and 36 with moderate to 
large effect sizes. SRT only and CBT only participants were more likely to seek new additional 
psychopharmacological treatments during the maintenance phase than were COMB 
participants. 
This study’s significant strength and value contributed positively to the EBP project. In 
conclusion, the efficacy and durability of the use of CBT and an SSRIs were greatly supported 
for treatment of severe childhood anxiety disorders (Piacentini et al., 2014). Combined CBT and 
an SSRI was deemed as the best treatment for prompt benefit, but CBT only and an SSRI only 
also gave promising benefits after 6 months of treatment. Therefore, these three interventions 
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are all viable treatment choices, and availability, cost, burden, and family preference should also 
be considered among deciding factors.  
This level II RCT received a high quality appraisal after review. The sample size was 
adequate and the largest to date of its kind (Piacentini et al., 2014). Generalizability of findings 
was enhanced by high subject retention, age distribution, diverse population sample, broad 
eligibility criteria, geographic distribution of study sites, and replication of “real world” delivery of 
treatment. Study limitations were addressed including concomitant treatment usage and lack of 
a placebo comparison group at weeks 24 and 36. Offering participants in the placebo group to 
select treatment if they desired supported ethical care and beneficence. Characteristics and 
demographics were similar among the four different groups. Instruments utilized were described 
in detail and were valid and reliable. The majority of participants completed the follow up 
questionnaires and outcomes measurements. Consistent recommendations and definitive 
conclusions were drawn. 
Level III evidence. A non-randomized controlled trial published by Calleo and 
colleagues (2013) examined outcomes of CBT delivered by experienced and nonexperienced 
counselors for older adults with GAD including feasibility, satisfaction, and clinical measures.  
This pilot study was conducted prior to a similar study by Freshour and colleagues (2016) that 
was previously discussed within level II evidence. A total of 47 participants recruited from 
primary care clinics in the United States agreed to participate, and 19 received treatment based 
on eligibility. At their initial visit, participants signed an informed consent, answered questions 
regarding demographic information, and completed anxiety screening. Inclusion criteria, 
exclusion criteria, and intervention were mirrored in the RCT by Freshour and colleagues 
(2016). However, important differing outcomes were measured in each study, which provides a 
rationale for the inclusion of both pieces.  
Inclusion criteria included patients who were diagnosed with a principal or coprincipal 
diagnosis of GAD. Exclusion criteria included patients who had mental impairment, active 
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suicidal intent, active substance use, psychosis, or bipolar disorder. The CBT intervention was 
delivered over a period of 3 months and included up to 10 skills-based sessions lasting 30-40 
minutes each. The first two sessions were conducted in person with the remaining sessions 
conducted via telephone or in person in accordance with patient preference. CBT homework 
included workbook pages and practice exercises. All patients received anxiety education, 
awareness training, motivational interviewing, deep breathing, and coping self-statements. 
Additional skills that patients could select included behavioral activation, exposure, sleep 
management, problem solving, progressive muscle relaxation, thought stopping, and cognitive 
restructuring. CBT was administered by anxiety counselor specialists who had training and 
experience in CBT, late-life mental health, or anxiety disorders or by counselors with no 
previous mental health training or experience. Ten patients received CBT via an anxiety 
counselor specialist with training, and nine patients received CBT via a counselor without 
training. Ongoing communication with the primary care provider occurred.  
Outcomes that were measured included feasibility, satisfaction, and worry/anxiety 
outcomes (Calleo et al., 2013). Feasibility of the treatment was assessed via content and patient 
delivery choice, attrition rates, comparison of provider/EMR and self-referral procedures, and 
treatment credibility-expectancy. An exit interview with a 4-point Likert scale assessed patients’ 
satisfaction with the treatment and included topics such as how useful the program was in 
helping them manage anxiety, how confident they were that they would continue to use the 
skills, how well their therapist understood their anxiety, and how helpful they found written 
materials. Positive outcomes were indicated by higher scores. The Penn State Worry 
Questionnaire (PSWQ) was used to assess worry. This scale consists of 16 items and has 
adequate psychometric properties for use among older adults. The Generalized Anxiety 
Disorder Severity Scale (GADSS), a six-item, clinical-rated scale with adequate internal 
consistency and validity, was used to assess GAD symptom severity. The Beck Anxiety 
Inventory (BAI), a 21-item self-report scale, measured anxiety severity. The Structured Interview 
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Guide for the Hamilton Anxiety Scale (SIGH-A) is a 14-item, clinician rated scale with higher 
reliability than the Hamilton Anxiety Rating Scale and was also used to assess anxiety severity. 
Outcomes were measured at baseline, 3 months after treatment initiation, and 6 months after 
treatment initiation.  
Data were analyzed using descriptive statistics and nonparametric tests for treatment 
characteristics, attrition, and satisfaction (Calleo et al., 2013). Demographic information included 
age, education, gender, ethnicity, comorbidities, and medication use. Approximately 57.8% 
were Caucasian, 31.6% were African American, and 10.5% were Hispanic. Approximately 
52.6% were female. In terms of feasibility, most patients perceived the treatment as highly 
credible after the first session (mean [SD], 7.29 [1.76]) and believed that the treatment would be 
successful (mean [SD], 6.79 [2.12]). A total of 75% of participants completed the exit interview. 
Results indicated that patients reported that the treatment did successfully help them manage 
anxiety (mean [SD], 3.61 [0.49]). Scores on the PSWQ and GADSS declined significantly from 
baseline to 3 months for those who completed treatment. The other anxiety measured did not 
yield statistically significant effect sizes changes. Patients who received CBT treatment by ACSs 
and counselors experienced no significant differences in ratings of treatment expectancy and 
credibility (credibility: mean, 7.39 for ACSs and 7.21 for counselors, p = 0.70; and expectancies: 
mean, 6.33 for ACSs and 7.13 for counselors, p = 0.41).  
In conclusion, this modified CBT intervention is promising for reducing worry and 
sustaining outcomes in older adults with GAD (Calleo et al., 2013). Gains were maintained at 6 
months. Patient preferences allowed for shared decision making and patient-centered care. 
Television sessions provided improved access to treatment for patients with financial, health, 
and geographic barriers. This study provided support that counselors with a bachelor’s degree 
or less who have not had extensive mental health experience are still a viable option for the 
administration of CBT and can provide a more cost-effective option. The feasibility, 
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acceptability, and effectiveness of CBT were upheld by this study and provide valuable 
information for culturally diverse primary care clinics across the country. 
A quality rating of good was assigned to this level III non-randomized controlled trial 
(Calleo et al., 2013). The results are generalizable and were shown to be consistent with a 
larger primary care study previously conducted. However, the sample size of 19 participants 
was small. Further limitations of the study were also described, including lack of control. 
Instrument validity and reliability was discussed and was adequate for the outcomes measured. 
Interrater agreements between evaluators were good. Definitive conclusions were appropriately 
drawn from results.  
Level V evidence. Campbell (2016) explored the best available evidence regarding 
pharmacotherapy for patients with GAD via an evidence summary. This is considered a level V 
piece of evidence due to the inclusion of one qualitative study. Among the other pieces of 
literature included in the summary were seven systematic reviews, one evidence-based 
guideline, one clinical guideline, and one prospective trial. There was strong support for the use 
of SSRIs as first-line treatment for GAD. Fluoxetine (SSRI) was most strongly recommended for 
its outcomes related to response and remission, and sertraline (SSRI) was most strongly 
recommended for its tolerability as compared to other medications including duloxetine (SNRI), 
escitalopram (SSRI), lorazepam (benzodiazepine), paroxetine (SSRI), pregabalin 
(anticonvulsant), tiagabine (anticonvulsant), and venlafaxine (SNRI). Duloxetine also had high 
rates of response, escitalopram was effective for remission, and pregabalin had high tolerability. 
SSRIs and SNRIs elicited comparable outcomes of improved anxiety symptoms and response 
rates. Benzodiazepines should not be used as first-line treatment. The evidence supported not 
only pharmacotherapy for the treatment of GAD, but also psychological therapy and self-care. 
The addition of CBT enhanced remission rates from symptoms of anxiety while omitting the 
need for long-term pharmacotherapy. The use of CBT received a Grade B recommendation, 
and the use of antidepressants (imipramine, venlafaxine, paroxetine, fluoxetine, sertraline, 
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duloxetine, and escitalopram), second-generation antipsychotic (quetiapine) and anticonvulsant 
pregabalin with individual consideration for each clinical situation received a Grade A 
recommendation. Thus, this evidence summary provided great detail regarding the 
effectiveness and tolerability of many specific medications used in the treatment of GAD and 
made a strong case for the inclusion of SSRIs in treatment. This provided more clarity and 
knowledge for the prescribing details of the intervention. Support was also expressed for the 
CBT portion of the intervention. 
 A high-quality appraisal rating utilizing the AGREE II Instrument was assigned to this 
level V evidence summary as the six domains received strong ratings, and the overall 
assessment indicated such high quality as well as a recommendation to use this guideline for 
research and practice (Campbell, 2016). The design, sample, and outcomes of included studies 
were presented briefly, but clearly. The guideline recommended that clinical situation, risks, and 
benefits be taken into account. Current literature yielded from a systematic search was utilized. 
Recommendations were clearly linked to the corresponding source of evidence. Definitive 
conclusions were stated and were logical based upon the outcomes of the included studies. 
Construction of Evidence-based Practice 
Synthesis of Critically Appraised Literature 
The thorough literature review yielded overall consistent results and recommendations. 
As only good and high quality evidence and a majority of high level pieces were included, strong 
evidence was available to support best practice for GAD treatment across the lifespan. Several 
common themes, or subtopics, were apparent within the literature selected. These recurrent 
subtopics included a target population of school-age children through older adults, the use of 
many of the same interventions throughout the literature, including CBT and SSRIs, and 
outcome measurements of reduced anxiety symptoms and decreased GAD severity.  
Population. The literature was consistent in including children aged 7 years and above, 
adolescents, adults, and older adults 60 years of age and older within the population sample. As 
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it was unable to be determined whether children ages 6 years and younger possess the 
cognitive maturity to participate in CBT, they were often excluded (James et al., 2015). A 
diagnosis of GAD according to DSM criteria was required for inclusion. Comorbidities were often 
allowed to enhance generalizability as most patients with GAD have comorbidities. Patients with 
active suicidal thoughts were frequently excluded. Patients recruited from outpatient primary 
care or family practice settings were included while patients in inpatient settings were excluded. 
Interventions. Although there was some variability in the format and delivery method of 
CBT utilized among the evidence, there was a consensus that CBT was effective in reducing 
anxiety symptoms, associated with long-term maintenance of gains, and acceptable to patients 
(Calleo et al., 2013; James et al., 2015; Jayasekara, 2016a; Jayasekara, 2016b; Nguyen, 2017; 
Piacentini et al., 2014; Sawyer & Nunez, 2014; Wetherell et al., 2013). Individual CBT 
administered via bibliotherapy format using either guided self-help or unguided self-help 
methods was found to not only be beneficial for patients with GAD, but also decreased barriers 
associated with therapist-administered CBT, increased cost-effectiveness, and improved access 
to and feasibility of CBT. CBT was not found to be more effective when delivered by expert 
counselors (Freshour et al., 2016). Greater engagement in CBT materials was associated with 
better outcomes (Glenn et al., 2013). 
The literature also supported use of pharmacotherapy in the form of antidepressants for 
treatment of GAD (Campbell, 2016; Kapczinski et al., 2003; Nguyen, 2017; Piacentini, et al., 
2014; Strawn et al., 2017; Wetherell et al., 2013). SSRIs were shown to be most effective, and 
many pieces of evidence favored the effectiveness, tolerability, and safety of sertraline in 
particular for children, adolescents, and adults. There was support for the effectiveness of 
monotherapy CBT and monotherapy SSRI use. However, there was overwhelming support 
within the literature that better outcomes were achieved with combination therapy of CBT and 
an SSRI (Nguyen, 2017; Piacentini et al., 2014; Wetherell et al., 2013). Sequenced use of an 
SSRI followed by CBT was shown to be effective. However, there was greater support for 
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tandem CBT and SSRI use, which was linked to more prompt benefit. To support patient-
centered care, patient preferences should be considered and discussed. 
Outcomes. A significant number of both primary and secondary outcomes utilizing a 
multitude of measurement tools were discussed among the included evidence (Calleo et al., 
2013; Campbell, 2016; James et al., 2015; Jayasekara, 2016a; Jayasekara, 2016b; Kapczinski 
et al., 2003; Nguyen, 2017; Piacentini et al., 2014; Sawyer & Nunez, 2014; Strawn et al., 2017; 
Wetherell et al., 2013). Such primary outcomes often included reduction in anxiety symptoms, 
improved GAD severity, response to treatment, and remission. Secondary outcomes measured 
often included reduction in depressive symptoms, improvement in worry severity and general 
mental health, relapse rates, changes in GAD status, reduced rates of anxiety diagnoses, 
diagnostic recovery, improvements in mental health quality of life and sleep, long-term 
maintenance gains in worry, acceptability of treatment, reductions in worry, and improved 
functioning. Many different scales were discussed to measure these outcomes, including the 
HAM-A, PSWQ, GAD-7, PHQ, Mental Wellness Scale, Insomnia Severity Index, Hamilton 
Anxiety Scale Revised, CGI-I, CGI-S, GADSS, Beck Anxiety Inventory and Structure Interview 
Guide for Hamilton Anxiety Scale, 12-Item Brief Symptom Inventory, Sheehan Disability Scale, 
PARS, Children’s Global Assessment Scale, and more. The evidence supported at least a 
minimum measurement of outcomes at pre-intervention and post-intervention, but monthly 
measurement was preferred. 
High levels of evidence supported the use of the Generalized Anxiety Disorder 7-Item 
(GAD-7) Scale to measure anxiety symptoms (Andersen et al., 2014). The Clinical Global 
Impression-Improvement (CGI-I) Scale was often used within the literature to measure changes 
in GAD status, such as “very much improved” (James et al., 2015; Kapczinski et al., 2003). 
Much support was present for use of the Patient Health Questionnaire (PHQ-9) to measure 
depressive symptoms. Acceptability of treatment was frequency measured within the literature 
via the number of participants who dropped out prior to the completion of the study (James et 
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al., 2015). Patient satisfaction upon completion of treatment was also measured via Likert scale 
format (Calleo et al., 2013). 
Best Practice Model Recommendation 
 The synthesis of critically appraised literature indicated that current best practice for the  
treatment of GAD in the target population includes combination therapy with CBT, particularly 
individual, self-help via bibliotherapy, and pharmacotherapy, particularly SSRI use. In 
accordance with best practice, bibliotherapy in the form of CBT workbooks for GAD was utilized 
as well as the prescribing of an SSRI, sertraline with a maximum daily dose of 200 mg, if 
acceptable. The Cognitive Behavioral Workbook for Anxiety: A Step-By-Step Program (2014) 
written by licensed psychologist, William J. Knaus, EdD, with over forty years of experience in 
the treatment of anxiety and depression was utilized for adults 18 years and older. Education 
was provided to patients, and close monitoring by providers occurred. Outcomes were 
measured at baseline and monthly and included assessment of anxiety symptoms, depressive 
symptoms, GAD status, acceptability, and patient satisfaction. This best practice intervention 
protocol described was created in a document by the project manager from the best available 
evidence and is presented in Appendix K. 
How the Best Practice Model will Answer the Clinical Question 
Based on this best practice recommendation, a protocol for the treatment of GAD in  
adults 18 years of age and older, including treatment with CBT and an SSRI was developed to 
answer the clinical question regarding the best treatment for decreasing symptoms of anxiety in 
this target population. This best practice model sought to incorporate patient preferences, 
effective interventions supported by quality evidence, and organized delivery of feasible and 
accessible treatment. The implementation phase took place over a period of 12 weeks. In 
accordance with the literature, participants received monthly telephone calls in order to provide 
them with support, discuss progress, and measure outcomes. Clear measurements were 
obtained prior to implementation of the intervention (baseline) and at monthly increments 
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throughout the implementation phase until the completion of the intervention to assess 
outcomes. These measurements were interpreted to provide definitive results and conclusions. 
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CHAPTER 3 
IMPLEMENTATION OF PRACTICE CHANGE  
By creating and implementing an evidence-based protocol including SSRI and CBT use 
for the best treatment of adult patients with GAD, a worthwhile practice change was initiated. 
The project included the project manager’s collaboration with a family practice NP, office 
manager, and medical assistants (MAs) who greatly value the significance and intent of the 
practice change. A multitude of barriers, including the stigma associated with mental illness, 
lack of available and affordable CBT, and inappropriate prescribing and use of medications 
contribute to the hindrance of the provision of best practice recommendations in the 
management of GAD. This EBP project aimed to help eliminate these barriers, educate 
providers about best practice interventions, provide better treatment of patients with GAD, 
decrease patient symptoms of GAD through the implementation of best practice, and improve 
overall quality of life of affected patients. The purpose of this project was to improve treatment of 
GAD by implementing an evidence-based protocol that includes CBT and SSRI use. 
Participants and Setting 
 Conduction of the EBP project took place in a rural family practice office that provides 
primary care services to patients across the lifespan. This facility is located in Northwest Indiana 
and was the only site of project implementation. A masters-prepared NP who owns the office in 
addition to two MAs provide care in this practice. The owner has 15 years of experience as an 
NP and extensive experience as a registered nurse. The project manager is not and has never 
been employed within this facility, which helped to eliminate the potential for selection bias. 
Written permission for the project’s implementation was granted on May 21, 2018 by the 
facility’s office manager who clearly stated her belief in the need for this project, its congruence 
with the facility’s aims and patient population, its feasibility at this primary care location, and her 
staff’s interest and welcoming attitude toward the project. 
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 Participants who were eligible to participate were recruited during their appointments, 
either initial or follow up, at the family practice office from September 25, 2018 to December 6, 
2018. The project manager and NP reviewed patient charts to determine initial eligibility based 
on diagnosis and age. The patient was seen by the project manager and NP, and a diagnosis of 
GAD based upon the DSM-5 criteria was confirmed or negated. Patients without a diagnosis of 
GAD were excluded from the project. In addition to a diagnosis of GAD, inclusion criteria for 
participation was an age of 18 years or older and the ability to speak and understand spoken 
and written English.  
The presence of comorbid anxiety and/or mental disorders, including depression, panic 
disorder, social anxiety disorder, active substance abuse or dependence, current participation in 
CBT outside of the project and/or sessions with a licensed therapist, and the use of other 
classes of medications for the treatment of GAD were also allowed, but disclosed. This decision 
was made on the premise of many factors. Many patients with GAD have comorbid diagnoses. 
There is also a higher likelihood that patients with GAD have substance abuse and dependence 
problems. Thus, excluding these patients would limit the sample size, hinder generalizability, 
and limit important data that could be gathered among this population. Treatment with SSRI 
medication prior to the start of project implementation was also allowed as many patients are 
treated with SSRIs for GAD in the clinical setting and as this would still allow for the 
implementation of both SSRIs and CBT. 
It has become apparent through experience with patients with GAD that despite seeing 
therapists and taking medications for anxiety for significant periods of time, symptoms of anxiety 
may still persist, and further treatment is necessary. Thus, it is believed that this project had the 
potential to benefit these patients by providing them with the additional treatment they needed. It 
is illogical, unethical, and unsafe to expect patients, such as those taking benzodiazepines, 
SNRIs, and other medications for anxiety, to cease current anxiety medications and change to 
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only SSRIs immediately. These patients may benefit from the addition of CBT and SSRI use, 
and their exclusion from participation could have significantly limited the sample size.  
Additional exclusion criteria included patients with current suicide intent, psychosis, 
cognitive impairment, inability to understand and speak English, and current pregnancy. Such 
participants were excluded for safety reasons, time constraints, as well as lack of ability to 
properly participate in the activities of the project. Patients eligible for participation were 
provided a handout explaining the project. This explanation of project document for patients is 
presented in Appendix C. After reviewing the information and having any questions answered, 
patients decided whether or not they wanted to participate in the project. Upon deciding to 
participate in the project, patients were asked to read and sign the informed consent document, 
which is displayed in Appendix D. After providing their written informed consent, participants of 
the project were asked to complete a demographic questionnaire, which is available in Appendix 
E. 
Outcomes 
 Multiple outcomes were selected for measurement in accordance with the literature. The 
primary outcome measured was a reduction in anxiety symptoms via the GAD-7 scale. 
Secondary outcomes measured included changes in GAD status as measured by the Clinical 
Global Impression-Improvement (CGI-I) Scale, a reduction in depressive symptoms as 
measured by the Patient Health Questionnaire (PHQ-9), patient satisfaction via the Patient 
Satisfaction Questionnaire (PSQ), and acceptability of treatment measured by attrition rates, 
including the number of participants who dropped out prior to completion of the entire 
implementation phase and outcomes measurement. The GAD-7 and PHQ-9 Scales were 
participant-reported scales that were completed via written documentation during each 
participant’s initial appointment prior to the implementation of the intervention, and once every 
month (every four weeks) during the three-month implementation period of the intervention via 
telephone calls with the project manager. During such telephone follow up sessions every four 
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weeks, the project manager recorded participant-reported answers for the GAD-7 and PHQ-9. 
The CGI-I Scale was completed by the project manager monthly after the initiation of treatment 
and was not applicable at baseline. The PSQ and attrition rates were measured upon 
completion of the three-month implementation period. The project manager recorded 
participant-reported answers for the PSQ during the final telephone follow up session and 
calculated the attrition rate as a percentage of the total participant population. The pre-
intervention scores and post-intervention scores were compared to determine whether the 
intervention had an effect on GAD symptoms, GAD status of illness, and depressive symptoms. 
Scores throughout the implementation phase were also compared to determine the progression 
of the effect, including the amount of time necessary for noticeable change to begin.  
Intervention 
 The intervention consisted of the development of a protocol based on best practice 
recommendations from good and high quality pieces of evidence. The intervention protocol 
included combination CBT bibliotherapy and an SSRI. The literature provided the most support 
for the effectiveness of combination therapy, but also provided support for the effectiveness of 
CBT monotherapy and SSRI monotherapy. Provides should also consider shared decision 
making and patient safety. Because combination therapy was most effective and considered 
best practice, it was implemented for this project.   
Each participant who consented to participate in the project received combination SSRI 
and CBT use. They were provided with self-help CBT bibliotherapy in the form of an age-
appropriate CBT workbook for GAD at their initial appointment. The appropriate workbook 
administered to adults 18 years of age and older throughout this project was The Cognitive 
Behavioral Workbook for Anxiety: A Step-By-Step Program (2014) by licensed psychologist, 
William J. Knaus. Participants were provided with written information from the project manager 
describing CBT as well as its purpose, including restructuring of thoughts to allow for a more 
positive mindset to cope with anxiety. Participants were also provided with further instructions 
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regarding assigned workbook chapters and completion due dates. The Cognitive Behavioral 
Workbook for Anxiety: A Step-By-Step Program for adults is divided into four parts. Therefore, 
based on the 12-week period of the intervention, participants were instructed to complete Part I 
by week 3 of the implementation phase, Part II by week 6, Part II by week 9, and Part IV by 
week 12. To clarify via example, week 3 of the implementation phase is approximately 3 weeks 
after the initiation of the intervention for the participant. Participants had different initiation dates 
based on varying appointment dates throughout the implementation phase. In addition to CBT, 
participants were prescribed an SSRI at their initial appointment. They were then required to go 
to their selected pharmacy to pick up their prescription. They were educated about potential side 
effects and adverse effects as well as when and how to take their medication including dosage 
and frequency. They were advised to take their medication as directed and to not stop taking it 
abruptly. Education was provided to patients verbally as well as via a written document created 
by the project manager. This education document is presented in Appendix K. 
The participants were informed that follow up would occur every four weeks by 
telephone sessions with the project manager. Initially, follow up was planned via either in person 
sessions or telephone sessions based on patient preference. However, this was not feasible 
within the family practice office due to time and billing constraints per the NP. If patients had 
appointments at the office during such designated follow up times, follow up could be obtained 
at those appointments rather than by phone call. Patients’ follow up telephone sessions and 
workbook homework completion schedule were included along with their education documents. 
Follow up telephone sessions included completion of the GAD-7, PHQ-9, CGI-I, and PSQ when 
appropriate. The project manager answered any questions that the participants had and 
provided support and encouragement to the participants, but the main purpose of the follow up 
telephone sessions was outcomes measurement. Additional topics covered included discussion 
of patient thoughts, symptoms, functional impairment, and progress as well as inquiry of side 
effects of SSRI medication and CBT, and assessment of workbook completion. The participants 
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were scheduled for in-person follow up visits with the NP per clinic policy. For example, if SSRIs 
were initiated for the first time at the start of project implementation, follow up visits with the NP 
occurred after six weeks. If patients had been already been taking SSRIs at the start of project 
implementation, follow up visits with the NPs occurred after 3 months.  
Planning 
 A significant amount of time and effort was devoted to the planning phase of this EBP 
project to ensure its completeness, strong grounding in evidence, and likelihood of successful 
implementation. A need for practice change and best practice recommendations were 
determined based on clinical practice experience and a thorough literature search of current 
evidence. The project manager met and engaged with key stakeholders, including the family 
practice NP, office manager, and MAs, and an overview of the intended project was discussed. 
During this time, best practice information was shared with key stakeholders, and they reviewed 
the protocol and provided their input for suggestions and changes. Support for the project and 
permission to implement the project at the family practice clinic was granted by key 
stakeholders in May 2018 at the beginning of project development. Project planning continued 
with input from the project manager, key stakeholders, project advisor, program professors, 
further research, available interventions, and additional worthwhile sources.  
Data 
Measures. The primary outcome measured was anxiety symptoms via the GAD-7 
Scale, a 7-item self-report scale used to measure anxiety symptom severity in the primary care 
setting (Beard & Bjorgvinsson, 2014; VISN 4 Mental Illness Research, Education and Clinical 
Center, 2017). This scale involves use of DSM-5 criteria and is an effective tool for assessing 
GAD cases. It helps to provide important information regarding the patient’s overall clinical 
condition, guide treatment planning, track treatment progress or lack thereof, improve 
communication between providers, and provide continuity among various patient care services. 
It may be completed in the office by the patient or via the telephone using an interviewer to 
GENERALIZED ANXIETY DISORDER PROTOCOL 89 
 
 
record patient responses. It can be administered via paper and pencil or electronic devices. It is 
quick to administer, often taking 2-5 minutes to complete. Questions within the GAD-7 ask 
patients to rate the frequency of their anxiety symptoms that they have experienced within the 
last 2 weeks via a Likert scale from 0-3 for each of the seven items with 0 indicating not at all, 1 
indicating several days, 2 indicating more than half the days, and 3 indicating nearly every day. 
Total scores indicate anxiety severity and range from 0-21 with 1-4 indicating minimal 
symptoms, 5-9 indicating mild symptoms, 10-14 indicating moderate symptoms, and 15-21 
indicating severe symptoms. Thus, greater levels of symptoms are indicated by greater scores. 
The GAD-7 is available in Appendix G.  
The GAD-7 is considered a valid and reliable tool, and these findings have been 
supported by numerous studies (Spitzer, Kroenke, Williams, & Lowe, 2006). There is evidence 
to support its good sensitivity (89%) and specificity (82%) in primary care settings for the 
assessment of GAD (Williams, 2014). It is also found to have greater sensitivity for identifying 
changes in symptom severity as compared to other anxiety scales, such as the Penn State 
Worry Questionnaire for Measuring Response. It has excellent internal consistency with a 
Cronbach’s alpha of 0.92 and good test-retest reliability with an intraclass correlation of 0.83 
(Spitzer et al., 2006). GAD-7 self-reported scores correlate well with clinician-reported scores, 
indicating good procedural validity, and with similar anxiety scales, indicating good convergent 
validity. Good construct validity is evident as higher scores are associated with higher levels of 
functional impairment. Patients with a diagnosis of GAD typically have higher GAD-7 scores as 
compared to those without a diagnosis of GAD, also demonstrating good construct validity 
(Kertz, Bigda-Peyton, & Bjorgvinsson, 2013).The GAD-7 can also be described as having good 
criterion and factorial validity. It is generalizable across the general population with no variation 
among gender or age (Lippincott William & Wilkins, 2008). Thus, the GAD-7 is useful among 
both men and women as well as younger and older individuals. 
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A secondary outcome of depressive symptoms was measured via the PHQ-9, a self-
report tool used for diagnosing depressive disorder as well as determining depressive symptom 
severity (Kroenke, Spitzer, & Williams, 2001). There are many variations of the PHQ, but the 
PHQ-9 was selected as most appropriate for this project. The PHQ-9 can be administered 
quickly, making it desirable in busy clinical practice settings. It consists of nine items that 
address DSM-IV criteria for depressive disorder. Items within the PHQ-9 ask patients to rate the 
frequency of their depressive symptoms within the last two weeks via a Likert scale from 0-3 for 
each of the nine items with 0 indicating not at all, 1 indicating several days, 2 indicating more 
than half the days, and 3 indicating nearly every day. Total PHQ-9 scores range from 0-27 with 
scores of 0-4 indicating minimal symptoms, 5-9 indicating mild symptoms, 10-14 indicating 
moderate symptoms, 15-19 indicating moderately severe symptoms, and 20-27 indicating 
severe symptoms. Higher levels of symptoms are indicated by higher scores. The PHQ-9 is 
presented in Appendix H.  
Like the GAD-7, the PHQ-9 is also a valid and reliable tool (Kroenke et al., 2001). It has 
a high sensitivity as well as a high specificity of 88% for the assessment of major depression. A 
study implemented in the primary care setting supported that the PHQ-9 has excellent internal 
reliability with a Cronbach’s alpha of 0.89 and an excellent test-retest reliability. External validity 
is also high as findings from this study were able to be replicated among an obstetrics-
gynecology patient population. This also supports the generalizability of the PHQ-9 across 
various outpatient settings. The PHQ-9 highly correlates with other tools used to measure 
depression symptoms. High PHQ-9 scores correlate with worsening functioning among similar 
scales, demonstrating high construct validity. The PHQ-9 also has high criterion validity and 
high positive predictive value. 
The CGI-I scale was utilized to measure another secondary outcome of changes in GAD 
status. The CGI is composed of two scales including the CGI-S, which measures changes in 
symptom severity, and the CGI-I, which measures improvement or worsening of the disorder as 
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aforementioned (Busner & Targum, 2007). Only the CGI-I was used for this project as the 
patient reported GAD-7 scores were used to measure symptom severity, and a concise number 
of measurements was desired for the project. The CGI-I describes a patient’s change in 
disorder status as a result of treatment. It represents the provider’s view of the patient’s disorder 
as responses are provided by the provider based on knowledge of the patient’s history, 
symptoms, behavior, and functional impact of the disorder. It also provides an overall clinical 
interpretation beyond symptomology and displays trends in clinical progress and responses. 
The CGI-I helps to identify interventions that have provided benefit to the patient’s condition as 
well as identify those that have provided no benefit. The CGI-I can be easily and quickly 
administered, often taking approximately 1 minute to complete. It consists of a seven-point scale 
ranging from 1) very much improved since the initiation of treatment to 7) very much worse 
since the initiation of treatment. Proper use of the CGI-I includes a comparison of the patient’s 
current clinical presentation to the patient’s clinical presentation at the baseline visit, or the one 
week period prior to initiation of treatment. Thus, changes are not compared from week to week, 
but rather always compared to baseline. Important considerations for rating include present 
symptoms, frequency of occurrence over the past 7 days, severity of symptoms, and functional 
impact of the symptoms on the patient’s life. Information gathered to determine a CGI-I rating 
may come from interviews with the patient, chart notes, family members, nurses, school 
teachers, caseworkers, significant others, or additional sources. The rating is overall given 
based on clinical judgement. Side effects of treatment should not be included in the rating. The 
CGI-I is depicted in Appendix I.  
The CGI-I is considered a well-established tool for assessing psychiatric disorders, 
including anxiety and depression (Busner & Targum, 2007). The CGI-I is often used in FDA-
regulated and other trials, and its reliability and validity for measuring changes in GAD status 
based on treatment response are well-supported (Busner & Targum, 2007; James et al., 2015; 
Kapczinski et al., 2003). It correlates well with similar yet more complex tools, including the 
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Health of the Nation Outcomes Scales, another clinician-rated scale (Berk, Ng, Dodd, Callaly, 
Campbell, Bernardo, Trauer, 2008; Busner & Targum, 2007). There is also a high correlation 
among CGI-S scores and CGI-I scores (Berk et al., 2008). Evidence has supported that the 
CGI-I is sensitive to change, valid among diverse groups, and reliable when administered 
appropriately by clinicians. 
 Patient satisfaction of the self-administered CBT utilized within this project was 
measured via the Patient Satisfaction Questionnaire (PSQ), a six-item questionnaire developed 
by the project manager. It addresses important aspects of patient satisfaction including 
convenience, ease of use, efficacy, overall satisfaction, worthiness, and engagement. As this is 
a newly developed tool, there is no information regarding its validity and reliability. The PSQ is 
available in Appendix J. 
 Acceptability of treatment was measured via the number of participants who dropped out 
of the project prior to completion or who did not complete outcome measurements, also known 
as the attrition rate. This was calculated as a total percentage of participants. 
Collection. Data collection took place both in the clinical setting and via telephone by 
the project manager from September 25, 2018 to February 28, 2018. It commenced at the initial 
patient appointment when the patient signed consent and received interventions of combined 
CBT and SSRI therapy. Data collection included paper copies of instruments utilized for 
outcomes measurement, including the GAD-7, PHQ-9, CGI-I, and PSQ. During telephone follow 
up to assess outcomes, patient responses were recorded via paper copies of the scales by the 
project manager. Data collection was completed at the final follow up after the patient received 
the intervention for a duration of 12 weeks, or 3 months. As continuous recruitment took place, 
this completion date varied among participants, but was consistently 12 weeks after treatment 
commencement for each individual.  
 Patient confidentiality was protected by coding. Each participant was assigned a code 
number at random determined by drawing a number from a bag. The code was recorded on all 
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participant data collected in a designated area of the top right corner of each document 
including the demographic form, GAD-7, PHQ-9, CGI-I, and PSQ. The code number served as 
the method by which to identify the patient and was used to compare pre-intervention and post-
intervention data. A list of patient names with corresponding codes was kept in a locked box 
with access to the project manager only. An example of this code sheet is available in Appendix 
F. The project manager placed data collected in the clinical setting, including patient GAD-7, 
PHQ-9, and PSQ scales and provider CGI-I scales, with code numbers into a folder clearly 
marked with the project title located in an authorized personnel only area. The multiple 
documents for each patient were paper clipped together for organizational purposes and to 
ensure that each patient’s data gathered remained together. Telephone calls to patients were 
made by the project manager in the safety of the project manager’s home when no one else 
was home or in a private room with the door closed to ensure patient confidentiality. Data 
collected during this time was stored in a folder clearly marked with the project title located in a 
private and safe area of the project manager’s home with access only to the project manager.  
Management and analysis. The project manager accessed the designated folder in 
order to perform data analysis. Patient data with code numbers only was taken from the folder 
at the office to the project manager’s home while the code list remained safely stored in the 
locked box aforementioned. Patient names and other identifying information were never 
disclosed, and only code numbers were referenced in discussions regarding the project. 
Following completion of the project, including data analysis, the coding list was destroyed. Pre-
intervention and post-intervention data were analyzed via a paired t-test. Demographic data 
were also analyzed via Chi-square. Software utilized to run data analysis was IBM SPSS 
Statistics Base 24. 
Protection of Human Subjects 
 Protection of human subjects was upheld throughout the project. The project manager 
was properly educated about protection of human subjects and completed an ethics course 
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within the DNP curriculum during the fall semester of 2017 as well as an online training course 
through the National Institutes of Health (NIH) titled “Protecting Human Research Participants” 
in April 2018. A certificate of completion of the NIH course is available in Appendix A. The 
project manager applied for approval from Valparaiso University’s Institutional Review Board 
(IRB) by mailing in a detailed application explaining the project on August 12, 2018. 
Suggestions for revisions to the project were provided by the IRB, and such revisions within the 
project were made and made known to the IRB. Approval for the project was obtained by 
Valparaiso University’s IRB on September 21, 2018. Consent from adult participants was 
obtained. A thorough explanation of the project, including risks, benefits, and time commitment, 
was provided to potential participants prior to obtaining consent. Questions from potential 
participants were thoroughly answered. Potential participants were also informed that patient 
confidentially would be upheld, participation is voluntary, and participants who do not want to 
participate will still receive the standard of care. Patients were not coerced, nor pressured into 
participating. Participants that consented were informed that they could withdraw from the 
project at any time without retribution. Data were kept in a secure and private location, and the 
coding list with patient names was destroyed by shredding upon project completion. 
 
 
 
 
 
 
 
 
 
 
GENERALIZED ANXIETY DISORDER PROTOCOL 95 
 
 
CHAPTER 4 
FINDINGS 
The purpose of this EBP project was to implement an evidence-based protocol involving 
combination therapy with CBT and SSRI medication in order to improve patient outcomes 
through more accessible, standardized treatment of GAD. Patient outcomes, including anxiety 
and depression symptoms, were measured via the GAD-7 Scale and PHQ-9 respectively in 
order to compare baseline scores to follow up scores over a period of 12 weeks. Additional 
outcomes, including change in GAD status, patient acceptability, and patient satisfaction were 
also measured. Both participant demographic characteristics and outcomes were analyzed. 
Participants 
Size. Upon commencement of project implementation, 20 eligible participants consented 
to participate, completed the demographic form, and completed self-report baseline measures 
of the GAD-7 Scale and PHQ-9. SSRI medication was either initiated or continued at this time, 
and self-administered CBT was initiated in accordance with the developed protocol. Participants 
agreed to independently administer their SSRI medication as directed and complete the CBT 
workbook independently as instructed. In total, 12 participants completed follow up at week 4 as 
well as at week 8 for an attrition rate of 40% at each of these times of measurement. A total 
number of 10 participants completed the final follow up at week 12 yielding a final attrition rate 
of 50%.  
Characteristics. Demographic characteristics for participants (n=10) were analyzed 
using descriptive statistics. Pre-intervention demographic data for the initial 20 participants that 
enrolled in the project and completed baseline data were collected. As outcomes were analyzed 
for only the 10 participants who completed the project in full, including baseline, week 4, week 8, 
and week 12 data, demographic data for only the remaining 10 participants were analyzed for 
consistency. Analysis of the characteristic of age was reported via the mean and range while 
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the remaining demographic characteristics were reported via frequencies. Participant ages 
ranged from 18 to 75 years with a mean age of 49.60 years (SD = 17.86). The majority of 
participants were female (70%) (Figure 4.1), Caucasian (100%) (Figure 4.2), and married (60%) 
(Figure 4.3). The majority also had private insurance (70%) (Figure 4.4), held a high school 
diploma or GED as their highest level of education (60%) (Figure 4.5), were employed full time 
(30%) (Figure 4.6), made an annual household income of over $100,000 (30%) (Figure 4.7). 
Descriptive statistics regarding demographic data are presented in Table 4.1. 
Intervention Information. As aforementioned, the intervention protocol consisted of 
combination therapy of an SSRI antidepressant medication with self-administered CBT in the 
form of a workbook. Sertraline was recommended in accordance with the literature based on its 
safety and tolerability, but the prescribing of any SSRI was acceptable within this project. Of the 
10 participants who completed all follow ups throughout the 12 weeks of project implementation, 
60% were prescribed sertraline, 20% were prescribed escitalopram, 10% were prescribed 
fluoxetine, and 10% were prescribed paroxetine. All participants (100%) within the remaining 
sample of 10 participants had already been taking an SSRI prior to baseline assessment. A total 
of 95% of the original sample of 20 participants had been taking an SSRI prior to baseline 
assessment while 5% of original sample started taking an SSRI immediately after baseline 
assessment. Thus, CBT was added immediately after the baseline assessment in order to fulfill 
the protocol of combination therapy. As it would have been unethical and unsafe to discontinue 
as needed benzodiazepines immediately at the baseline appointment, participants who were 
taking or began taking an SSRI medication were eligible even if they also had been prescribed 
an as needed benzodiazepine. A total of 10% of the remaining 10 participants at week 12 had 
been taking an as needed benzodiazepine.  
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Table 4.1 
Demographic Characteristics 
 
Demographic 
 
Frequency (%) 
 
 
Number of participants 
 
10 (100%) 
Age 
Mean/SD 
Range 
Gender 
Male 
Female 
Race 
Caucasian 
Native American 
Marital status 
Single 
Married 
Divorced 
Widowed 
Health insurance 
No insurance 
Medicare 
Medicaid 
Private 
 
49.60/17.86 
18 - 75 
 
3 (30) 
7(70) 
 
10 (100) 
0 (0) 
 
2 (20) 
6 (60) 
1 (10) 
1 (10) 
 
1 (10) 
2 (20) 
0 (0) 
7 (70) 
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Highest level of education 
High school/GED 
Some college 
2-year degree 
4-year degree 
Employment status 
Full time 
Part time 
Student 
Retired 
Homemaker 
Self-employed 
Unable to work 
Annual household income 
Less than $20,000 
$20,000 - $34,999 
$35,000 - $49,999 
$50,000 - $74,999 
$75,000 - $99,999 
Over $100,000 
 
6 (60) 
2 (20) 
0 (0) 
2 (20) 
 
3 (30) 
0 (0) 
1 (10) 
2 (20) 
1 (10) 
1 (10) 
2 (20) 
 
2 (20) 
1 (10) 
2 (20) 
0 (0) 
2 (20) 
3 (30) 
  
GED = General Education Diploma; SD = Standard Deviation 
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Figure 4.1. Gender Pie Chart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2. Race Pie Chart 
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Figure 4.3. Marital Status Pie Chart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4. Health Insurance Pie Chart 
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Figure 4.5. Highest Level of Education Pie Chart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6. Employment Status Pie Chart 
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Figure 4.7. Annual Household Income Pie Chart 
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Changes in Outcomes 
This EBP project addressed the following PICOT question, “Among adults presenting 
with generalized anxiety disorder (GAD) in the family practice setting (P), does the introduction 
of an intervention protocol to treat patients with a selective serotonin reuptake inhibitor (SSRI) 
and self-administered cognitive behavioral therapy (CBT) via bibliotherapy (I) compared to the 
current practice of no protocol (C), improve GAD symptoms as measured by patient-reported 
scores on the Generalized Anxiety Disorder 7-item (GAD-7) scale (O) over a 12-week period 
(T)?” The primary outcome of anxiety symptoms was measured using the GAD-7 Scale at 
baseline, 4-weeks, 8-weeks, and 12-weeks post-intervention. Secondary outcomes, including 
depression symptoms via the PHQ-9, change in GAD status via the CGI-I, and patient 
satisfaction were also measured. 
Statistical testing. Data were entered into the Statistical Package for Social Sciences 
(SPSS) Version 25 for analysis. The text titled How to use SPSS: A step-by-step guide to 
analysis and interpretation by Cronk (2017) was utilized to guide the process of analysis and 
interpretation. A repeated measures ANOVA was used for comparison of anxiety symptoms and 
depression symptoms at four different times, including baseline, 4-weeks post-intervention, 
which is also referred to as week 4, 8-weeks post-intervention, which is also referred to as week 
8, and 12-weeks post intervention, which is also referred to as week 12. A repeated measures 
ANOVA was also used to analyze changes in GAD status, which was measured at three 
different times, including week 4, week 8, and week 12. Statistical significance for all analyses 
was determined as p < 0.05. Patient satisfaction data were measured via the PSQ at 12-weeks 
post-intervention only and analyzed via descriptive statistics. Patient acceptability data were 
measured via attrition rate and also analyzed via descriptive statistics. 
Anxiety symptoms. Anxiety symptoms were scored using the GAD-7, which asked 
participants to rate 7 items, or anxiety-related problems, on a Likert scale indicating their 
frequency within the last 2 weeks of 0 (not at all), 1 (several days), 2 (more than half the days), 
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or 3 (nearly every day). These items were tallied into a total score ranging from 0 to 21 with 
higher scores consistent with higher levels of anxiety severity. Scores 0-4 indicate minimal 
symptoms, scores 5-9 indicate mild symptoms, scores 10-14 indicate moderate symptoms, and 
scores 15-21 indicate severe symptoms. A one-way repeated-measures ANOVA was calculated 
comparing the exam scores of participants at four different times: baseline, week 4, week 8, and 
week 12. No significant effect was found (F(3,27) = 1.94, p > 0.05). No significant difference 
exists among baseline (M = 4.20, SD = 4.32), week 4 (M = 3.40, SD = 2.72), week 8 (M = 2.40, 
SD = 3.13), and week 12 (M = 1.60, SD = 2.12) means. Repeated measures ANOVA data with 
means and standard deviations for anxiety symptoms are presented in Table 4.2. A visual 
representation of the decreasing trend in mean GAD-7 scores over 12 weeks indicating 
improvement in anxiety symptom severity is depicted in a line graph in Figure 4.8. 
In addition to the one-way repeated-measures ANOVAs that were calculated for total 
GAD-7 scores, one-way repeated-measures ANOVAs were also calculated for each individual 
item within the GAD-7 Scale. No significant difference was found among any of the individual 
items, including Question 1 (F(3,27) = 0.669, p > 0.05), Question 2 (F(3,27) = 0.588, p > 0.05), 
Question 3 (F(3,27) = 0.355, p > 0.05), Question 4 (F(3,27) = 1.736, p > 0.05), Question 5 
(F(3,27) = 1.919, p > 0.05), Question 6 (F(3,27) = 2.197, p > 0.05), Question 7 (F(3,27) = 1.090, 
p > 0.05), or Question 8 (F(3,27) = 1.636, p > 0.05). 
Depression symptoms. Similar to anxiety symptoms, depression symptoms were 
scored using the PHQ-9, which asked participants to rate 9 items, or depression-related 
problems, on a Likert scale indicating their frequency within the last 2 weeks of 0 (not at all), 1 
(several days), 2 (more than half the days), or 3 (nearly every day). These items were tallied 
into a total score ranging from 0 to 27 with higher scores consistent with higher levels of 
depression severity. Scores 0-4 indicate minimal symptoms, scores 5-9 indicate mild symptoms, 
scores 10-14 indicate moderate symptoms, scores 15-19 indicate moderately severe symptoms, 
and scores 20-27 indicate severe symptoms. A one-way repeated measures ANOVA was 
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calculated comparing the PHQ-9 scores of participants at four different times: baseline, 4-weeks 
post-intervention, 8-weeks post-intervention, and 12-weeks post-intervention. A significant effect 
was found (F(3,27) = 4.34, p < 0.05). Repeated measures ANOVA data with means and 
standard deviations for depression symptoms are presented in Table 4.2. Follow-up protected t 
tests revealed scores decreased significantly from baseline (M = 4.80, SD = 3.58) to week 8 (M 
= 2.90, SD = 2.02), baseline to week 12 (M = 1.90, SD = 2.81), week 4 (M = 3.90, SD = 2.77) to 
week 8, and week 4 to week 12. Such post hoc paired t test data for depression symptoms are 
displayed in Table 4.3. No significant difference exists among baseline and week 4 means or 
week 8 and week 12 means. A visual representation of the decreasing trend in mean PHQ-9 
scores over 12 weeks indicating improvement in depression symptom severity is depicted in a 
line graph in Figure 4.8. 
In addition to the one-way repeated-measures ANOVAs that were calculated for total 
PHQ-9 scores, one-way repeated-measures ANOVAs were also calculated for each individual 
item within the PHQ-9. No significant difference was found among any of the individual items, 
including Question 1 (F(3,27) = 1.615, p > 0.05), Question 2 (F(3,27) = 0.915, p > 0.05), 
Question 3 (F(3,27) = 1.761, p > 0.05), Question 4 (F(3,27) = 2.374, p > 0.05), Question 5 
(F(3,27) = 2.656, p > 0.05), Question 6 (F(3,27) = 0.310, p > 0.05), Question 7 (F(3,27) = 2.769, 
p > 0.05), Question 8 (F(3,27) = 1.976, p > 0.05), Question 9 (F(3,27) = no change), or Question 
10 (F(3,27) = 0.783, p > 0.05). 
Change in GAD status. Change in GAD status from baseline was determined using the 
CGI-I scale and scored by the project manager as 1 (very much improved), 2 (much improved), 
3 (minimally improved), 4 (no change), 5 (minimally worse), 6 (much worse), or 7 (very much 
worse). A one-way repeated measures ANOVA was calculated comparing CGI-I scores of 
participants at three different times: week 4, week 8, and week 12. No significant effect was 
found (F(2, 18) = 3.05, p > 0.05). No significant different exists among week 4 (M = 3.60, SD = 
1.07), week 8 (M = 2.80, SD = 1.40), and week 12 (M = 2.30, SD = 1.57) means. Repeated 
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measures ANOVA data with means and standard deviations for change in GAD status are 
presented in Table 4.2. 
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Table 4.2 
Repeated Measures ANOVAs with Means and Standard Deviations (n = 10) 
Variable Mean SD F p 
 
Anxiety 
symptoms 
 
Baseline 
Week 4 
Week 8 
Week 12 
 
 
Depression 
symptoms 
 
Baseline 
Week 4 
Week 8 
Week 12 
 
 
Change in GAD 
status 
 
Week 4 
Week 8 
Week 12 
 
 
 
 
4.20 
3.40 
2.40 
1.60 
 
 
 
 
 
4.80 
3.90 
2.90 
1.90 
 
 
 
 
 
3.60 
2.80 
2.30 
 
 
 
 
 
4.32 
2.72 
3.13 
2.12 
 
 
 
 
 
3.58 
2.77 
2.02 
2.81 
 
 
 
 
 
1.07 
1.40 
1.57 
 
 
 
 
1.94 
 
 
 
 
 
 
 
 
4.34 
 
 
 
 
 
 
 
 
3.05 
 
 
 
 
0.146 
 
 
 
 
 
 
 
 
 0.013* 
 
 
 
 
 
 
 
 
0.072 
     
 
* =  Denotes statistical significance 
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Table 4.3 
PHQ-9 Post Hoc Paired t Tests (n = 10) 
Variable Mean 
Difference 
SD t df p 
 
Depression 
symptoms 
 
Baseline – 
Week 4 
 
Baseline – 
Week 8 
 
Baseline – 
Week 12 
 
Week 4 – 
Week 8 
 
Week 4 – 
Week 12 
 
Week 8 – 
Week 12 
 
 
 
 
 
1.33 
 
 
1.83 
 
 
2.90 
 
 
1.27 
 
 
2.00 
 
 
1.00 
 
 
 
 
 
 
 
3.80 
 
 
2.79 
 
 
3.93 
 
 
1.56 
 
 
2.05 
 
 
1.70 
 
 
 
 
1.22 
 
 
2.28 
 
 
2.33 
 
 
2.71 
 
 
3.08 
 
 
1.86 
 
 
 
 
11 
 
 
11 
 
 
9 
 
 
10 
 
 
9 
 
 
9 
 
 
 
 
0.249 
 
 
 0.044* 
 
 
 0.044* 
 
 
 0.022* 
 
 
 0.013* 
 
 
0.096 
      
* =  Denotes statistical significance 
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Figure 4.8. Improvement in Mean Anxiety (GAD-7) and Depression (PHQ-9) Symptom Severity 
with Combination Therapy (n = 10)  
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Acceptability. Patient acceptability of the combined SSRI and CBT protocol was 
measured via the attrition rate from pre- to post-intervention, or baseline to week 12. As 
aforementioned, 20 participants (N = 20) consented to project enrollment and completed 
baseline measurements. At week 4, the participant response rate was 60% (n = 12) with an 
attrition rate of 40%. At week 8, the participant response rate and attrition rate did not change 
from the aforementioned values of week 4. At week 12, the participant response rate decreased 
to 50% (n = 10) while the attrition rate rose to 50%. 
Patient satisfaction. Patient satisfaction scores were measured at week 12 using the 
PSQ and analyzed using descriptive statistics, including frequency, mean, and range. One 
participant declined to complete the PSQ, and thus, nine remaining participants completed the 
PSQ in total. The majority of participants rated use of the CBT workbook as very convenient 
(33.3%) (Figure 4.9), easy (44.4%) (Figure 4.10), and very worthwhile (55.6%) (Figure 4.11). 
The majority also reported their satisfaction with the CBT workbook’s impact on their anxiety 
symptoms as a tie between satisfied (44.4%) and very satisfied (44.4%) (Figure 4.12) with an 
overall satisfaction level with the CBT workbook of satisfied (44.4%) (Figure 4.13). Time spent 
using the CBT workbook per week ranged from 15 minutes to 30 hours as reported by 
participants. The mean amount of time spent using the CBT workbook per week was 301.11 
minutes, or approximately 5 hours, with a standard deviation of 576.21 minutes, or 
approximately 9.5 hours.  
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Figure 4.9. Patient Satisfaction Questionnaire Convenience Pie Chart 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10. Patient Satisfaction Questionnaire Ease of Use Pie Chart 
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Figure 4.11. Patient Satisfaction Questionnaire Worthwhile Pie Chart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12. Patient Satisfaction Questionnaire Satisfaction with Impact on Anxiety Symptoms  
                    Pie Chart 
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Figure 4.13. Patient Satisfaction Questionnaire Satisfaction Overall 
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Significance. To summarize, no statistical significance was achieved for evaluation the 
primary outcome of anxiety symptoms via the GAD-7 Scale (F(3,27) = 1.94, p > 0.05) nor for 
evaluation of the secondary outcome of change in GAD status via the CGI-I Scale (F(2, 18) = 
3.05, p > 0.05). Statistical significance was achieved for evaluation of the secondary outcome of 
depression symptoms via the PHQ-9 (F(3,27) = 4.34, p < 0.05).  
Reliability and validity. The reliability and validity of each tool utilized to evaluate 
outcomes was assessed. The GAD-7 was utilized to evaluate anxiety symptoms. There is much 
evidence to support the GAD-7’s high reliability and validity (Spitzer et al., 2006). With a high 
Cronbach’s alpha of 0.92, the GAD-7 demonstrates excellent internal consistency. It is also 
noted to have good sensitivity (89%) and specificity (82%), good construct and convergent 
validity, and good criterion and factorial validity (Kertz et al., 2013; Spitzer et al, 2006; Williams, 
2014). A Cronbach’s alpha regarding the GAD-7 Scale relative to this project specifically was 
calculated using SPSS software and found to be 0.87. This is similar to that reported within the 
literature, and thus, high reliability of the GAD-7 was demonstrated within this project. 
Similarly, the PHQ-9, used to evaluate anxiety symptoms, also demonstrates high 
reliability and validity within the literature (Kroenke et al., 2001). It’s excellent internal reliability is 
supported with a Cronbach’s alpha of 0.89 reported within the literature. The PHQ-9 also has 
excellent test-retest reliability, high sensitivity and specificity, and high construct, criterion, and 
external validity. Specifically regarding use of the PHQ-9 within this project, a Cronbach’s alpha 
was calculated as 0.90. Thus, again, excellent internal consistency and reliability is supported.  
The CGI-I, which was utilized to evaluate GAD status, also boasts high reliability and 
validity supported by evidence (Busner & Targum, 2007). It correlates well with other tools and 
has high sensitivity (Berk et al., 2008). It has high validity and is able to be used among diverse 
groups. It has specific instructions to promote its appropriate use and high reliability. 
The PSQ was developed by the patient manager to evaluate patient satisfaction with 
self-administered CBT. Thus, validity cannot be established for the PSQ as it has not been 
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reviewed by experts. Reliability tests were performed within SPSS in order to determine the 
PSQ’s reliability. A Cronbach’s alpha was calculated as 0.84. Thus, this supports good internal 
consistency and high reliability of the PSQ. 
GENERALIZED ANXIETY DISORDER PROTOCOL 116 
 
 
CHAPTER 5 
DISCUSSION 
This EBP project served the purpose of answering the following PICOT question, 
“Among adults presenting with generalized anxiety disorder (GAD) in the family practice setting 
(P), does the introduction of an intervention protocol to treat patients with a selective serotonin 
reuptake inhibitor (SSRI) and self-administered cognitive behavioral therapy (CBT) via 
bibliotherapy (I) compared to the current practice of no protocol (C), improve GAD symptoms as 
measured by patient-reported scores on the Generalized Anxiety Disorder 7-item (GAD-7) scale 
(O) over a 12-week period (T)?” The project examined the impact of the combination therapy 
protocol involving simultaneous self-administered CBT and SSRI antidepressant medication use 
on decreasing anxiety and depression symptoms, improving GAD status, and demonstrating 
patient acceptability and satisfaction among adults presenting to the family practice setting with 
a diagnosis of GAD. This chapter will detail an explanation and interpretation of project findings 
as well as an evaluation of the applicability of the theoretical framework and EBP model used to 
guide the project. Project strengths and limitations will be explored as will consideration of 
implications for future practice, theory, research, and education. 
Explanation of Findings 
 Project findings support the effectiveness of combination therapy regarding CBT and 
SSRIs for the treatment of GAD among adults. Such results were consistent with current 
literature overall. Participant findings, including sample size, demographic characteristics, and 
intervention information, will be discussed. Outcomes, including anxiety symptoms, depression 
symptoms, change in GAD status, acceptability, patient satisfaction, and incidental qualitative 
data, will also be explained. 
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Participant Findings 
 Based on information reported within high quality, current literature, including the high 
prevalence of GAD and larger sample sizes reported in studies within the literature review, a 
larger participant sample size was expected. The sample size of this project was limited by 
several factors that will be further discussed later on within this chapter. The sample population 
was predominantly female (70%) within this project. This was an expected finding as women are 
affected by GAD twice as often as men (Edmund & Sheppard, 2018). The majority of 
participants earned an annual household income of over $100,000, which can be considered of 
high socioeconomic status. Although the link between socioeconomic status and rates of GAD 
is conflicting (McBride, 2015), the results of this project support that high socioeconomic status 
could be linked to higher rates of GAD as compared with those of low socioeconomic status. As 
the majority of participants were already taking an SSRI prior to baseline, this project allowed 
the effects of the addition of self-administered CBT to be assessed and visible. The majority of 
participants who completed follow up in its entirety were prescribed sertraline (60%), which was 
recommended in the literature. Thus, this added strength to the project and also demonstrated 
that patient safety, medication tolerability, and the best interests of participants were priorities. 
A small number of participants had been prescribed an as needed benzodiazepine prior 
to baseline and had this available for administration during the implantation phase of this 
project. As aforementioned, it was decided that it would be unethical and unsafe to immediately 
discontinue the benzodiazepine at baseline. Excluding these participants, those taking an SSRI 
and benzodiazepine, from the project was decided against as it was determined that these 
participants could also significantly benefit from the intervention. It was also hoped that the 
benzodiazepine could eventually be discontinued due to the improvement from combination 
therapy. As such a minimal number of the remaining participants were taking an as needed 
benzodiazepine (10%), it is not thought that this had an effect on results. It was also not 
confirmed as to how often, if at all, the participants were taking benzodiazepines during the 
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implementation phase. It would have been helpful for the project manager to have asked 
participants this information during follow up phone calls, but due to human error, this was not 
done. 
Anxiety Symptoms 
Although a statistically significant decrease in anxiety symptoms was not achieved upon 
project completion, mean GAD-7 scores did decrease every 4 weeks of project implementation. 
Therefore, lack of statistical significance does not negate the positive impact of combination 
therapy on anxiety symptoms and may be accounted for by project limitations. Mean GAD-7 
scores indicating anxiety symptom severity among the 10 participants who completed final 
follow up steadily decreased with mean scores of 4.20 at baseline, 3.40 at week 4, 2.40 at week 
8, and 1.60 at week 12. Patient-reported GAD-7 Scale scores range from 0 - 21 with scores of 0 
- 4 indicating minimal symptom severity, 5 - 9 indicating mild symptom severity, 10 - 14 
indicating moderate symptom severity, and 15 - 21 indicating severe symptom severity. Thus, 
mean scores were decreased from levels of symptom severity indicating minimal to mild 
symptom severity at baseline to minimal symptom severity by week 12. This indicated that 
anxiety symptoms decreased as a result of combination therapy. As these 10 participants had 
been taking SSRIs prior to project implementation, this specifically indicated that the addition of 
CBT yielded a positive effect in the form of a decrease in anxiety symptoms. Participants’ use of 
SSRI medication prior to the implementation of the project may explain why participants’ 
symptom severity was minimal to mild when beginning the project, which did not allow for large 
scale improvement. Also, it is important to note that many of the 10 participants who did not 
follow up until project completion and were not included in data analysis rated high GAD-7 
scores at baseline that indicated severe symptom severity. Therefore, results of this project in 
no way indicate that the impact of GAD anxiety symptomology is less than what is described by 
current literature. It was surprising that a statistically significant decrease in GAD-7 scores was 
not achieved as often was reported within current literature. However, this was likely related to 
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many limitations of the study. The small patient sample and attrition was unable to account for 
the extreme symptom severity and debilitating potential of GAD, yet many participants reported 
that their anxiety symptoms prior to project completion interfered with their lives and made it 
difficult to work, take care of things at home, or get along with other people. Therefore, the 
decreased anxiety symptoms displayed by steadily reduced mean GAD-7 scores over 12 weeks 
of project implementation, although not statistically significant, were of great benefit to 
participants. 
Depression Symptoms 
 A statistically significant decrease in depression symptoms was achieved upon 
completion of project implementation at week 12. Mean PHQ-9 scores indicating depression 
symptom severity among the 10 participants who completed final follow up steadily decreased 
with mean scores of 4.80 at baseline, 3.90 at week 4, 2.90 at week 8, and 1.90 at week 12. 
Patient-reported PHQ-9 scores range from 0 - 27 with scores of 0 - 4 indicating minimal 
symptom severity, 5 - 9 indicating mild symptom severity, 10 - 14 indicating moderate symptom 
severity, 15 - 19 indicating moderately severe symptom severity, and 20 - 27 indicating severe 
symptom severity. Thus, mean scores were decreased from levels of depression symptom 
severity indicating minimal to mild symptom severity at baseline to minimal symptom severity by 
week 12. Thus, results indicate that depression symptoms significantly decreased as a result of 
combination therapy with CBT and SSRIs. Like anxiety symptoms, the low level of depression 
symptoms at baseline may again be accounted for as the remaining 10 participants were all 
taking SSRI medication prior to the start of project implementation. The statistically significant 
decrease in depression symptoms achieved by completion of project implementation supports 
the significant benefit of combination therapy with self-administered CBT and SSRI medication 
for the treatment of adults with GAD. Such results also demonstrate the strong link between 
depression and anxiety that was addressed in the literature and the need to address not only 
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anxiety symptoms, but also depression symptoms, in patients presenting with GAD at every 
visit. 
Change in GAD Status 
 In congruence with anxiety symptoms, change in GAD status did not achieve statistical 
significance. Again, the positive impact of combination therapy on change in GAD status is not 
negated by lack of significance as the 10 remaining participants who completed week 12 follow 
up demonstrated an improvement in GAD status. It was surprising that statistical significance 
was not achieved in accordance with current literature. However, again, statistical significant 
within this project likely would have been achieved had it not been for the limitations of the 
project. This level of improvement or worsening of disease course was rated by the project 
manager using the CGI-I Scale with a score of 1 indicating very much improved, 2 indicating 
much improved, 3 indicating minimally improved, 4 indicating no change, 5 indicating minimally 
worse, 6 indicating much worse, and 7 indicating very much worse. The CGI-I Scale was utilized 
appropriately by always comparing change in GAD status to baseline GAD status. Mean CGI-I 
scores decreased when measured every 4 weeks, indicating improvement in GAD status. Mean 
scores decreased from 3.90 at week 4, 2.90 at week 8, and 1.90 at week 12. Thus, mean 
change in GAD status improved from no change/minimally improved at week 4 to much 
improved/very much improved at week 12. Therefore, project findings support that combination 
therapy with SSRIs and CBT improves GAD status. 
Acceptability 
 Participant acceptance of the combination therapy, particularly the addition of CBT, was 
determined by the rate of attrition, or the number of participants lost to follow up. Attrition rates 
were 40% at week 4, 40% at week 8, and 50% at week 12. Typically, attrition rates of 50% and 
lower are considered acceptably low while attrition rates greater than 50% are considered high 
(Deke, Sama-Miller, & Hershey, 2015). Thus, the attrition rates for this project are considered 
low, indicating high levels of acceptability among participants regarding the intervention. The 
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attrition can likely be explained by difficulties in reaching participants via phone, full or 
nonfunctioning voicemail boxes, and busy participant schedules limiting availability for follow up. 
The low attrition rate was expected and similar to that reported within high quality literature. 
Patient Satisfaction 
 Patient satisfaction regarding CBT was rated by participant responses to the PSQ 
created by the project manager. Findings indicated that participants were satisfied with the CBT 
workbook, which coincides with high patient satisfaction yielded within the literature. The 
majority of participants found the CBT workbook very convenient to use, easy to use, and very 
worthwhile to use. In addition, the majority of participants were satisfied or very satisfied with the 
impact that use of the CBT workbook had on their anxiety symptoms and satisfied with use of 
the CBT workbook overall. There were large variations reported regarding the amount of time 
that participants spent utilizing the CBT workbook per week with a wide range of 15 minutes to 
30 hours per week. Participants spent an average of 5 hours per week utilizing the CBT 
workbook. The most common response provided regarding approximate time spent utilizing the 
CBT workbook per week was 1 hour. Thus, some participants spent a brief time utilizing the 
CBT workbook per week while others spent extensive time utilizing the CBT workbook per 
week.  
Qualitative Data 
 During initial in-person patient visits at the clinic at baseline as well as follow-up 
telephone encounters with the project manager at week 4, week 8, and week 12, participants 
expressed comments regarding use of such combined CBT and SSRI intervention. These 
patient comments are useful in depicting patients’ unique experiences, thoughts, and beliefs 
with combination therapy. Several common themes emerged from this incidental qualitative 
data. Such themes explore effectiveness, understanding, side effects, endorsement, 
accessibility/ease of transport of self-administered CBT, applicability of self-administered CBT 
components, and busy lifestyle. These themes will be discussed in further detail as follows. 
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One common theme was that self-administered CBT and SSRIs were effective in 
helping participants feel better by minimizing symptoms associated with GAD. For example, 
participants noted positive changes with comments including, “I feel like the book and 
medication are helping a lot. I notice a big difference from my last visit,” “The CBT is helping. 
I’ve noticed a big change in myself. The [SSRI] also helps, and I notice when I don’t take it 
because I feel more anxious,” and “I like to read the book. It is very beneficial. I feel better with 
the [SSRI], and I feel the book helps, too.” Participants also reported improved productivity, 
increased levels of patience, and decreased depression symptoms. One patient expressed, “I 
accomplish more things now. I am feeling better from the start from talking to you and reading 
the book. I reevaluate my thoughts. I feel good.” Another stated, “I can see the difference, 
especially when it comes to irritation. I have more patience.” A  third mentioned, “The [SSRI] 
has changed me around a lot and made me less depressed.” 
As a second commonly identified theme, self-administered CBT provided useful 
education to participants and increased their understanding of GAD and coping skills. 
Participants were quoted saying, “As I read more of the workbook, I understand generalized 
anxiety disorder better.” Additional noteworthy patient reports included, “The book has helped 
me understand a lot more and puts things into perspective,” “I feel like the book is teaching me 
things I didn’t know and didn’t realize until now,” “It tells me things that I can do when my anxiety 
comes on,” and “Now, I’m able to work through my anxiety. The workbook taught me things that 
I wasn’t fully aware of and didn’t know how to do before.” Thus, participants were able to make 
important realizations through use of self-administered CBT and utilize this learned information 
to manage their anxiety and depression symptoms. Another participant stated, “I learned 
everything I wanted to know from the workbook. It’s therapeutic and makes you think” while 
another expressed, “I’m more conscious of things now because of the workbook.”  
Another theme supported that participants experienced minimal to no side effects 
associated with self-administered CBT and SSRIs. One participant reported, “I was getting 
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sweaty palms from the [SSRI], but that’s the only side effect I’ve noticed. [The NP] told me to 
take it at night instead of in the morning to help with this.” Another mentioned, “I haven’t had any 
side effects.” 
It was another commonly identified theme that participants endorsed self-administered 
CBT through expressions of satisfaction, enjoyment, desire for earlier use, plans to continue 
use, and plans to share self-administered CBT with others. Satisfaction and enjoyment were 
supported by participant comments, including “I’m so glad you offered this to me,” “I’ve been 
using the workbook more, and it’s helped a lot with my symptoms. I’m very satisfied,” “I like the 
CBT workbook and find it useful. I am pleasantly surprised how much the book has helped. It’s 
like a breath of fresh air. My symptoms are not as frequent,” and “I notice an improvement from 
a month ago. I find it interesting. It’s been a while since I had to read a book and study. I enjoy 
it.” Others shared their desire for earlier self-administered CBT use and intent to continue use 
with, “I wish I’d had this book a long time ago. So is this all? Are we done? Because I want to 
keep doing this. I plan to continue using this because I really like it. It was fun. Thank you for 
this,” as well as “ I’m very excited about the workbook. This is great! I wish I had this when I 
started the medication.” Many participants were excited to share CBT to allow others to benefit 
from it as exemplified by the following quotations, “I was telling my boss about it and even she is 
interested in the CBT workbook now,” and “My daughter also has anxiety, and I am going to 
have her do this with me.” At the beginning of the project, one participant expressed, “I am 
excited to do this workbook. I work as a nurse at an addiction center and am excited to use this 
and learn from it in order to help my patients. This would be great for a lot of them,” and at the 
end of week 12 follow up mentioned, “I have been telling the counselors at work about this CBT 
and plan to share what I have learned with a class I teach.” 
An additional common theme attested that the self-administered CBT was easy to keep 
nearby the participant and to transport. For example, one participant reported, “I take the book 
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with me wherever I go, including work and to my mother-in-law’s house.” Another noted, “I’ve 
been keeping the book by my chair.” 
Several participants expressed that some information within the CBT workbook applied 
to them greatly while other information did not apply to them at all. A participant was quoted as 
reporting, “Some of the things in this book don’t apply to me, like anxiety around crowds, but I 
will keep reading it” while another stated, “The chapter about procrastination hit home and 
helped me. I often procrastinate, which causes me more anxiety.” Another participant felt a 
combination of these opinions with, “Some parts of the CBT workbook don’t pertain to me, but 
some are spot on.” 
Finally, busy lifestyles and stressful life events making it difficult to use self-administered 
CBT was a common theme. This also contributed to difficulty achieving follow up and the 
resulting attrition throughout the project. For example, a participant expressed, “I haven’t done 
the CBT book yet because things have been so crazy since my accident, but I will get to it.” 
Similarly, another patient reported, “I had major surgery recently, and I need to focus on 
physical therapy so I have not used the book much yet.” Another stated, “I am driving now and 
am busy with my three kids and their activities tonight. I will call you tomorrow.” However, the 
patient did not call nor return calls. Unfortunately, another participant reported sad family 
circumstances that hindered his ability for completion and follow up with the statement, “My dad 
is dying. I read one chapter. Things have been hectic. I can’t answer questions now, but you 
can call me back in a week.” Follow up was not achieved with this patient. Additional remarks 
included, “It has been difficult to use because of my busy schedule, but I feel that the book is 
helpful,” “I’m in the middle of something with my daughter and will call you back in a little bit,” 
and “I haven’t used the book a lot recently because it’s finals weeks, but it is helping.” 
Evaluation of Applicability of Theoretical and EBP Frameworks 
 The Neuman Systems Model served as the theoretical basis of the EBP project while the 
Stetler Model was the EBP model that guided the project. Use of these models aided in 
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successful implementation of the practice change by providing frameworks that the project 
manager could follow. Incorporating such models allowed important components to be upheld 
throughout the project as the principles of the Neuman Systems Model and the Stetler Model 
aligned with those of the project. 
Theoretical Framework 
 The Neuman Systems Model served as a very effective and applicable theoretical 
framework to guide this EBP project (Neuman, 1982). Successful implementation of combined 
self-administered CBT and SSRI medication was able to occur in the family practice setting by 
utilizing this framework. Strengths of the Neuman Systems Model included its focus on the 
patient achieving an optimal level of wellness. This was a goal congruent with the EBP project. 
Through combination therapy to decrease anxiety and depression symptoms and improve GAD 
status, wellness was promoted within this project. In addition to considering patient wellness, 
the Neuman Systems Model assisted the project manager in considering lines of resistance and 
defense. The SSRI medication was able to serve as a defense against any harm to patient 
wellness through chemical changes within the brain to decrease feelings of anxiety. The CBT 
workbook was able to provide a defense mechanism through teaching coping skills to deflect 
stressors within the environment. The Neuman Systems Model brought concepts of the 
environment, stressors, health, and nursing to the forefront in order to develop a project that 
strived to address interactions between the patient and stressors within the environment, 
implement a beneficial nursing intervention to modify the manner in which the patient responds 
to such interactions, and improve patient’s health and wellness through collaboration via a 
positive relationship between the patient and nurse practitioner providing care. Weaknesses of 
the Neuman Systems Model included suggestions for prevention of invasion of stressors into 
beyond the lines of resistance and defense that were inapplicable to this project. Examples 
included blood pressure control and exercise. Although these are great interventions for the 
reduction of anxiety, only CBT and SSRI medications were utilized within this project on the 
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basis of best practice. In addition, limitations of the Neuman Systems Model include the risk of 
oversimplifying the theory as a whole during its application. Therefore, the need to thoroughly 
explore and understand the theoretical framework is necessary in order to use it properly. The 
Neuman Systems Model can be challenging to implement and consider all parts and subparts 
addressed within the framework, particularly as there are complexities in considering the 
interactions among an individual and the environment. Thus, an individual, holistic patient 
approach and the consideration of a multitude of variables and dynamic nature of GAD is 
necessary for proper use of the Neuman Systems Model. 
EBP Framework 
 It can be concluded that the Stetler Model was a good fit as the EBP framework utilized 
to guide this EBP project. As the project manager was a novice in regard to implementing 
practice changes, the detailed steps of the Stetler Model aided in the consideration of important 
information that otherwise could have been missed or omitted. The Stetler Model is comprised 
of the following five steps: preparation, validation, comparative evaluation/decision making, 
translation/application, and evaluation (Melnyk & Fineout-Overholt, 2015). The basic premise of 
the project was formed using the preparation stage, which provided instructions to determine a 
practice change that was in great need and perform a literature search. During experiences 
within the clinical setting in family practice, the project manager noticed that GAD was extremely 
prevalent and severely affecting the lives of patients. After wondering if there was a better way 
to treat patients for GAD than the various medications that were being prescribed, lack of follow 
through with referrals for counseling, or lack of recommendation for counseling provided, the 
project manager found strong information within the literature to support the need for a change 
in practice via self-administered CBT and SSRI medication use. Evidence was critiqued during 
the validation stage, and much good and high quality and high level evidence was utilized to 
support the project. Throughout the comparative evaluation/decision making stage, the project 
manager further determined how to utilize the evidence in a feasible and beneficial manner. 
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Numerous methods of CBT were recommended. However, self-administered CBT was 
proposed as a cost-effective, accessible, effective method that would be feasible to implement 
within the family practice setting.  
Modifications were made to the plans outlined for the translation/application stage, which 
included further planning and actual implementation of the project. Initially, the project manager 
intended to include children ages 7 years of age and older, adolescents, and pregnant women 
as participants in congruence with current literature. However, due to rigorous IRB requirements 
for approval to include such vulnerable populations, time constraints regarding start of 
implementation, and an anticipated small sample of this population at the project site, children, 
adolescents under the age of 18, and pregnant women were excluded from the project. A 
further change occurred when translating the plans of the project into practice. It was originally 
planned that patient preferences would be upheld in the form of allowing participants to choose 
between interventions of self-administered CBT only, SSRI use only, or combined self-
administered CBT and SSRI use. This would have created three different groups within the 
project. A decision to change the available intervention solely to combination therapy with self-
administered CBT and an SSRI was made after the VU IRB suggested that as combination 
therapy is best practice, it should be the only intervention offered. Additional modifications 
included provider involvement in project participant recruitment. It was originally planned that 
the two nurse practitioners in the family practice office at the project site would recruit eligible 
participants every day that they were present in the office, which would have totaled 5 days per 
week. This became altered when one NP left the practice shortly before project implementation 
began. As the remaining NP then was taking on a greater workload unexpectedly, patient 
recruitment became challenging for her due to time constraints. Therefore, the project manager 
came to the office more frequently than initially planned in order to recruit participants.  
The evaluation stage within the Stetler Model was also very useful to this project. Goals 
were evaluated as well as the degree to which the project was implemented and adopted. 
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Overall, the project was implemented in full as planned yet with revisions, and many goals were 
met, including a statistically significant decrease in depression symptoms and high levels of 
patient satisfaction reported. Goals that were not met included a sample population of at least 
25 adults with GAD and achieving a statistically significant decrease in anxiety symptoms and 
statistically significant improvement in GAD status. After completion of implementation, adoption 
of the project at the project site was discussed. As the CBT workbooks were purchased by the 
project manager using a generous grant from Sigma Theta Tau Zeta Epsilon Chapter, a new 
method for acquiring the CBT workbooks was discussed with the NP who owns the practice. 
The combination therapy protocol implemented via this project involving self-administered CBT 
and SSRI use, patient education, and close monitoring is sustainable. It was decided that the 
best way to adopt and sustain this practice change would be to provide patients with information 
regarding self-administered CBT, its benefits associated with GAD treatment, where it is 
available for purchase, and the potential cost. Best practice via the combined prescribing of 
SSRI medication and the recommendation of CBT will continue to be incorporated into the 
treatment of GAD at the project site. Such information will now be provided verbally as well as 
via a patient handout for all adults with GAD in order to provide them with a helpful resource 
encouraging them to purchase and utilize self-administered CBT, similar to the way in which 
they would be instructed to purchase an over-the-counter medication. The practice is not 
affiliated with nor receiving any funds from the companies listed based on the purchase of CBT. 
The handout was developed by the project manager and given to the project site for use. Such 
handout is presented within Appendix N. Thus, the project site has adopted the practice change 
associated with this EBP project and plans to sustain the combination therapy protocol 
implemented are in place. Future plans may include the making of a self-administered CBT 
packet by the NP and project manager to provide to patients with GAD while at the office. 
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Strengths and Limitations of the EBP Project 
 Overall, successful implementation and results of this EBP project were yielded. 
Although there were numerous strengths of this project identified, there were also numerous 
limitations identified. By addressing such aspects, results of this project may be explained and 
future related projects can be strengthened.  
Strengths 
 A strength of the project was its frequent follow up with participants every 4 weeks for a 
period of 12 weeks. This provided much information regarding the typical time period required 
for effects of self-administered CBT to become visible. It also allowed for participants to give 
detailed feedback regarding their unique experience multiple times throughout implementation. 
Another strength included measurement of a variety of outcomes, which provided much 
information regarding the vast effects of the combination therapy protocol. Further project 
strengths included the evaluation of both quantitative and incidental qualitative data. The site 
facilitator greatly believed in the need for this practice change, and many participants showed 
great interest and excitement for use of self-administered CBT. Many participants also 
expressed satisfaction and compliance with administration of their prescribed SSRIs prior to the 
start of project implementation. Another strength is that this project provided an alternative to 
inaccessible, expensive treatment through a convenient, affordable method that patients could 
utilize essentially anytime and anywhere. Although a statistically significant difference in anxiety 
symptoms was not achieved from baseline to week 12, this in no way negates the positive 
impact of this project and combined CBT and SSRI use. A statistically significant decrease in 
depression symptoms was achieved from baseline to week 12, mean anxiety symptom severity 
steadily decreased from baseline to week 12, and participants reported satisfaction with the 
CBT workbook. Thus, overall results of this project were similar to those reported within high 
quality evidence. Many participants noted their surprise at just how effective the addition of the 
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CBT component was as well as their desire to continue to utilize self-administered CBT after 
completion of this project.  
Limitations 
 The small sample size was certainly a limitation of this project, and unfortunately, it was 
not reflective of the high prevalence of GAD. This small sample size was limited by time 
constraints for recruitment as well as site facilitator decisions regarding who could be 
approached for participation within the project. Participants were recruited at a single-provider, 
rural clinic. Due to the busy nature of the practice and recent loss of a second provider, the 
remaining provider had limited time for project implementation. Therefore, participants were only 
recruited when the project manager was present in the clinic. The project manager was unable 
to be at the clinic more than typically two days per week during recruitment due to clinicals, 
class, and work. As patients with GAD were seen 5 days per week at the clinic, there was a 
large number of potential participants that could not be recruited. Also, the aforementioned sole 
provider and site facilitator, the NP whom opened and owned the clinic, knew most of her 
patients very well. There were some potentially eligible patients that the NP requested that the 
project manager not approach regarding this project for various reasons, such as time 
constraints or life events. This could have introduced some selection bias to the sample. The 
sample size was also limited by excluding children, adolescents younger than 18, and pregnant 
women as a result of IRB requirements and time constraints. Another limitation was the rather 
homogenous sample population. Of the 10 participants who completed follow up, all were 
Caucasian. Thus, there was a lack of racial diversity among participants, which could limit 
generalizability. The sample size was further limited by ineligibility based on maintenance 
medication use other than SSRIs as it would have been unsafe and unethical to immediately 
discontinue and/or change medications in many cases. Finally, mean GAD-7 and PHQ-9 scores 
indicated minimal anxiety and depression symptom severity at baseline. This was likely related 
to the majority of participants already taking an SSRI prior to project implementation. The low 
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scores limited the ability to see greater effects of the intervention protocol that may have been 
apparent provided there had been greater room for improvement. 
Implications for the Future 
 This EBP project provided worthwhile information for the advanced practice nursing 
profession related to the effects of combination therapy of SSRIs and self-administered CBT. 
Future implications for practice, theory, research, and education will be explored. Such 
implications can be used to guide and improve future EBP projects and practice changes as 
well as to positively shape the way GAD is treated both nationally and globally.  
Practice 
 This combination therapy utilizing SSRIs and CBT has been established as best practice 
in current, high quality literature. Unfortunately, it is not implemented in all primary care offices. 
This project allowed for this combination protocol to become standardized practice at the project 
site, and it is encouraged for all primary care offices to adopt this protocol. This project 
supported the feasibility, low cost, effectiveness, and high levels of patient satisfaction 
associated with combination therapy. A grant from Sigma Theta Tau Zeta Epsilon Chapter 
covered the costs of the CBT workbooks at no expense to the family practice office nor 
participants. It may not be feasible for offices to cover the expenses of the workbooks for 
patients. Therefore, additional planning is necessary in order to determine how patients can 
obtain the workbooks. This is still being discussed with the NP at the project site. Potential 
options that have been proposed include the NP and project manager developing their own form 
of self-administered CBT to pass out to patients with GAD, providing patients with a handout 
indicating types of self-administered CBT, cost, and where to purchase them, or having self-
administered CBT available for patient purchase at the office.  
 There are many future EBP considerations to address. Future EBP projects related to 
GAD with larger population sizes, greater diversity, and higher levels of anxiety and depression 
symptom severity would be beneficial to further explore significance and generalizability. 
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Additional recommendations for future projects include comparison of therapist-guided CBT 
versus self-administered CBT outcomes. This would aide in the ability to compare and contrast 
effectiveness and establish superiority regarding delivery method. It would also be beneficial for 
future EBP projects to explore the effect of CBT and SSRIs on children and adolescents 
younger than 18 years of age to further evaluate the effectiveness of this intervention across the 
lifespan. 
Theory 
 Use of the Neuman Systems Model as the theoretical foundation for this EBP project 
aided in successful implementation of this EBP project. It allowed for a patient-centered 
approach that considers the unique and individualized interactions that patients encounter with 
the environment as well as the unique way in which they interpret and react to stressors within 
the environment. This project was able to consider such reactions to stressors and provide 
methods in which patients could become resilient and defensive against potential stressors 
through the use of CBT and SSRI medication. These interventions were able to restructure the 
way in which patients think about stressors and anxiety, leading to decreased symptoms of 
anxiety as well as depression. The achievement of optimal wellness was a central component of 
the Neuman Systems Model. Ultimately, a main goal of the EBP project was to promote quality 
of life and improved disease status, or put more simply, to promote wellness. The Neuman 
Systems Model was an excellent fit for this project, allowing for exploration and applicability of 
the model on a deeper level while upholding a holistic, patient-centered, wellness focus as the 
goal. As it assisted with successful development and implementation of this EBP project, the 
Neuman Systems Model is recommended for future EBP practice projects that focus on 
concepts of anxiety, stress, or depression. Future projects could also utilize the concepts of 
primary, secondary, and tertiary prevention exemplified by the Neuman Systems Model. The 
model describes the importance of primary prevention to strengthen the patient’s flexible line of 
defense, or first barrier against stressors, secondary prevention to decrease the reaction that 
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the patient has to the stressor within the lines of resistance, and rebuild wellness through 
treatment when stressors have invaded the patient’s core. As this theoretical model is so 
complex, future EBP projects could explore the model in even further detail and utilize as 
applicable for improved patient outcomes. 
Research 
 Further research is needed in order to explore the effects of therapist-guided CBT in 
comparison to self-administered CBT. It may be that CBT guided by a therapist yields superior 
outcomes to those of self-administered CBT. However, self-administered CBT is useful in 
reducing the barriers associated with therapist-guided CBT, including lack of available 
therapists, lack of insurance coverage, expense, time constraints, and patient reluctance. Thus, 
self-administered CBT is beneficial for those who are unable or unwilling to go to CBT guided by 
a therapist as it provides the opportunity for the patient to participate in CBT as opposed to no 
CBT option. Self-administered CBT does not have to substitute therapist-guided CBT for 
patients willing and able to attend, but rather could be implemented during the waiting period, if 
one exists, between the time the patient is recommended for CBT and the patient’s established 
appointment. 
Education 
 Patient education is a vital part of the role and responsibly of the advanced practice 
nurse. Educating participants about best practice treatment, side effects of medication, purpose 
of therapy, and additional information was incorporated into the protocol implemented through 
this project. Education was also a main component within the self-administered CBT workbook. 
Participants expressed much increased knowledge about GAD and coping skills through use of 
the CBT. Participants relayed that as a result of this education, their symptoms improved and 
they felt better overall. This also allowed participants to become well-informed consumers and 
take charge of their own health. Provider education is also extremely important regarding 
treatment for GAD. SSRIs are safer than many other medications for treatment of GAD. For 
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example, benzodiazepines are potentially addictive while SSRIs do not have this potential. 
Many providers may also not be aware of the CBT resources available within their community 
as well as globally. This project shines a light on the importance of familiarizing oneself with 
such resources, recommending them to patients, providing support to patients, and assisting 
them with accessing such resources. 
Conclusion 
This EBP project has allowed the NP site facilitator and project participants to see the 
value of the addition of CBT to their treatment regimen. The site facilitator has expressed her 
satisfaction with project results and her desire to continue to incorporate this combination 
therapy of SSRI antidepressant medication and self-administered CBT at her practice. Methods 
for sustainability were implemented at the project site. The site facilitator was receptive to such 
informative handout for patients interested in self-administered CBT and plans to continue to 
distribute this to eligible patients. Participants of the project also expressed their interest in 
continuing to utilize self-administered CBT along with taking SSRIs after experiencing the 
benefits first-hand. Such participants were encouraged to do so and provided with guidance 
regarding additional self-administered CBT resources. 
In conclusion, results of this project support the effectiveness of combination therapy 
with self-administered CBT and SSRI medication for the treatment of adults with GAD in 
decreasing anxiety and depression symptoms, improving GAD status, and yielding patient 
acceptability and satisfaction, which is consistent with current literature. No statistical 
significance was achieved for evaluation of anxiety symptoms nor for evaluation of change in 
GAD status. However, mean GAD-7 and CGI-I scores decreased, indicating decreased anxiety 
symptoms and improved GAD status. Statistical significance was achieved for the evaluation of 
PHQ-9 scores, indicating a significant decrease in depression symptoms. 
Patient education and close monitoring are also important components of such best 
practice protocol that should be followed to assess patient safety and response to treatment as 
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well as to facilitate patient understanding. Thus, this is a patient-centered protocol that upholds 
the best interests of patients and has a holistic focus. Providers are recommended to 
incorporate this combination therapy protocol including self-administered CBT and SSRI 
antidepressant medication for the treatment of adults with GAD as a cost-effective, accessible, 
effective method for improving GAD symptoms. 
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Appendix C 
 
Evidence-Based Practice Project Explanation 
 
Anxiety is Something to Worry About: The Effects of a Cognitive Behavioral Therapy and 
Selective Serotonin Reuptake Inhibitor Intervention Protocol on Generalized Anxiety Disorder 
 
Dear Patient, 
 
 My name is Alesha McClanahan. I am a registered nurse and a student in the Doctorate 
of Nursing Practice (DNP) program at Valparaiso University. Upon obtaining this degree and 
certification, I will be a nurse practitioner (NP). To fulfill this program’s curriculum, I will be 
implementing an evidence-based practice (EBP), or quality improvement, project at this clinic. 
The providers at this clinic including, L. K***, NP, support this project and will be overseeing its 
implementation. An evidence-based practice, or quality improvement project, aims to utilize 
current best practice recommendations from research and integrate them into the practice 
setting to improve clinical practice and patient outcomes.  
My EBP project will assess the effectiveness of cognitive behavioral therapy (CBT) in 
combination with a selective serotonin reuptake inhibitor (SSRI) on symptoms of generalized 
anxiety disorder (GAD). I am serving as the project manager of this project. CBT is a 
noninvasive, nonpharmacologic treatment that aims to change ways of thinking to elicit more 
positive thoughts and develop methods for coping with anxiety. It will be delivered in the form of 
an established CBT workbook written by a licensed psychologist. An SSRI is an oral 
antidepressant medication used to treat GAD as well as depression, which is strongly linked to 
GAD. Current, high quality evidence supports the combined use of CBT and an SSRI as the 
best treatment for the management of generalized anxiety disorder in children, adolescents, 
adults, and older adults. Therefore, if you would like to participate in this project, you will be 
prescribed an SSRI and a CBT workbook.  
The project will be implemented over a period of three months. Participants who agree to 
participate will be asked to complete a consent form, demographic information, including age 
and ethnicity, as well as an anxiety scale and a depression scale prior to treatment initiation and 
monthly over the three month period of the project. Participants will be asked to complete a 
satisfaction questionnaire upon project completion. For convenience, these measurements will 
occur via telephone calls by the project manager. These phone calls will likely be 5-10 minutes 
long. Participants will be asked to actively engage in the CBT workbook on their own and take 
their SSRI medication as directed. You are invited to participate in this project. If you choose not 
to participate in this project, there will be no penalty nor effect on the care provided to you today 
or any other time at this clinic. Participation is voluntary, and you may withdraw at any time if 
you wish. Patient confidentiality will be upheld, and patient information will be kept in a secure 
and private location. 
 
        Thank you for your consideration, 
 
  Alesha McClanahan, BSN, RN, DNP Student Valparaiso University 
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Appendix D 
 
Informed Consent Form 
 
Project Title: Anxiety is Something to Worry About: The Effects of a Cognitive Behavioral 
Therapy (CBT) and Selective Serotonin Reuptake Inhibitor (SSRI) Intervention Protocol on 
Symptoms of Generalized Anxiety Disorder (GAD) 
 
Project Manager: Alesha McClanahan, BSN, RN, DNP Student Valparaiso University College 
of Nursing and Health Professions 
 
Purpose: This is a consent form for evidence-based practice participation. It contains important 
information about the project and what to expect if I decide to participate. I understand that I am 
being asked to join an evidence-based practice project for patients of this clinic that will examine 
the effects of combined self-administered cognitive behavioral therapy (CBT) and selective 
serotonin reuptake inhibitor (SSRI) medication use on symptoms of anxiety. 
 
Voluntary participation/withdrawal: I understand that my participation is voluntary. I am being 
asked to please read and consider the information carefully. I may ask questions before making 
my decision regarding participation and at any time during and after the project’s 
implementation. If I decide to participate, I will be asked to indicate my consent to participate 
with my signature. I understand that I may leave the project at any time. If I decide to stop 
participating in the project, there will be no penalty to me, and I will not lose any benefits to 
which I am otherwise entitled. My decision will not affect my relationship with nor the care 
provided to me at K*** Family Medicine today nor in the future. 
 
Procedure: If I participate in this project, I will utilize the CBT workbook for anxiety and take the 
prescribed SSRI medication. I understand that such CBT and SSRI use may be referred to as 
interventions, therapy, or treatment throughout this project. The CBT utilized for this project may 
be referred to as self-help or self-administered CBT as I will work on the workbook by myself, or 
independently, rather than with a therapist. I understand that the evidence indicates that this 
combined therapy yields the best outcomes for GAD. I will be asked to read and complete the 
CBT workbook provided to me independently and as directed throughout the 3-month study 
period. I will also be asked to take my SSRI medication regularly as directed throughout the 3-
month period. If I participate, I will sign consent to participate and answer a demographic, 
anxiety, depression, and satisfaction questionnaire. The demographic questionnaire will need to 
be answered once at the start of the project’s implementation, and the satisfaction questionnaire 
will need to be answered once at the end of the project’s implementation. The anxiety and 
depression questionnaires will need to be answered four times, including prior to the initiation of 
treatment and monthly (every four weeks) for 3 months. The questionnaires will initially be 
answered in the office during your scheduled appointment while the other three times in which 
the same questionnaires will be answered will occur via telephone calls by the project manager. 
If I participate in this project, I understand that I give consent for the project manager to call my 
phone number(s) that I have provided, and I give consent for a message to be left if I am 
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unavailable. I will make an effort to answer the project manager’s phone calls and to call the 
project manager back shortly if I miss a call. The phone calls will typically last 5-10 minutes 
each. Phone calls will include completion of the aforementioned questionnaires. I may also ask 
the project manager any questions that I have during these phone calls and feel free to provide 
any comments about the therapy, process, etc. I am asked to be open and honest and will not 
receive any repercussions for my responses or comments. 
 
Duration: I will tentatively participate in the study for 3 months (12 weeks). I will be regularly 
evaluated by the project manager and NP for my safety and to evaluate the effectiveness of the 
interventions. In addition to phone calls by the project manager, I may have follow up 
appointments with the NP per office policy to evaluate the effects of the interventions, including 
tolerability, side effects, and satisfaction with treatment. I will be instructed to complete certain 
portions of the workbook by designated times and to complete the entire workbook within 3 
months. I will be asked to complete the anxiety and depression questionnaires at 1 month (4 
weeks), 2 months (8 weeks), and 3 months (12 weeks) after the start of the interventions. 
 
Risks: The potential risks to participating in this project are minimal but include side effects and 
adverse effects of SSRI medications which may include drowsiness, nausea, dry mouth, 
insomnia, diarrhea, nervousness, agitation, restlessness, dizziness, headache, blurred vision, 
sexual problems, reduced sexual desire, difficulty reaching orgasm, or inability to maintain an 
erection. Additional safety concerns include potential drug interactions, serotonin syndrome, and 
pregnancy or breastfeeding. You should inform your provider of all medications you are 
currently taking. Serotonin syndrome may occur when levels of serotonin are too high in the 
body, which typically occurs when multiple medications that raise serotonin levels are taken. 
Seek medical attention if you have signs and symptoms of serotonin syndrome, including 
anxiety, agitation, sweating, confusion, tremors, restlessness, lack of coordination, and a rapid 
heart rate. Speak with your provider regarding antidepressant use and pregnancy or 
breastfeeding if you are or plan to become pregnant or breastfeed as some antidepressants 
may cause harm to your baby. Do not stop taking SSRI medication abruptly as this may pose 
risks including withdrawal-like symptoms including uneasiness, nausea, dizziness, lethargy, and 
flu-like symptoms. Although most antidepressants are safe, an increase in suicidal thoughts or 
behavior can occur particularly upon initiation or dose change. Antidepressants are likely to 
reduce suicide risk long-term. However, you should be closely monitored and contact your 
provider or emergency services if you have suicidal thoughts. SSRIs are generally well 
tolerated. 
 
The potential risks to participating in this project associated with CBT are minimal but include 
emotional vulnerability, emotional discomfort, frustration, crying, anger, feeling physically 
drained, temporary stress, and temporary anxiety as CBT aims to address negative thoughts 
that cause anxiety and fear and correct such maladaptive thoughts. Thus, CBT may involve the 
confronting of sensitive thoughts and events which may evoke unpleasant thoughts and 
emotions. 
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Benefits: The benefits of participating in this project include receiving treatment based on the 
recommendations of the best available evidence that aims to elicit the best outcomes and 
increase quality of life for patients. A CBT workbook will be administered free of charge to those 
who participate in this project. Researchers hope to gain valuable information regarding whether 
incorporating CBT and an SSRI into the treatment plan will make an impact on anxiety 
symptoms. The information provided may help to make advancements in nursing practice and 
care provided. 
 
Confidentiality: I understand that efforts will be made to keep my project-related information 
confidential. However, there may be circumstances where this information must be released. 
For example, personal information regarding my participation in this project may be disclosed if 
required by state law. In the event that I indicate any potential for self-harm or harm of others, it 
will be necessary to break confidentiality for my safety and the safety of others. Any information 
containing my identifying information will be kept in a locked box with access only to the project 
manager. My responses to questionnaires will be kept in a secure and private location with only 
access to the project manager and office staff. The project manager and staff will work to 
ensure that no one sees my questionnaire responses without my approval. A code will be used 
in place of my name in order to further uphold confidentiality and reduce the risk that others can 
view my responses. General information obtained from this project may be utilized in nursing 
journals, presentations, or other publications, but no one will be able to identify me from this 
information as no patient identifiers will be released. 
 
Contacts and Questions: For questions and concerns about the project, I may contact the 
project manager, Alesha McClanahan, at (219) 689-3369 or alesha.mcclanahan@valpo.edu. I 
may also contact L. K***, NP, with questions at her office (219) 956-3004. Christina Cavinder, 
the project’s faculty advisor, may be contacted at (219) 548-7797 or 
christina.cavinder@valpo.edu. I may also contact Jennifer Winquist, Chair of the Institutional 
Review Board at Valparaiso University at (219) 464-6841 or jennifer.winquist@valpo.edu if I 
have questions or concerns regarding the conduction of the evidence-based practice project. 
 
Consent to Participate: I have read (or someone has read to me) this form, and I am aware 
that I am being asked to participate in an evidence-based practice project. I have had the 
opportunity to ask questions and have had them answered to my satisfaction. I voluntarily agree 
to participate in this project. I understand the information that has been presented to me. By 
signing and submitting this form, I agree to participate in this project. I will be offered a copy of 
this form for my records. 
 
The project manager may call me at this phone number(s):  ____________________________ 
 
        ___________________________ 
   
Participant’s Signature:       Date: 
 
Printed first and last name: 
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Appendix E                                               
 
Demographic Form 
 
Please answer the following questions about yourself. 
 
1. What is your age? _____ 
 
2. Are you male or female? 
 
a. Male 
b. Female 
 
3. What is the highest level of education that you have completed? 
a. Less than high school 
b. High school/GED 
c. Some college (no degree) 
d. 2-year college degree (Associates) (e.g. BA, BS) 
e. 4-year college degree (Bachelors) (e.g. BA, BS) 
f. Master’s degree (e.g. MA, MS, Med) 
g. Professional degree (e.g. MD, DDS, DVM) 
h. Doctoral degree (e.g. PhD, EdD) 
 
4. What is your race? 
a. African American 
b. Asian-Pacific Islander 
c. Caucasian 
d. Hispanic 
e. Native American 
f. Other 
g. Prefer not to answer 
 
5. What form of health insurance do you currently have? 
a. No insurance 
b. Medicare 
c. Medicaid 
d. Private insurance 
 
6. What is your marital status? 
a. Single (never married) 
b. Married 
c. Separated 
d. Divorced 
e. Widowed 
Code Number: 
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7. What is your annual household income? 
a. Less than $20,000 
b. $20,000 to $34,999 
c. $35,000 to $49,999 
d. $50,000 to $74,999 
e. $75,000 to $99,999 
f. Over $100,000 
 
8. What is your current employment status? 
a. Employed full time (40 or more hours per week) 
b. Employed part time (up to 39 hours per week) 
c. Unemployed and currently looking for work 
d. Unemployed and not currently looking for work 
e. Student 
f. Retired 
g. Homemaker  
h. Self-employed 
i. Unable to work 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Code Number: 
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Appendix F 
 
Code Sheet 
 
 
Patient Name (Last, First) 
 
 
Code Number 
  
1 
 
  
2 
 
  
3 
 
  
4 
 
  
5 
 
  
6 
 
  
7 
 
  
8 
 
  
9 
 
  
10 
 
  
11 
 
  
12 
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Appendix G 
 
Generalized Anxiety Disorder 7-item (GAD-7) Scale 
 
Over the last 2 weeks, how often have you been 
bothered by the following problems? 
 
Use “√ ” to indicate your answer. 
Not at all Several 
days 
More 
than half 
the days 
Nearly 
every 
day 
 
1. Feeling nervous, anxious, or on edge 
 
 
0 
 
1 
 
2 
 
3 
 
2. Not being able to stop or control worrying 
 
 
0 
 
1 
 
2 
 
3 
 
3. Worrying too much about different things 
 
 
0 
 
1 
 
2 
 
3 
 
4. Trouble relaxing 
 
 
0 
 
1 
 
2 
 
3 
 
5. Being so restless that it’s hard to sit still 
 
 
0 
 
1 
 
2 
 
3 
 
6. Becoming easily annoyed or irritable 
 
 
0 
 
1 
 
2 
 
3 
 
7. Feeling afraid as if something awful might 
happen 
 
0 
 
1 
 
2 
 
3 
 
For office coding: Add the score for each 
column 
    
 
Total score (add column scores) = 
 
If you checked off any problems, how difficult have these problems made it for you to do your 
work, take care of things at home, or get along with other people? 
 
Not difficult at all             Somewhat difficult             Very difficult             Extremely difficult 
 
 
Adapted from Spitzer, R. L., Kroenke, K., Williams, J. B. W., & Lowe, B. (2006). A brief measure for assessing 
generalized anxiety disorder. Archives of Internal Medicine, 166, 10920-1097. Retrieved from 
http://www.archinternmed.com 
Code Number: 
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Generalized Anxiety Disorder 7-item (GAD-7) Scale Scoring 
 
 
 
 
Scores on the GAD-7 range from 0-21 with each of the 7 items scored from 0-3. Each column is 
added together in order to determine the total score. The total score indicates the level of 
severity of anxiety symptoms. 
 
 
 
 
 
GAD-7 Scale Score 
 
 
Level of Anxiety Severity 
 
 
0-4 
 
Minimal symptoms 
 
5-9 Mild symptoms 
 
10-14 Moderate symptoms 
 
15-21 Severe symptoms 
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Appendix H 
 
Patient Health Questionnaire (PHQ-9) 
 
Over the last 2 weeks, how often have you been 
bothered by the following problems? 
 
Use “√ ” to indicate your answer. 
Not at all Several 
days 
More 
than half 
the days 
Nearly 
every 
day 
1. Little interest or pleasure in doing things 
 0 1 2 3 
2. Feeling down, depressed, or hopeless 
 0 1 2 3 
3. Trouble falling or staying asleep, or sleeping 
too much 
0 1 2 3 
4. Feeling tired or having little energy 0 1 2 3 
5. Poor appetite or overeating 0 1 2 3 
6. Feeling bad about yourself – or that you are 
a failure or have let yourself or your family 
down 
 
0 
 
1 
 
2 
 
3 
7. Trouble concentrating on things, such as 
reading the newspaper or watching 
television 
 
0 
 
1 
 
2 
 
3 
8. Moving or speaking so slowly that other 
people could have noticed? Or the opposite 
– being so fidgety or restless that you have 
been moving around a lot more than usual 
0 1 2 3 
9. Thoughts that you would be better off dead 
or of hurting yourself in some way 
0 1 2 3 
 
For office coding: Add the score for each 
column 
    
                         Total score (add column scores) = 
 
If you checked off any problems, how difficult have these problems made it for you to do your 
work, take care of things at home, or get along with other people? 
 
Not difficult at all             Somewhat difficult             Very difficult             Extremely difficult 
 
  
Adapted from Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001). The PHQ-9: Validity of a brief depression 
severity measure. Journal of General Internal Medicine, 16, 606-613. Retrieved from http://www.jgim.org/ 
Code Number: 
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Patient Health Questionnaire (PHQ-9) Scoring 
 
 
 
 
Scores on the PHQ-9 range from 0-27 with each of the 9 items scored from 0-3. Each column is 
added together in order to determine the total score. The total score indicates the level of 
severity of depression symptoms. 
 
 
 
 
 
PHQ-9 Scale Score 
 
 
Level of Depression 
Severity 
 
 
0-4 
 
Minimal symptoms 
 
5-9 Mild symptoms 
 
10-14 Moderate symptoms 
 
15-19 Moderately severe 
symptoms 
 
20-27 Severe symptoms 
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Appendix I 
 
Clinical Global Impressions-Improvement (CGI-I) Scale 
 
 
1 – Very Much Improved 
 
Nearly all better; good level of functioning; 
minimal symptoms; represents a very 
substantial change 
 
 
2 – Much Improved 
 
Notably better with significant reduction of 
symptoms; increase in the level of functioning 
but some symptoms remain 
 
 
3 – Minimally Improved 
 
Slightly better with little or no clinically 
meaningful reduction of symptoms. 
Represents very little change in basic clinical 
status, level of care, or functional capacity 
 
 
4 – No Change 
 
 
Symptoms remain essentially unchanged 
 
5 – Minimally Worse   
 
Slightly worse but may not be clinically 
meaningful; may represent very little change 
in basic clinical status or functional capacity 
 
 
6 – Much Worse 
 
 
Clinically significant increase in symptoms 
and diminished functioning 
 
 
7 – Very Much Worse  
 
 
Severe exacerbation of symptoms and loss of 
functioning 
 
 
 
 
 
Adapted from Busner, J. & Targum, S. D. (2007). The clinical global impressions scale: Applying a research tool in 
clinical practice. Psychiatry (Edgmont), 4(7), 28-37. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/journals/901/ 
 
 
Code Number: 
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Clinical Global Impressions-Improvement (CGI-I) Scale Scoring 
 
 
 
 
Score 
 
 
Change in Disease Status 
 
1 
 
Very much improved 
 
 
2 
 
Much improved  
 
 
3 
 
Minimally improved 
 
 
4 
 
No change  
 
 
5 
 
Minimally worse 
 
 
6 
 
Much worse 
 
 
7 
 
Very much worse 
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Appendix J 
 
Patient Satisfaction Questionnaire (PSQ) 
Self-administered Cognitive Behavioral Therapy (CBT) Workbook 
 
 
Please circle your responses. 
 
1. How convenient or inconvenient is it for you to use the CBT workbook? 
 
1) Extremely Inconvenient 
2) Very Inconvenient 
3) Inconvenient 
4) Somewhat Convenient 
5) Convenient 
6) Very Convenient 
7) Extremely Convenient 
 
2. How easy or difficult is it for you to use the CBT workbook? 
 
1) Extremely Difficult 
2) Very Difficult 
3) Difficult 
4) Somewhat Easy 
5) Easy 
6) Very Easy 
7) Extremely Easy 
 
3. How satisfied or dissatisfied are you with the impact that use of the CBT workbook has had 
on your anxiety symptoms? 
 
1) Extremely Dissatisfied 
2) Very Dissatisfied 
3) Dissatisfied 
4) Somewhat Satisfied 
5) Satisfied 
6) Very Satisfied 
7) Extremely Satisfied 
 
4. How satisfied or dissatisfied are you with use of the CBT workbook overall? 
 
1) Extremely Dissatisfied 
2) Very Dissatisfied 
3) Dissatisfied 
4) Somewhat Satisfied 
5) Satisfied 
6) Very Satisfied 
7) Extremely Satisfied 
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5. How worthwhile or worthless do you find use of the CBT workbook to be? 
 
1) Extremely Worthless 
2) Very Worthless 
3) Worthless 
4) Somewhat Worthwhile 
5) Worthwhile 
6) Very Worthwhile 
7) Extremely Worthwhile 
 
 
Please fill in the blank. 
 
6. How much time did you approximately spend completing the CBT workbook per week? 
 
_______  minutes      OR      _______  hours 
 
 
 
 
 
McClanahan, A. (2018). Patient Satisfaction Questionnaire. 
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Patient Satisfaction Questionnaire (PSQ) Scoring 
 
 
 
PSQ Scale Score 
 
 
Level of Patient 
Satisfaction 
 
 
5 
 
Extremely Dissatisfied 
 
6-10 Very Dissatisfied 
 
11-15 Dissatisfied 
 
16-20 Somewhat Satisfied 
 
21-25 Satisfied 
 
26-30 
 
Very Satisfied 
31-35 Extremely Satisfied 
 
 
 
 
 
This scoring system for the PSQ was created by the project manager and is optional. Results 
may instead be reported per individual question via percentages as was ultimately done for this 
project. 
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Appendix K 
 
Selective Serotonin Reuptake Inhibitor (SSRI) and Cognitive Behavioral Therapy (CBT)  
Patient Instructions – Adult 18+ years 
 
SSRI use 
• The purpose of this medication is to help manage your anxiety by decreasing your 
symptoms of anxiety. 
• Take your prescribed medication as directed and attend regular follow up appointments. 
• Do not discontinue your medication abruptly. 
• Call your provider or seek emergency attention if necessary if you experience alarming 
adverse effects. 
• Side effects of the medication may include drowsiness, nausea, dry mouth, insomnia, 
diarrhea, nervousness, agitation, restlessness, dizziness, headache, or sexual problems. 
 
CBT use 
• The purpose of this intervention is to help manage your anxiety by teaching you coping 
mechanisms and changing negative and distorted thoughts into more positive and 
realistic thoughts. 
• A CBT workbook will be provided to you at the office for you to complete independently. 
• This is CBT in the form of self-help, and thus, this is not guided by a therapist. However, 
you are welcome to ask your provider or the project manager, Alesha, any questions. 
• You will be enrolled in this project for 3 months (12 weeks), and the workbook is divided 
into four parts. Please complete Part 1 by 3 weeks, Part 2 by 6 weeks, Part 3 by 9 
weeks, and Part 4 by 12 weeks. 
• Side effects of CBT may include emotional discomfort, frustration, crying, anger, feeling 
drained, or temporary stress and anxiety when confronting sensitive thoughts. 
 
Progress Measurement 
• Your response to these interventions of SSRIs and CBT will be measured throughout 
this project by the project manager, Alesha. These measurements will occur at baseline 
(prior to starting these interventions) in the office and via phone calls by Alesha at 1 
month, 2 months, and 3 months after starting these interventions. Phone calls will 
typically last 5-10 minutes or less.  
• Phone calls will include completion of the Generalized Anxiety Disorder 7-item (GAD-7) 
Scale to assess for symptoms of anxiety and the Patient Health Questionnaire (PHQ-9) 
to assess for symptoms of depression. You are welcome to share any comments, 
concerns, or questions during these phone calls. 
• These phone calls are important in order to measure these outcomes to determine the 
effectiveness of the interventions and to further evidence-based nursing practice. 
 
 
 
 
• Tentative dates of 
measurement include: 
▪ Baseline –  
▪ 1 month –  
▪ 2 months –  
▪ 3 months –  
 
Alesha McClanahan, BSN, RN,  
DNP Student Valparaiso University 
219-689-3369 
Alesha.mcclanahan@valpo.edu 
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Appendix L 
 
Best Practice Intervention Protocol 
 
SUBJECT: Generalized Anxiety Disorder 
Treatment Protocol 
REFERENCE #: 1 
LOCATION: Primary Care Clinic PAGES: 1 
LAST REVISION: 9/12/18 EFFECTIVE: 9/21/18 
APPROVED BY: Primary Care Clinic Nurse 
Practitioner and Office Manger 
REVISED: 
REVIEWED: 
 
Purpose: 
• To provide a protocol for nurse practitioners and other providers to follow in order to 
provide best practice treatment of patients with generalized anxiety disorder (GAD) 
 
Protocol: 
• Primary care adult patients ages 18 years old and older with a diagnosis of GAD based 
on DSM-5 criteria are eligible 
 
• Combination therapy with a selective serotonin reuptake inhibitor (SSRI) plus cognitive 
behavioral therapy (CBT) is recommended for best outcomes 
 
o Age-appropriate self-help CBT bibliotherapy in the form of a workbook for anxiety 
▪ Adults 18+: The Cognitive Behavioral Workbook for Anxiety: A Step-By-
Step Program (Knaus, 2014) 
                AND 
o Prescribing of an SSRI 
▪ Sertraline with a maximum daily dose of 200 mg PO is recommended 
▪ Any type of SSRI will fulfill protocol requirements, and individual patient 
factors should be considered, such as previous medications tried, drug 
interactions, etc. 
 
• Education should be provided to patients regarding safe and proper use of CBT and 
SSRIs and potential side effects 
 
• Close monitoring of patients taking SSRIs is recommended 
 
• Outcomes must be measured at baseline and monthly (every 4 weeks) 
o Anxiety symptoms, depressive symptoms, GAD status, patient satisfaction, and 
acceptability 
o Generalized Anxiety Disorder 7-item (GAD-7) Scale, Patient Health 
Questionnaire (PHQ-9), Clinical Global Impressions-Improvement (CGI-I) Scale, 
Patient Satisfaction Questionnaire (PSQ), and attrition rate 
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Appendix M 
 
 
 
phone: 219.464.5798         Institutional Review Board 
    fax: 219.464.5511                                        212 Arts & Sciences Building 
        www.valpoirb.edu     1400 Chapel Drive 
         Valparaiso, Indiana  46383-4520 
 
To: Alesha McClanahan 
  
 
From: Rasha Abed 
 Associate Director of Sponsored Research 
 
RE: Anxiety is Something to Worry About: The Effects of a Cognitive Behavioral Therapy 
(CBT) and Selective Serotonin Reuptake Inhibitor (SSRI) Intervention Protocol on 
Symptoms of Generalized Anxiety Disorder (GAD) 
 
Date: September 21, 2018 
 
The IRB has approved the above study on September 20, 2018. The project was reviewed in 
accordance with all research statues and regulations pursuant to Federal regulations, 45 CFR 
46.101(b). 
 
The researcher has approval of this project until one year from the identified date.  
 
If additional protocol changes are needed, approval must be sought from the IRB prior to 
implementing those changes. Please submit a new expedited request to the IRB for 
consideration.  
 
When the project is completed, notify the IRB. If the research protocol needs to extend beyond 
one year, written approval must be sought from the IRB. 
 
Good luck with your work. Please retain a copy of this letter for your records. 
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Appendix N 
 
Handout for Sustainability 
 
Cognitive Behavioral Therapy for Generalized Anxiety Disorder Resources 
 
Current, high quality evidence supports the combined use of cognitive behavioral 
therapy (CBT) and selective serotonin reuptake inhibitor (SSRI) medication as the best 
treatment for generalized anxiety disorder (GAD) in children, adolescents, and adults. The 
purpose of both CBT and SSRIs for GAD is to help manage anxiety by decreasing symptoms of 
anxiety and depression. An SSRI is an oral antidepressant medication used to treat GAD as 
well as depression, which is strongly linked to GAD. SSRIs are typically well tolerated and safe. 
CBT is a noninvasive, nonpharmacologic treatment that aims to change ways of thinking to elicit 
more positive thoughts and teach ways to cope. Self-administered CBT via workbook is 
recommended as an inexpensive, convenient, and effective form of CBT. Information regarding 
cost, examples, and where CBT workbooks are available for purchase is listed below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
There are a multitude of other CBT workbooks available for purchase both online and in 
stores. Other methods of CBT to consider include mobile apps, free online resources including 
CBT worksheets, and counseling with a licensed therapist. Consult with your provider if you 
have any questions or would like more information. Combination therapy with CBT and SSRI 
medication should be considered for the treatment of anxiety as it has been shown to decrease 
anxiety and depression symptoms within current research and evidence-based practice. 
The Cognitive Behavioral 
Workbook for Anxiety: A 
Step-By-Step Program by 
William J. Knaus, EdD 
www.amazon.com  
$18.85 Paperback  
     $12.49 Kindle 
www.walmart.com 
$18.85 Paperback 
$16.59 eBook 
www.target.com  
$21.20 Paperback 
 
The Generalized Anxiety 
Disorder Workbook: A 
Comprehensive CBT Guide 
for Coping with Uncertainty, 
Worry, and Fear by Melisa 
Robichaud, PhD & Michel J. 
Dugas, PhD 
www.amazon.com 
$18.62 Paperback 
 $9.99 Kindle 
www.barnesandnoble.com  
$25.95 Paperback 
$12.49 Nook Book 
 
The Anxiety & Worry 
Workbook: The Cognitive 
Behavioral Solution by David 
A. Clack, PhD & Aaron T. 
Beck, MD 
www.amazon.com 
$14.89 Paperback 
$14.15 Kindle 
www.target.com 
$14.89 Paperback 
www.walmart.com 
 $14.89 Paperback 
 
 
Cognitive Behavioral 
Therapy Made Simple: 10 
Strategies for Managing 
Anxiety, Depression, Anger, 
Panic, and Worry by Seth J. 
Gillihan, PhD 
www.amazon.com 
$9.75 Paperback 
$0.00 Kindle 
www.barnesandnoble.com  
$15.99 Paperback 
$14.99 Audiobook 
 
Photo credit: (Amazon, 2019) 
